0001213900-22-000893.txt : 20220106 0001213900-22-000893.hdr.sgml : 20220106 20220106110917 ACCESSION NUMBER: 0001213900-22-000893 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 37 CONFORMED PERIOD OF REPORT: 20211130 FILED AS OF DATE: 20220106 DATE AS OF CHANGE: 20220106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Better For You Wellness, Inc. CENTRAL INDEX KEY: 0001852707 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56262 FILM NUMBER: 22514011 BUSINESS ADDRESS: STREET 1: 1349 EAST BROAD STREET CITY: COLUMBUS STATE: OH ZIP: 43205 BUSINESS PHONE: 6143689898 MAIL ADDRESS: STREET 1: 1349 EAST BROAD STREET CITY: COLUMBUS STATE: OH ZIP: 43205 FORMER COMPANY: FORMER CONFORMED NAME: Fast Track Solutions, Inc. DATE OF NAME CHANGE: 20210322 10-Q 1 f10q1121_betterforyou.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2021

 

OR

 

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

COMMISSION FILE NUMBER: 000-56262

  

Better For You Wellness, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   87-2903933

(State or other jurisdiction

of incorporation or organization)

  (I.R.S. Employer
Identification No.)

 

1349 East Broad Street

Columbus, OH

  43205
 (Address of Principal Executive Offices)   (Zip Code) 

 

1 (614) 368-9898

 

(registrant’s telephone number, including area code)

 

N/A

 

(former name or former mailing address, if changed since last report)

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer     Accelerated filer     Non-accelerated filer  
Smaller reporting company   Emerging growth company        

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

☐Yes No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

As of January 1, 2022, there were 370,072,945 shares of Common Stock and 700,000 shares of Series A Preferred Stock issued and outstanding. 

 

 

 

 

 

 

PART I - FINANCIAL INFORMATION

 

Better For You Wellness, Inc.

FKA Fast Track Solutions, Inc. 

Balance Sheet

 

  

November 30,
2021

   February 28,
2021
(Audited)
 
         
TOTAL ASSETS  $
-
   $
-
 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
CURRENT LIABILITIES          
Loans to Company – related party  $156,756   $
-
 
Accrued Expenses  $117,017   $3,750 
           
TOTAL LIABILITIES  $273,773   $3,750 
           
Stockholders’ Equity (Deficit)          
Preferred stock ($.0001 par value, 200,000,000 shares authorized; 700,000 and 0 issued and outstanding as of November 30, 2021 and February 28, 2021, respectively)   70    
-
 
Common stock ($.0001 par value, 500,000,000 shares authorized, 363,024,072 and 0 issued and outstanding as of November 30, 2021 and February 28, 2021,respectively)   36,302    
-
 
Additional paid-in capital   846,943    1,185 
Accumulated deficit   (1,157,088)   (4,935)
Total Stockholders’ Equity (Deficit)   (273,773)  $(3750)
           
TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)  $
-
   $
-
 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

1

 

 

Better For You Wellness, Inc.

FKA Fast Track Solutions, Inc. 

Statement of Operations

(Unaudited)

 

   Three Months
Ended
November 30,
2021
  

Nine Months

Ended
November 30,
2021

 
         
Operating Expenses:        
Selling, general and administrative expenses  $533,854   $542,910 
           
Share-based expense   532,243    609,243 
Total operating expenses   1,066,097    1,152,153 
           
Net loss  $(1,066,097)  $(1,152,153)
           
Basic and Diluted net loss per common share  $(0.00)  $(0.00)
           
Weighted average number of common shares outstanding - Basic and Diluted   361,664,351    287,241,405 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

2

 

 

Better For You Wellness, Inc.

FKA Fast Track Solutions, Inc. 

Statement of Changes in Stockholders’ Equity (Deficit)

For the Period December 1, 2020 (Inception) to November 30, 2021

(Unaudited)

 

   Common Shares   Par Value Common Shares   Series A Preferred Shares   Par Value Series A Preferred Shares   Additional
Paid-in
Capital
    Accumulated Deficit    Total   
                             
Balances, December 1, 2020   
-
   $
-
    
-
   $
        -
   $
-
   $
-
   $
-
 
                                    
Expenses paid on behalf of the Company and contributed to capital   -    
-
    -    
-
    1,185    
-
    1,185 
Net loss   -    
-
    -    
-
    
-
    (4,935)   (4,935)
Balances, February 28, 2021   
-
   $
-
    
-
   $
-
   $1,185   $(4,935)  $(3,750)
Common shares issued after reorganization   359,996,332    36,000    
-
    
-
    (36,000)   
-
    
-
 
Preferred shares issued after reorganization   -    
-
    700,000    70    69,930    
-
    70,000 
Expenses paid on behalf of the Company and contributed to capital   -    
-
    -    
-
    3,951    
-
    3,951 
Net loss   -    
-
    -    
-
    
-
    (72,051)   (72,051)
Balance, May 31, 2021  $359,996,332   $36,000    700,000   $70   $39,607   $(76,986)  $(1,850)
Common shares issued for services   50,000    5    
-
    
-
    6,995    
-
    7,000 
                                    
Expenses paid on behalf of the Company and contributed to capital   -    
-
    -    
-
    2,990    
-
    2,990 
Net loss   -    
-
    -    
-
    
-
    (14,005)   (14,005)
Balances, August 31, 2021  $ 360,046,332   $36,005    700,000   $70   $49,052   $(90,992)  $(5,865)
Common share issued for services to the Company   2,977,740    298    
-
    
-
    531,945    
-
    532,243 
Stock options expense   -    
-
    -    
-
    265,946    
-
    265,946 
Net loss   -    
-
    -    
-
    
-
    (1,066,097)   (1,066,097)
Balances, November 30, 2021  $363,024,072   $36,302    700,000   $70   $846,943   $(1,157,088)  $(273,773)

 

The accompanying notes are an integral part of these unaudited financial statements.

 

3

 

 

Better For You Wellness, Inc.

FKA Fast Track Solutions, Inc. 

Statement of Cash Flows

(Unaudited)

 

  

Nine Months Ended
November 30,
2021

 
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss  $(1,152,153)
Adjustment to reconcile net loss to net cash used in operating activities:     
Common stock issued   539,243 
Preferred stock issued   70,000 
Stock options expense   265,946 
Changes in current assets and liabilities:     
Accrued expenses   113,267 
Net cash used in operating activities   (163,697)
      
CASH FLOWS FROM FINANCING ACTIVITIES     
Expenses contributed to capital  $6,941 
Loan to company – related party   156,756 
Net cash provided by financing activities   163,697 
Net change in cash  $
-
 
Beginning cash balance   
-
 
Ending cash balance  $
-
 
      
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:     
Interest paid  $0 
Income taxes paid  $0 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

4

 

 

Better For You Wellness, Inc.

FKA Fast Track Solutions, Inc. 

Notes to Unaudited Financial Statements

 

Note 1 - Organization and Description of Business

 

Better For You Wellness, Inc. (we, us, our, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we cancelled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.

 

5

 

 

The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time

 

After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.

 

On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.

 

Pursuant to the Agreement, on July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.

 

On July 30, 2021, Mr. Ian James was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors and Mr. Stephen Letourneau was appointed as a Director.

 

On August 18, 2021, we filed an amendment to the Company’s Articles of Incorporation with the Nevada Secretary of State to change our name to Better For You Wellness, Inc. On September 30, 2021, we began trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.

 

6

 

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company. On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per quarter, paid in equal distributions quarterly, 200,000 shares of common stock issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. The Directors were officially seated September 12, 2021, after notification to shareholders. 

 

The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.

 

The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.

 

The Company has elected February 28th as its year end.

 

As of November 30, 2021, the Company had not yet commenced operations.

 

Note 2 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at November 30, 2021 and February 28, 2021 were $0 for both periods. 

 

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.”  Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs.  A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at November 30, 2021.

 

7

 

 

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company does not have any potentially dilutive instruments as of November 30, 2021 and, thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.  

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of November 30, 2021. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

 

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

 

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.”  Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:  (a) the goods or services received; or (b) the equity instruments issued.  The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.  

 

8

 

 

The Company had no stock-based compensation plans as of November 30, 2021 and February 28, 2021.

 

The Company’s stock-based compensation for the periods ended November 30, 2021 and February 28, 2021 was $609,243 and $0, respectively.

 

Recently Issued Accounting Pronouncements

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 is amended by ASU 2018-01, ASU2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01, which FASB issued in January 2018, July 2018, July 2018, December 2018 and March 2019, respectively (collectively, the amended ASU 2016-02). The amended ASU 2016-02 requires lessees to recognize on the balance sheet a right-of-use asset, representing its right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from current GAAP. The amended ASU 2016-02 retains a distinction between finance leases (i.e. capital leases under current GAAP) and operating leases. The classification criteria for distinguishing between finance leases and operating leases will be substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current GAAP. The amended ASU 2016-02 also requires qualitative and quantitative disclosures designed to assess the amount, timing, and uncertainty of cash flows arising from leases. A modified retrospective transition approach is permitted to be used when an entity adopts the amended ASU 2016-02, which includes a number of optional practical expedients that entities may elect to apply.

 

We have no assets and or leases and do not believe we will be impacted in the foreseeable future by the newly adopted accounting standard(s) mentioned above.

 

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

Note 3 - Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The Company has not established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

 

Note 4 - Income Taxes

 

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. As of November 30, 2021, the Company has incurred a net loss of approximately $1,157,088 which resulted in a net operating loss for income tax purposes.  The loss results in a deferred tax asset of approximately $242,988 at the effective statutory rate of 21%. The deferred tax asset has been offset by an equal valuation allowance. Given our inception on December 1, 2020, and our fiscal year end of February 28, 2021, we have completed only one taxable fiscal year.

 

9

 

 

Note 5 - Commitments and Contingencies

 

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies.  Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of November 30, 2021 other than the following:

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital. Pursuant to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

Note 6 - Shareholder Equity

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 and 0 shares issued and outstanding as of November 30, 2021 and February 28, 2021, respectively.

 

During the three months ended May 31, 2021, 700,000 shares of Series A Preferred Stock were issued to CRS Consulting, LLC (“CRS”), a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody. CRS is our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock. Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. On July 19, 2021, these shares were purchased. As of November 30, 2021, our CEO, Ian James, and Director, Stephen Letourneau, each hold 350,000 shares of Series A Preferred Stock (See Note 1).

 

10

 

 

Common Stock

 

The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 363,024,072 and 0 shares of common stock issued and outstanding as of November 30, 2021 and February 28, 2021, respectively.

 

At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.

 

On July 19, 2021, 250,000,000 shares of Restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).

 

On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $7,000.

 

On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $468,493.

 

On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $45,000.

 

On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $18,750.

 

Stock Options

 

During the nine months ended November 30, 2021, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 2,500,000 fully vested on September 30, 2021. 17,500,000 shares vest over the next 2 years, 2,500,000 shares per quarter. The options have the exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options as of November 30, 2021, was $0.

 

The Company fair valued the options on the grant date at $2,127,565 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 per share (based on the quoted trading price on the date of grant), volatility of 151.08%, expected term of 5 years, and a risk-free interest rate range of .98%. The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the nine months ended November 30, 2021 was $265,946. The total unamortized stock option expense at November 30, 2021 was $1,861,619.

   

Additional Paid-In Capital

 

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $6,441 during the period ended November 30, 2021. During the period ended November 30, 2021, former related party Paul Moody paid expenses on behalf of the Company totaling $500.

 

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $1,185 during the period ended February 28, 2021.

 

The $8,126 in total payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

 

11

 

 

Note 7 - Related-Party Transactions

 

Loan to Company

 

During the period ended November 30, 2021, our CEO, Ian James, paid expenses on behalf of the Company totaling $65 and shareholder, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totaling $156,691. These payments are considered as loans to the Company, which are noninterest-bearing, unsecured and payable on demand.

  

Note 8 - Subsequent Events

 

On December 3, 2021, the Company executed an Amended and Corrected Equity Purchase Agreement (the “Equity Purchase Agreement”) with Williamsburg Venture Holdings LLC, a Nevada limited liability Company (“WVH”). The Equity Purchase Agreement provides that WVH shall purchase from the Company, upon the filing of a Current Report on Form 8-K regarding the Company ceasing to be a “shell” company and on the approval of an uplisting to the OTCQB or higher market, $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s common stock as reported by the OTC Markets Group.  The Equity Purchase Agreement also provides that, upon the filing of a registration statement on Form S-1 covering all the shares sold to WVH under the Equity Purchase Agreement and related Amended and Corrected Registration Rights Agreement (the “Registration Rights Agreement”), WVH shall purchase an additional $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s common stock as reported by the OTC Markets Group.

 

On December 3, 2021, the Company also executed the Registration Rights Agreement with WVH.  Under the terms and conditions of the Registration Rights Agreement, and to induce WVH to enter into the Equity Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended (the “Securities Act”).  The Registration Rights agreement provides that the Company shall, on or before the one hundred and eightieth (180th) day after December 3, 2021, file with the SEC a prospectus supplement on effective Form S-1 covering the maximum number of Registrable Securities (as defined therein) as shall be permitted to be included thereon in accordance with applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the WVH, including but not limited to under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices), as mutually determined by both the Company and the WVH (the “Initial Registration Statement”). The Initial Registration Statement shall register only Registrable Securities. The Company shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment thereto declared effective by the SEC at the earliest possible date (in any event, within ninety (90) calendar days after the filing date of the Initial Registration Statement).  The Registration Rights Agreement also provides that the Company is obligated to file additional registration statements under certain circumstances.

 

12

 

   

ITEM 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.”

 

These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.

 

Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

 

Company Overview

 

Corporate History

 

Better For You Wellness, Inc. (we, us, our, the “Company” or the “Registrant”), formerly known as Fast Track Solutions, Inc., was incorporated in the State of Nevada on December 1, 2020.

 

On January 28, 2021, as a result of an Application for Custodianship granted by the Eighth Judicial District Court, Clark County Nevada, styled as “In the matter of: Sauer Energy, Inc., a Nevada corporation, Case Number: A-20-826848-P”, Jeffrey DeNunzio was appointed Custodian of Sauer Energy, Inc. (the “Predecessor”).

 

On April 26, 2021, the Company entered into a “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Better For You Wellness, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Jeffrey DeNunzio was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021 at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Better For You Wellness, Inc.’s (“Successors”) common stock.

 

13

 

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we cancelled all of the stock we held in Sauer Energy, Inc. resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

On July 19, 2021, Fast Track Solutions entered into a Share Purchase Agreement by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021, CRS sold 700,000 shares of the Fast Track Solutions’ Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of Fast Track Solutions; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000). The consummation of the transactions contemplated by this Share Purchase Agreement resulted in a change in control of Fast Track Solutions, with Ian James, Stephen Letourneau and GOHV becoming the largest controlling stockholders.

 

Ian James and Stephen Letourneau retained a majority of the membership interests (collectively constituting approximately 84.12%) of GOVH.

 

On July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer. In addition, Mr. DeNunzio resigned as Director on July 30, 2021. Mr. Ian James was also appointed as the Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors, and Mr. Stephen Letourneau was appointed Director. The resignation of Mr. DeNunzio was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices. .

 

On August 18, 2021, a Certificate of Amendment to change our name to “Better For You Wellness, Inc.” was filed with the Nevada Secretary of State.

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company.

 

On September 17, 2021, we entered into “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital. Pursuant to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.

 

14

 

 

On September 17, 2021, we entered into an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

On September 17, 2021, we entered into another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case by case basis, as may be requested by the Company.

 

On September 17, 2021, Mr. David H. Deming was appointed Secretary of the Company’s Board of Directors.

 

On September 17, 2021, we engaged Carter Ledyard Milburn LLP as the Company’s legal counsel going forward, to be consulted on a case by case basis as may be necessary. Any future legal fees that may be incurred are to be billed hourly and may not be static. We believe legal counsel to be important to the growth of the Company going forward.

 

On September 30, 2021, we began trading under the symbol BFYW. The new CUSIP number associated with our common stock is 08771B105.

 

On November 18, 2021, Ms. Leslie Bumgarner advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective upon December 31, 2021.The resignation of Ms. Bumgarner was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On December 3, 2021, the Company executed an Amended and Corrected Equity Purchase Agreement (the “Equity Purchase Agreement”) with Williamsburg Venture Holdings LLC, a Nevada limited liability Company (“WVH”). The Equity Purchase Agreement provides that WVH shall purchase from the Company, upon the filing of a Current Report on Form 8-K regarding the Company ceasing to be a “shell” company and on the approval of an uplisting to the OTCQB or higher market, $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s common stock as reported by the OTC Markets Group.  The Equity Purchase Agreement also provides that, upon the filing of a registration statement on Form S-1 covering all the shares sold to WVH under the Equity Purchase Agreement and related Amended and Corrected Registration Rights Agreement (the “Registration Rights Agreement”), WVH shall purchase an additional $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s common stock as reported by the OTC Markets Group.

 

On December 3, 2021, the Company also executed the Registration Rights Agreement with WVH.  Under the terms and conditions of the Registration Rights Agreement, and to induce WVH to enter into the Equity Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act.  The Registration Rights agreement provides that the Company shall, on or before the one hundred and eightieth (180th) day after December 3, 2021, file with the SEC a prospectus supplement on effective Form S-1 covering the maximum number of Registrable Securities (as defined therein) as shall be permitted to be included thereon in accordance with applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the WVH, including but not limited to under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices), as mutually determined by both the Company and the WVH (the “Initial Registration Statement”). The Initial Registration Statement shall register only Registrable Securities. The Company shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment thereto declared effective by the SEC at the earliest possible date (in any event, within ninety (90) calendar days after the filing date of the Initial Registration Statement). The Registration Rights Agreement also provides that the Company is obligated to file additional registration statements under certain circumstances.

 

15

 

 

On December 6, 2021, we announced that the Company has formed a wholly-owned subsidiary, Glow Market LLC (“Glow Market”), an Ohio Limited Liability Company, to build and operate digitally-native, mission-driven brands within the clean beauty sector in multiple consumer product categories. The Company’s subsidiary, Glow Market, has launched its first brand, Better Suds, an impact-driven brand that sells cruelty-free natural soap. Better Suds is committed to positively impacting the environment by removing 1 pound of plastic from the ocean for every soap sold through donations to Ocean Blue Project Inc., which is a 501(c)(3) organization removes plastics from oceans and waterways.

 

With the Company’s launch of Glow Market and Better Suds, we announced that the Company has ceased to be a shell company, as defined in Rule 12b-2 under the Exchange Act, and is no longer a blank-check company.

 

On December 9, 2021, we announced that the Company has submitted an application to the OTC Markets Group to up-list its common stock for trading on the OTC Markets Venture Market, or the OTCQB, and pending the completion of the application process and its acceptance by the OTC Markets Group, the Company expects that its common stock will begin trading on the OTCQB under the Company’s current ticker symbol “BFYW”.

 

On December 14, 2021, we appointed Christina Jefferson to the Board as an Independent Director, effective January 1, 2022, in order to replace Leslie Bumgarner whose resignation became effective December 31, 2021.

 

On December 15, 2021, we reported on a phased fundraising of up to $1,000,000 USD in a Private Placement Offering of restricted Common Stock to investors who qualify as “accredited investors”. The purpose of this phased Private Placement Offering is to bolster the Company’s balance sheet as it works towards finalizing and closing the acquisitions contemplated in the Company’s three previously announced Letters of Intent with Ironwood Clay Co., Mary Louise Cosmetics, and Cannuka.

 

ITEM 9.01. Financial Statements and Exhibits.

 

The Company has been engaged in organizational efforts and obtaining initial financing. The Company was formed as a vehicle to pursue a business combination. The business purpose of the Company is to seek the acquisition of or merger with, an existing company.

 

The Company is an “emerging growth company” (“EGC”), that is exempt from certain financial disclosure and governance requirements for up to five years as defined in the Jumpstart Our Business Startups Act (the JOBS Act), that eases restrictions on the sale of securities; and increases the number of shareholders a company must have before becoming subject to the U.S. Securities and Exchange Commissions (SEC’s) reporting and disclosure rules (See Emerging Growth Companies Section Below).

 

The Company has elected February 28th as its year end.

 

Liquidity and Capital Resources 

 

Our cash balance is $0 as of November 30, 2021. We have been utilizing funds, may continue to utilize funds, from Ian James, our Chief Executive Officer.

 

Mr. James has no formal commitment, arrangement or legal obligation to advance or loan funds to the company. In order to implement our plan of operations for the next twelve-month period, we may require further funding. Being a start-up stage company, we have very limited operating history. After a twelve-month period we may need additional financing but currently do not have any arrangements for such financing.

 

If we need additional cash and cannot raise it, we will either have to suspend operations until we do raise the cash we need, or cease operations entirely. 

 

16

 

 

Revenues 

 

The company has generated no revenue to date, as the company is currently a shell company. The Company’s current business plan is to explore and evaluate various business opportunities in the plant-based food, beverage, and consumer packaged goods (“CPG”) sectors including but not limited to mergers, acquisitions, or business combination transactions after which the Company would cease to be a “shell” or “blank check” company.

 

Net Income

 

We recorded a net loss of $1,066,097and $1,152,153, respectively, for the three and nine months ended November 30, 2021.  

 

Cash flow

 

For the nine months ended November 30, 2021, we had negative cash flows from operating activities in the amount of $163,697.

 

Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

 

COVID-19

 

An outbreak of infectious respiratory illness caused by a novel coronavirus known as COVID-19 spread globally in 2020. This outbreak resulted in travel restrictions, closed international borders, enhanced health screenings at ports of entry and elsewhere, disruption of and delays in healthcare service preparation and delivery, prolonged quarantines, cancellations, supply chain disruptions, and lower consumer demand, layoffs, defaults and other significant economic impacts, as well as general concern and uncertainty.

 

Our operations have not been materially impacted by the pandemic in 2021. 

 

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

  

17

 

 

ITEM 4 CONTROLS AND PROCEDURES

 

Management’s Report on Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and our chief financial officer (who is acting as our principal executive officer, principal financial officer and principle accounting officer) to allow for timely decisions regarding required disclosure.

 

As of November 30, 2021, we carried out an evaluation, under the supervision of our chief executive officer, with the participation of our chief financial officer, of the effectiveness of the design and the operation of our disclosure controls and procedures. The officers concluded that the disclosure controls and procedures were not effective as of the end of the period covered by this report due to material weaknesses identified below. 

 

The matters involving internal controls and procedures that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: domination of management by a single individual without adequate compensating controls, and lack of an audit committee. These material weaknesses were identified by our Chief Executive Officer who also serves as our Chief Financial Officer in connection with the above evaluation.

 

Inherent limitations on effectiveness of controls

 

Internal control over financial reporting has inherent limitations which include but is not limited to the use of independent professionals for advice and guidance, interpretation of existing and/or changing rules and principles, segregation of management duties, scale of organization, and personnel factors. Internal control over financial reporting is a process which involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements on a timely basis, however these inherent limitations are known features of the financial reporting process and it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal controls over financial reporting that have occurred for the fiscal quarter ended November 30, 2021, that have materially or are reasonably likely to materially affect, our internal controls over financial reporting.

   

18

 

 

PART II-OTHER INFORMATION

  

ITEM 1 LEGAL PROCEEDINGS

 

There are no legal proceedings against the Company and the Company is unaware of such proceedings contemplated against it.

 

ITEM 1A   RISK FACTORS

 

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item. 

 

ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3 DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4 MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5 OTHER INFORMATION

 

None.

 

ITEM 6 EXHIBITS

  

Exhibit No.   Description
     
3.1   Certificate of Incorporation (1)
     
3.11   Amendment to Certificate of Incorporation (2)
     
3.2   By-laws (1)
     
10.1   Amended and Corrected Equity Purchase Agreement by and between Better For You Wellness, Inc. and Williamsburg Venture Holdings LLC (3)
     

10.2

 

Amended and Corrected Registration Rights Agreement by and between Better For You Wellness, Inc. and Williamsburg Venture Holdings LLC (3) 

     
31   Certification of the Company’s Principal Executive and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s report on Form 10-Q for the period ended August 31, 2021 (4)
     
32   Certification of the Company’s Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (4)
     
101.INS   Inline XBRL Instance Document (5)
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document. (5)
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document. (5)
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document. (5)
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document. (5)
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.(5)
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).(5)

   

(1) Filed as an exhibit to the Company’s Form 10-12G, as filed with the SEC on March 23, 2021, and incorporated herein by this reference.
   
(2) Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on August 19, 2021, and incorporated herein by this reference.
   
(3) Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on December 8, 2021, and incorporated herein by this reference.
   
(4) Filed herewith.
   
(5) Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or Annual Report for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Exchange Act of 1934 and otherwise are not subject to liability.

 

19

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Better For You Wellness, Inc.
   

Date: January 6, 2022

By: /s/ Ian James
  Name: Ian James
  Title: Chief Executive Officer and Chief Financial Officer
   

(Principal Executive Officer)

(Principal Financial Officer)

(Principal Accounting Officer)

 

 

20

 

 

 

false --02-28 Q3 2022 0001852707 0001852707 2021-03-01 2021-11-30 0001852707 2022-01-01 0001852707 2021-11-30 0001852707 2021-02-28 0001852707 2021-09-01 2021-11-30 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-11-30 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2020-11-30 0001852707 us-gaap:RetainedEarningsMember 2020-11-30 0001852707 2020-11-30 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-12-01 2021-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-01 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2020-12-01 2021-02-28 0001852707 us-gaap:RetainedEarningsMember 2020-12-01 2021-02-28 0001852707 2020-12-01 2021-02-28 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001852707 us-gaap:RetainedEarningsMember 2021-02-28 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-03-01 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-03-01 2021-05-31 0001852707 2021-03-01 2021-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-05-31 0001852707 2021-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-06-01 2021-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-01 2021-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2021-08-31 0001852707 us-gaap:RetainedEarningsMember 2021-06-01 2021-08-31 0001852707 2021-06-01 2021-08-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001852707 us-gaap:RetainedEarningsMember 2021-08-31 0001852707 2021-08-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-09-01 2021-11-30 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-01 2021-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2021-11-30 0001852707 us-gaap:RetainedEarningsMember 2021-09-01 2021-11-30 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-11-30 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001852707 us-gaap:RetainedEarningsMember 2021-11-30 0001852707 bfyw:PredecessorsMember 2021-11-30 0001852707 bfyw:FastTrackSolutionsIncMember 2021-11-30 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-18 0001852707 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-19 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:CommonStockMember 2021-07-19 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember bfyw:CRSConsultingsLLCMember 2021-07-19 0001852707 bfyw:IanJamesMember us-gaap:SeriesAPreferredStockMember 2021-07-19 0001852707 bfyw:StephenLetourneauMember us-gaap:SeriesAPreferredStockMember 2021-07-19 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-19 0001852707 bfyw:PurchasePriceMember 2021-07-01 2021-07-19 0001852707 bfyw:PurchasePriceMember 2021-07-19 0001852707 bfyw:MRKTSGroupIncMember 2021-08-01 2021-08-24 0001852707 bfyw:PurchasePriceMember bfyw:MRKTSGroupIncMember 2021-08-24 0001852707 bfyw:BetterForYouWellnessIncMember 2021-08-01 2021-08-25 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-08-25 0001852707 2021-08-01 2021-08-27 0001852707 bfyw:WilliamsburgVentureHoldingsLLCMember 2021-09-01 2021-09-17 0001852707 2021-09-01 2021-09-17 0001852707 2021-09-17 0001852707 bfyw:SRAXIncMember 2021-09-01 2021-09-17 0001852707 bfyw:CRSConsultingLLCMember us-gaap:SeriesAPreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2021-03-01 2021-11-30 0001852707 us-gaap:SeriesAPreferredStockMember 2021-11-30 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-01 2021-07-19 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-23 2021-08-25 0001852707 bfyw:CRSConsultingLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:SRAXIncMember 2021-10-01 2021-10-11 0001852707 bfyw:CRSConsultingLLCMember 2021-10-01 2021-10-11 0001852707 2021-10-01 2021-10-11 0001852707 2021-11-01 2021-11-17 0001852707 2021-09-01 2021-09-30 0001852707 bfyw:JeffreyDeNunzioMember 2021-03-01 2021-11-30 0001852707 bfyw:PaulMoodyMember 2021-03-01 2021-11-30 0001852707 bfyw:JeffreyDeNunzioMember 2021-02-01 2021-02-28 0001852707 bfyw:IanJamesMember 2021-03-01 2021-11-30 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-03-01 2021-11-30 0001852707 us-gaap:SubsequentEventMember 2021-12-01 2021-12-03 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-31 2 f10q1121ex31_betterfor.htm CERTIFICATION

EXHIBIT 31

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

 

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

 

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Ian James, certify that:

 

1. I have reviewed this report on Form 10-Q of Better For You Wellness, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

 

4. The small business issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The small business owner’s other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small issuer’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting.

 

Date: January 6, 2022

 

/s/ Ian James
  Ian James
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 

  

CERTIFICATION OF CHIEF FINANCIAL OFFICER

 

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

 

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Ian James, certify that:

 

1.I have reviewed this report on Form 10-Q of Better For You Wellness, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

 

4.The small business issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:

 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.Evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The small business owner’s other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small issuer’s board of directors (or persons performing the equivalent functions):

 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and

 

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting.

 

Date: January 6, 2022

 

  /s/ Ian James
  Ian James
  Chief Financial Officer
  (Principal Financial Officer)

 

 

 

EX-32 3 f10q1121ex32_betterfor.htm CERTIFICATION

EXHIBIT 32

 

CERTIFICATION PURSUANT TO

 

18 U.S.C. SECTION 1350

 

AS ADOPTED PURSUANT TO

 

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Better For You Wellness, Inc. (the “Company”) on Form 10-Q for the quarterly period ended November 30, 2021, as filed with the Securities and Exchange Commission (the “Report”), I, Ian James, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

A signed original of this written statement required by Section 906 has been provided to Ian James and will be retained by Better For You Wellness, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

Date: January 6, 2022

 

  /s/ Ian James
  Ian James
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 

  

CERTIFICATION PURSUANT TO

 

18 U.S.C. SECTION 1350

 

AS ADOPTED PURSUANT TO

 

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Better For You Wellness, Inc. (the “Company”) on Form 10-Q for the quarterly period ended November 30, 2021, as filed with the Securities and Exchange Commission (the “Report”), I, Ian James, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

A signed original of this written statement required by Section 906 has been provided to Ian James and will be retained by Better For You Wellness, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

Date: January 6, 2022

 

  /s/ Ian James
  Ian James
  Chief Financial Officer
  (Principal Financial Officer)

 

 

 

EX-101.SCH 4 bfyw-20211130.xsd XBRL SCHEMA FILE 001 - Statement - Balance Sheet link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Balance Sheet (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Statement of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Statement of Changes in Stockholders’ Equity (Deficit) (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statement of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Organization and Description of Business link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Shareholder Equity link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Related-Party Transactions link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Shareholder Equity (Details) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 5 bfyw-20211130_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 bfyw-20211130_def.xml XBRL DEFINITION FILE EX-101.LAB 7 bfyw-20211130_lab.xml XBRL LABEL FILE EX-101.PRE 8 bfyw-20211130_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document And Entity Information - shares
9 Months Ended
Nov. 30, 2021
Jan. 01, 2022
Document Information Line Items    
Entity Registrant Name Better For You Wellness, Inc.  
Document Type 10-Q  
Current Fiscal Year End Date --02-28  
Entity Common Stock, Shares Outstanding   370,072,945
Amendment Flag false  
Entity Central Index Key 0001852707  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Nov. 30, 2021  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Shell Company false  
Entity Ex Transition Period false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-56262  
Entity Incorporation, State or Country Code NV  
Entity Tax Identification Number 87-2903933  
Entity Address, Address Line One 1349 East Broad Street  
Entity Address, City or Town Columbus  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 43205  
City Area Code (614)  
Local Phone Number 368-9898  
Entity Interactive Data Current Yes  
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.21.4
Balance Sheet - USD ($)
Nov. 30, 2021
Feb. 28, 2021
Statement of Financial Position [Abstract]    
TOTAL ASSETS
CURRENT LIABILITIES    
Loans to Company – related party 156,756
Accrued Expenses 117,017 3,750
TOTAL LIABILITIES 273,773 3,750
Stockholders’ Equity (Deficit)    
Preferred stock ($.0001 par value, 200,000,000 shares authorized; 700,000 and 0 issued and outstanding as of November 30, 2021 and February 28, 2021, respectively) 70
Common stock ($.0001 par value, 500,000,000 shares authorized, 363,024,072 and 0 issued and outstanding as of November 30, 2021 and February 28, 2021,respectively) 36,302
Additional paid-in capital 846,943 1,185
Accumulated deficit (1,157,088) (4,935)
Total Stockholders’ Equity (Deficit) (273,773) (3,750)
TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.21.4
Balance Sheet (Parentheticals) - $ / shares
Nov. 30, 2021
Feb. 28, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 200,000,000 200,000,000
Preferred stock, shares issued 700,000 0
Preferred stock, shares outstanding 700,000 0
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 363,024,072 0
Common stock, shares outstanding 363,024,072 0
XML 12 R4.htm IDEA: XBRL DOCUMENT v3.21.4
Statement of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Nov. 30, 2021
Nov. 30, 2021
Operating Expenses:    
Selling, general and administrative expenses $ 533,854 $ 542,910
Share-based expense 532,243 609,243
Total operating expenses 1,066,097 1,152,153
Net loss $ (1,066,097) $ (1,152,153)
Basic and Diluted net loss per common share (in Dollars per share) $ 0 $ 0
Weighted average number of common shares outstanding - Basic and Diluted (in Shares) 361,664,351 287,241,405
XML 13 R5.htm IDEA: XBRL DOCUMENT v3.21.4
Statement of Changes in Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
Common
Shares
Series A
Preferred Shares
Additional Paid-in Capital
Accumulated Deficit
Total
Balances at Nov. 30, 2020
Balances (in Shares) at Nov. 30, 2020      
Expenses paid on behalf of the Company and contributed to capital 1,185 1,185
Net loss (4,935) (4,935)
Balances at Feb. 28, 2021 1,185 (4,935) (3,750)
Balances (in Shares) at Feb. 28, 2021      
Common shares issued after reorganization $ 36,000 (36,000)
Common shares issued after reorganization (in Shares) 359,996,332      
Preferred shares issued after reorganization $ 70 69,930 70,000
Preferred shares issued after reorganization (in Shares)   700,000      
Expenses paid on behalf of the Company and contributed to capital 3,951 3,951
Net loss (72,051) (72,051)
Balances at May. 31, 2021 $ 36,000 $ 70 39,607 (76,986) (1,850)
Balances (in Shares) at May. 31, 2021 359,996,332 700,000      
Common share issued for services to the Company $ 5 6,995 7,000
Common share issued for services to the Company (in Shares) 50,000      
Expenses paid on behalf of the Company and contributed to capital 2,990 2,990
Net loss (14,005) (14,005)
Balances at Aug. 31, 2021 $ 36,005 $ 70 49,052 (90,992) (5,865)
Balances (in Shares) at Aug. 31, 2021 360,046,332 700,000      
Common share issued for services to the Company $ 298 531,945 532,243
Common share issued for services to the Company (in Shares) 2,977,740      
Stock options expense 265,946 265,946
Net loss (1,066,097) (1,066,097)
Balances at Nov. 30, 2021 $ 36,302 $ 70 $ 846,943 $ (1,157,088) $ (273,773)
Balances (in Shares) at Nov. 30, 2021 363,024,072 700,000      
XML 14 R6.htm IDEA: XBRL DOCUMENT v3.21.4
Statement of Cash Flows (Unaudited)
9 Months Ended
Nov. 30, 2021
USD ($)
CASH FLOWS FROM OPERATING ACTIVITIES  
Net loss $ (1,152,153)
Adjustment to reconcile net loss to net cash used in operating activities:  
Common stock issued 539,243
Preferred stock issued 70,000
Stock options expense 265,946
Changes in current assets and liabilities:  
Accrued expenses 113,267
Net cash used in operating activities (163,697)
CASH FLOWS FROM FINANCING ACTIVITIES  
Expenses contributed to capital 6,941
Loan to company – related party 156,756
Net cash provided by financing activities 163,697
Net change in cash
Beginning cash balance
Ending cash balance
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:  
Interest paid 0
Income taxes paid $ 0
XML 15 R7.htm IDEA: XBRL DOCUMENT v3.21.4
Organization and Description of Business
9 Months Ended
Nov. 30, 2021
Accounting Policies [Abstract]  
Organization and Description of Business

Note 1 - Organization and Description of Business

 

Better For You Wellness, Inc. (we, us, our, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we cancelled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.

 

The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time

 

After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.

 

On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.

 

Pursuant to the Agreement, on July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.

 

On July 30, 2021, Mr. Ian James was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors and Mr. Stephen Letourneau was appointed as a Director.

 

On August 18, 2021, we filed an amendment to the Company’s Articles of Incorporation with the Nevada Secretary of State to change our name to Better For You Wellness, Inc. On September 30, 2021, we began trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company. On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per quarter, paid in equal distributions quarterly, 200,000 shares of common stock issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. The Directors were officially seated September 12, 2021, after notification to shareholders. 

 

The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.

The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.

 

The Company has elected February 28th as its year end.

 

As of November 30, 2021, the Company had not yet commenced operations.

XML 16 R8.htm IDEA: XBRL DOCUMENT v3.21.4
Summary of Significant Accounting Policies
9 Months Ended
Nov. 30, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at November 30, 2021 and February 28, 2021 were $0 for both periods. 

 

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.”  Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs.  A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at November 30, 2021.

 

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company does not have any potentially dilutive instruments as of November 30, 2021 and, thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.  

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of November 30, 2021. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

 

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

 

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.”  Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:  (a) the goods or services received; or (b) the equity instruments issued.  The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.  

 

The Company had no stock-based compensation plans as of November 30, 2021 and February 28, 2021.

 

The Company’s stock-based compensation for the periods ended November 30, 2021 and February 28, 2021 was $609,243 and $0, respectively.

 

Recently Issued Accounting Pronouncements

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 is amended by ASU 2018-01, ASU2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01, which FASB issued in January 2018, July 2018, July 2018, December 2018 and March 2019, respectively (collectively, the amended ASU 2016-02). The amended ASU 2016-02 requires lessees to recognize on the balance sheet a right-of-use asset, representing its right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from current GAAP. The amended ASU 2016-02 retains a distinction between finance leases (i.e. capital leases under current GAAP) and operating leases. The classification criteria for distinguishing between finance leases and operating leases will be substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current GAAP. The amended ASU 2016-02 also requires qualitative and quantitative disclosures designed to assess the amount, timing, and uncertainty of cash flows arising from leases. A modified retrospective transition approach is permitted to be used when an entity adopts the amended ASU 2016-02, which includes a number of optional practical expedients that entities may elect to apply.

 

We have no assets and or leases and do not believe we will be impacted in the foreseeable future by the newly adopted accounting standard(s) mentioned above.

 

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

XML 17 R9.htm IDEA: XBRL DOCUMENT v3.21.4
Going Concern
9 Months Ended
Nov. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

Note 3 - Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The Company has not established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

XML 18 R10.htm IDEA: XBRL DOCUMENT v3.21.4
Income Taxes
9 Months Ended
Nov. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

Note 4 - Income Taxes

 

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. As of November 30, 2021, the Company has incurred a net loss of approximately $1,157,088 which resulted in a net operating loss for income tax purposes.  The loss results in a deferred tax asset of approximately $242,988 at the effective statutory rate of 21%. The deferred tax asset has been offset by an equal valuation allowance. Given our inception on December 1, 2020, and our fiscal year end of February 28, 2021, we have completed only one taxable fiscal year.

XML 19 R11.htm IDEA: XBRL DOCUMENT v3.21.4
Commitments and Contingencies
9 Months Ended
Nov. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 5 - Commitments and Contingencies

 

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies.  Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of November 30, 2021 other than the following:

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital. Pursuant to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

XML 20 R12.htm IDEA: XBRL DOCUMENT v3.21.4
Shareholder Equity
9 Months Ended
Nov. 30, 2021
Stockholders' Equity Note [Abstract]  
Shareholder Equity

Note 6 - Shareholder Equity

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 and 0 shares issued and outstanding as of November 30, 2021 and February 28, 2021, respectively.

 

During the three months ended May 31, 2021, 700,000 shares of Series A Preferred Stock were issued to CRS Consulting, LLC (“CRS”), a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody. CRS is our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock. Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. On July 19, 2021, these shares were purchased. As of November 30, 2021, our CEO, Ian James, and Director, Stephen Letourneau, each hold 350,000 shares of Series A Preferred Stock (See Note 1).

 

Common Stock

 

The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 363,024,072 and 0 shares of common stock issued and outstanding as of November 30, 2021 and February 28, 2021, respectively.

 

At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.

 

On July 19, 2021, 250,000,000 shares of Restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).

 

On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $7,000.

 

On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $468,493.

 

On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $45,000.

 

On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $18,750.

 

Stock Options

 

During the nine months ended November 30, 2021, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 2,500,000 fully vested on September 30, 2021. 17,500,000 shares vest over the next 2 years, 2,500,000 shares per quarter. The options have the exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options as of November 30, 2021, was $0.

 

The Company fair valued the options on the grant date at $2,127,565 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 per share (based on the quoted trading price on the date of grant), volatility of 151.08%, expected term of 5 years, and a risk-free interest rate range of .98%. The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the nine months ended November 30, 2021 was $265,946. The total unamortized stock option expense at November 30, 2021 was $1,861,619.

   

Additional Paid-In Capital

 

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $6,441 during the period ended November 30, 2021. During the period ended November 30, 2021, former related party Paul Moody paid expenses on behalf of the Company totaling $500.

 

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $1,185 during the period ended February 28, 2021.

 

The $8,126 in total payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

XML 21 R13.htm IDEA: XBRL DOCUMENT v3.21.4
Related-Party Transactions
9 Months Ended
Nov. 30, 2021
Related Party Transactions [Abstract]  
Related-Party Transactions

Note 7 - Related-Party Transactions

 

Loan to Company

 

During the period ended November 30, 2021, our CEO, Ian James, paid expenses on behalf of the Company totaling $65 and shareholder, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totaling $156,691. These payments are considered as loans to the Company, which are noninterest-bearing, unsecured and payable on demand.

XML 22 R14.htm IDEA: XBRL DOCUMENT v3.21.4
Subsequent Events
9 Months Ended
Nov. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events

Note 8 - Subsequent Events

 

On December 3, 2021, the Company executed an Amended and Corrected Equity Purchase Agreement (the “Equity Purchase Agreement”) with Williamsburg Venture Holdings LLC, a Nevada limited liability Company (“WVH”). The Equity Purchase Agreement provides that WVH shall purchase from the Company, upon the filing of a Current Report on Form 8-K regarding the Company ceasing to be a “shell” company and on the approval of an uplisting to the OTCQB or higher market, $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s common stock as reported by the OTC Markets Group.  The Equity Purchase Agreement also provides that, upon the filing of a registration statement on Form S-1 covering all the shares sold to WVH under the Equity Purchase Agreement and related Amended and Corrected Registration Rights Agreement (the “Registration Rights Agreement”), WVH shall purchase an additional $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s common stock as reported by the OTC Markets Group.

 

On December 3, 2021, the Company also executed the Registration Rights Agreement with WVH.  Under the terms and conditions of the Registration Rights Agreement, and to induce WVH to enter into the Equity Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended (the “Securities Act”).  The Registration Rights agreement provides that the Company shall, on or before the one hundred and eightieth (180th) day after December 3, 2021, file with the SEC a prospectus supplement on effective Form S-1 covering the maximum number of Registrable Securities (as defined therein) as shall be permitted to be included thereon in accordance with applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the WVH, including but not limited to under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices), as mutually determined by both the Company and the WVH (the “Initial Registration Statement”). The Initial Registration Statement shall register only Registrable Securities. The Company shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment thereto declared effective by the SEC at the earliest possible date (in any event, within ninety (90) calendar days after the filing date of the Initial Registration Statement).  The Registration Rights Agreement also provides that the Company is obligated to file additional registration statements under certain circumstances.

XML 23 R15.htm IDEA: XBRL DOCUMENT v3.21.4
Accounting Policies, by Policy (Policies)
9 Months Ended
Nov. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at November 30, 2021 and February 28, 2021 were $0 for both periods. 

 

Income Taxes

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.”  Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs.  A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at November 30, 2021.

 

Basic Earnings (Loss) Per Share

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company does not have any potentially dilutive instruments as of November 30, 2021 and, thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.  

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of November 30, 2021. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

 

Related Parties

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

Share-Based Compensation

 

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.”  Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:  (a) the goods or services received; or (b) the equity instruments issued.  The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.  

 

The Company had no stock-based compensation plans as of November 30, 2021 and February 28, 2021.

 

The Company’s stock-based compensation for the periods ended November 30, 2021 and February 28, 2021 was $609,243 and $0, respectively.

 

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 is amended by ASU 2018-01, ASU2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01, which FASB issued in January 2018, July 2018, July 2018, December 2018 and March 2019, respectively (collectively, the amended ASU 2016-02). The amended ASU 2016-02 requires lessees to recognize on the balance sheet a right-of-use asset, representing its right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from current GAAP. The amended ASU 2016-02 retains a distinction between finance leases (i.e. capital leases under current GAAP) and operating leases. The classification criteria for distinguishing between finance leases and operating leases will be substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current GAAP. The amended ASU 2016-02 also requires qualitative and quantitative disclosures designed to assess the amount, timing, and uncertainty of cash flows arising from leases. A modified retrospective transition approach is permitted to be used when an entity adopts the amended ASU 2016-02, which includes a number of optional practical expedients that entities may elect to apply.

 

We have no assets and or leases and do not believe we will be impacted in the foreseeable future by the newly adopted accounting standard(s) mentioned above.

 

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

XML 24 R16.htm IDEA: XBRL DOCUMENT v3.21.4
Organization and Description of Business (Details) - USD ($)
1 Months Ended
Aug. 27, 2021
Aug. 25, 2021
Aug. 24, 2021
Jul. 19, 2021
Jul. 18, 2021
Nov. 30, 2021
Feb. 28, 2021
Organization and Description of Business (Details) [Line Items]              
Shares of common stock           363,024,072 0
Shareholder owning preferred stock           700,000 0
Independent director agreements, description Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company. On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per quarter, paid in equal distributions quarterly, 200,000 shares of common stock issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share.            
Series of Individually Immaterial Business Acquisitions [Member]              
Organization and Description of Business (Details) [Line Items]              
Owning, percentage   5.00%          
Purchase Price [Member]              
Organization and Description of Business (Details) [Line Items]              
Voting percentage       89.62%      
Paid consideration (in Dollars)       $ 335,000      
Fast Track Solutions, Inc. [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of common stock           1,000  
Predecessor [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of common stock           1,000  
CRS Consulting, LLC [Member] | Series of Individually Immaterial Business Acquisitions [Member]              
Organization and Description of Business (Details) [Line Items]              
Voting percentage       89.62%      
Green Ohio Ventures, LLC [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of common stock       250,000,000      
MRKTS Group Inc [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of restricted common stock     17,963,817        
MRKTS Group Inc [Member] | Purchase Price [Member]              
Organization and Description of Business (Details) [Line Items]              
Owning, percentage     5.00%        
Better for You Wellness, Inc. [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of restricted common stock   24,137,499          
Common Stock [Member] | CRS Consulting, LLC [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of common stock       250,000,000      
Series A Preferred Stock [Member]              
Organization and Description of Business (Details) [Line Items]              
Shareholder owning preferred stock           350,000  
Shares of restricted common stock         250,000,000    
Series A Preferred Stock [Member] | CRS Consulting, LLC [Member]              
Organization and Description of Business (Details) [Line Items]              
Shareholder owning preferred stock         700,000    
Sale of shares       700,000      
Series A Preferred Stock [Member] | Ian James [Member]              
Organization and Description of Business (Details) [Line Items]              
Transfer of shares       350,000      
Series A Preferred Stock [Member] | Stephen Letourneau [Member]              
Organization and Description of Business (Details) [Line Items]              
Transfer of shares       350,000      
XML 25 R17.htm IDEA: XBRL DOCUMENT v3.21.4
Summary of Significant Accounting Policies (Details) - USD ($)
Nov. 30, 2021
Feb. 28, 2021
Accounting Policies [Abstract]    
Cash and cash equivalents $ 0 $ 0
Stock-based compensation $ 609,243 $ 0
XML 26 R18.htm IDEA: XBRL DOCUMENT v3.21.4
Income Taxes (Details)
9 Months Ended
Nov. 30, 2021
USD ($)
Income Tax Disclosure [Abstract]  
Net loss $ 1,157,088
Deferred tax asset $ 242,988
Effective statutory rate 21.00%
XML 27 R19.htm IDEA: XBRL DOCUMENT v3.21.4
Commitments and Contingencies (Details)
1 Months Ended
Sep. 17, 2021
USD ($)
shares
Commitments and Contingencies (Details) [Line Items]  
Common stock discount, percentage 15.00%
Outstanding percentage 4.99%
Williamsburg Venture Holdings LLC [Member]  
Commitments and Contingencies (Details) [Line Items]  
Purchase of common stock value $ 30,500,000
Associated expenses $ 15,000
Purchase of restricted common stock (in Shares) | shares 250,000
SRAX, Inc [Member]  
Commitments and Contingencies (Details) [Line Items]  
Amount paid $ 20,000
XML 28 R20.htm IDEA: XBRL DOCUMENT v3.21.4
Shareholder Equity (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 11, 2021
Aug. 25, 2021
Nov. 17, 2021
Sep. 30, 2021
Aug. 24, 2021
Jul. 19, 2021
Feb. 28, 2021
May 31, 2021
Nov. 30, 2021
Shareholder Equity (Details) [Line Items]                  
Preferred stock, shares authorized             200,000,000   200,000,000
Preferred stock, par value (in Dollars per share)             $ 0.0001   $ 0.0001
Preferred stock, shares issued             0   700,000
Preferred stock, shares outstanding             0   700,000
Preferred Stock, Voting Rights                 Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock.
Common stock, shares authorized             500,000,000   500,000,000
Common stock, par value (in Dollars per share)             $ 0.0001   $ 0.0001
Common stock, shares issued             0   363,024,072
Common stock, shares outstanding             0   363,024,072
Common shares outstanding                 359,996,332
Restricted common stock     125,000            
Closing share price (in Dollars) $ 45,000   $ 18,750            
Grant option exercisable                 20,000,000
Number of vested shares       2,500,000          
Stock option description                 17,500,000 shares vest over the next 2 years, 2,500,000 shares per quarter.
Stock option exercise price (in Dollars per share)                 $ 25
Stock option expire                 5 years
Stock option outstanding intrinsic value (in Dollars)                 $ 0
Stock options fair value the grant date (in Dollars per share)                 $ 2,127,565
Stock price (in Dollars per share)                 $ 15
Volatility                 151.08%
Expected term                 5 years
Risk free interest rate range                 98.00%
The total stock option expense (in Dollars)                 $ 265,946
Total unamortized stock option expense (in Dollars)                 1,861,619
Total payments considered contributions (in Dollars)                 8,126
CRS Consulting, LLC [Member]                  
Shareholder Equity (Details) [Line Items]                  
Restricted common stock 250,000       50,000        
Closing share price (in Dollars)         $ 7,000        
Green Ohio Ventures, LLC [Member]                  
Shareholder Equity (Details) [Line Items]                  
Common stock, shares issued           250,000,000      
Restricted common stock   24,137,499     17,963,817 250,000,000      
Paid expenses (in Dollars)                 156,691
SRAX, Inc [Member]                  
Shareholder Equity (Details) [Line Items]                  
Restricted common stock 2,602,740                
Closing share price (in Dollars) $ 468,493                
Paul Moody [Member]                  
Shareholder Equity (Details) [Line Items]                  
Paid expenses (in Dollars)                 500
Jeffrey DeNunzio [Member]                  
Shareholder Equity (Details) [Line Items]                  
Paid expenses (in Dollars)             $ 1,185   $ 6,441
Series A Preferred Stock [Member]                  
Shareholder Equity (Details) [Line Items]                  
Preferred stock, shares issued                 350,000
Series A preferred stock were issued                 700,000
Shares of restricted common stock                 250,000,000
Series A Preferred Stock [Member] | CRS Consulting, LLC [Member]                  
Shareholder Equity (Details) [Line Items]                  
Series A preferred stock were issued               700,000  
XML 29 R21.htm IDEA: XBRL DOCUMENT v3.21.4
Related-Party Transactions (Details)
9 Months Ended
Nov. 30, 2021
USD ($)
Ian James [Member]  
Related-Party Transactions (Details) [Line Items]  
Paid expenses $ 65
Green Ohio Ventures, LLC [Member]  
Related-Party Transactions (Details) [Line Items]  
Paid expenses $ 156,691
XML 30 R22.htm IDEA: XBRL DOCUMENT v3.21.4
Subsequent Events (Details)
Dec. 03, 2021
Subsequent Event [Member]  
Subsequent Events (Details) [Line Items]  
Equity purchase agreement, description the Company executed an Amended and Corrected Equity Purchase Agreement (the “Equity Purchase Agreement”) with Williamsburg Venture Holdings LLC, a Nevada limited liability Company (“WVH”). The Equity Purchase Agreement provides that WVH shall purchase from the Company, upon the filing of a Current Report on Form 8-K regarding the Company ceasing to be a “shell” company and on the approval of an uplisting to the OTCQB or higher market, $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s common stock as reported by the OTC Markets Group.  The Equity Purchase Agreement also provides that, upon the filing of a registration statement on Form S-1 covering all the shares sold to WVH under the Equity Purchase Agreement and related Amended and Corrected Registration Rights Agreement (the “Registration Rights Agreement”), WVH shall purchase an additional $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s common stock as reported by the OTC Markets Group.
XML 31 f10q1121_betterforyou_htm.xml IDEA: XBRL DOCUMENT 0001852707 2021-03-01 2021-11-30 0001852707 2022-01-01 0001852707 2021-11-30 0001852707 2021-02-28 0001852707 2021-09-01 2021-11-30 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-11-30 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2020-11-30 0001852707 us-gaap:RetainedEarningsMember 2020-11-30 0001852707 2020-11-30 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-12-01 2021-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-01 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2020-12-01 2021-02-28 0001852707 us-gaap:RetainedEarningsMember 2020-12-01 2021-02-28 0001852707 2020-12-01 2021-02-28 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001852707 us-gaap:RetainedEarningsMember 2021-02-28 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-03-01 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-03-01 2021-05-31 0001852707 2021-03-01 2021-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-05-31 0001852707 2021-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-06-01 2021-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-01 2021-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2021-08-31 0001852707 us-gaap:RetainedEarningsMember 2021-06-01 2021-08-31 0001852707 2021-06-01 2021-08-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001852707 us-gaap:RetainedEarningsMember 2021-08-31 0001852707 2021-08-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-09-01 2021-11-30 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-01 2021-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2021-11-30 0001852707 us-gaap:RetainedEarningsMember 2021-09-01 2021-11-30 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-11-30 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001852707 us-gaap:RetainedEarningsMember 2021-11-30 0001852707 bfyw:PredecessorsMember 2021-11-30 0001852707 bfyw:FastTrackSolutionsIncMember 2021-11-30 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-18 0001852707 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-19 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:CommonStockMember 2021-07-19 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember bfyw:CRSConsultingsLLCMember 2021-07-19 0001852707 bfyw:IanJamesMember us-gaap:SeriesAPreferredStockMember 2021-07-19 0001852707 bfyw:StephenLetourneauMember us-gaap:SeriesAPreferredStockMember 2021-07-19 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-19 0001852707 bfyw:PurchasePriceMember 2021-07-01 2021-07-19 0001852707 bfyw:PurchasePriceMember 2021-07-19 0001852707 bfyw:MRKTSGroupIncMember 2021-08-01 2021-08-24 0001852707 bfyw:PurchasePriceMember bfyw:MRKTSGroupIncMember 2021-08-24 0001852707 bfyw:BetterForYouWellnessIncMember 2021-08-01 2021-08-25 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-08-25 0001852707 2021-08-01 2021-08-27 0001852707 bfyw:WilliamsburgVentureHoldingsLLCMember 2021-09-01 2021-09-17 0001852707 2021-09-01 2021-09-17 0001852707 2021-09-17 0001852707 bfyw:SRAXIncMember 2021-09-01 2021-09-17 0001852707 bfyw:CRSConsultingLLCMember us-gaap:SeriesAPreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2021-03-01 2021-11-30 0001852707 us-gaap:SeriesAPreferredStockMember 2021-11-30 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-01 2021-07-19 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-23 2021-08-25 0001852707 bfyw:CRSConsultingLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:SRAXIncMember 2021-10-01 2021-10-11 0001852707 bfyw:CRSConsultingLLCMember 2021-10-01 2021-10-11 0001852707 2021-10-01 2021-10-11 0001852707 2021-11-01 2021-11-17 0001852707 2021-09-01 2021-09-30 0001852707 bfyw:JeffreyDeNunzioMember 2021-03-01 2021-11-30 0001852707 bfyw:PaulMoodyMember 2021-03-01 2021-11-30 0001852707 bfyw:JeffreyDeNunzioMember 2021-02-01 2021-02-28 0001852707 bfyw:IanJamesMember 2021-03-01 2021-11-30 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-03-01 2021-11-30 0001852707 us-gaap:SubsequentEventMember 2021-12-01 2021-12-03 shares iso4217:USD iso4217:USD shares pure 10-Q true 2021-11-30 false 000-56262 Better For You Wellness, Inc. NV 87-2903933 1349 East Broad Street Columbus OH 43205 (614) 368-9898 Yes Yes Non-accelerated Filer true true false false 370072945 156756 117017 3750 273773 3750 0.0001 0.0001 200000000 200000000 700000 700000 0 0 70 0.0001 0.0001 500000000 500000000 363024072 363024072 0 0 36302 846943 1185 -1157088 -4935 -273773 -3750 533854 542910 532243 609243 1066097 1152153 -1066097 -1152153 0 0 361664351 287241405 1185 1185 -4935 -4935 1185 -4935 -3750 359996332 36000 -36000 700000 70 69930 70000 3951 3951 -72051 -72051 359996332 36000 700000 70 39607 -76986 -1850 50000 5 6995 7000 2990 2990 -14005 -14005 360046332 36005 700000 70 49052 -90992 -5865 2977740 298 531945 532243 265946 265946 -1066097 -1066097 363024072 36302 700000 70 846943 -1157088 -273773 -1152153 539243 70000 265946 113267 -163697 6941 156756 163697 0 0 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Note 1 - Organization and Description of Business</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>Better For You Wellness, Inc. (we, us, our, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On May 5, 2021, after the completion of the Holding Company Reorganization, we cancelled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Pursuant to the Agreement, on July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On July 30, 2021, Mr. Ian James was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors and Mr. Stephen Letourneau was appointed as a Director.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August 18, 2021, we filed an amendment to the Company’s Articles of Incorporation with the Nevada Secretary of State to change our name to Better For You Wellness, Inc. On September 30, 2021, we began trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company. On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per quarter, paid in equal distributions quarterly, 200,000 shares of common stock issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. The Directors were officially seated September 12, 2021, after notification to shareholders. </span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"/><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company has elected February 28th as its year end.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>As of November 30, 2021, the Company had not yet commenced operations.</span></p> 1000 1000 700000 250000000 700000 250000000 0.8962 350000 350000 250000000 335000 0.8962 17963817 0.05 24137499 0.05 Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company. On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per quarter, paid in equal distributions quarterly, 200,000 shares of common stock issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Note 2 - Summary of Significant Accounting Policies</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Basis of Presentation</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Use of Estimates</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Cash and Cash Equivalents</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at November 30, 2021 and February 28, 2021 were $0 for both periods.<b> </b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Income Taxes</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b> </b></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company accounts for income taxes under ASC 740, “<i>Income Taxes</i>.”  Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs.  A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at November 30, 2021.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Basic Earnings (Loss) Per Share</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b> </b></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The Company does not have any potentially dilutive instruments as of November 30, 2021 and, thus, anti-dilution issues are not applicable.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Fair Value of Financial Instruments</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>ASC 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of November 30, 2021. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span><b>Related Parties</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The Company follows ASC 850, <i>Related Party Disclosures,</i> for the identification of related parties and disclosure of related party transactions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span><b>Share-Based Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>ASC 718, “<i>Compensation – Stock Compensation</i>”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “<i>Equity – Based Payments to Non-Employees.”</i>  Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:  (a) the goods or services received; or (b) the equity instruments issued.  The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.  </span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The Company had no stock-based compensation plans as of November 30, 2021 and February 28, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company’s stock-based compensation for the periods ended November 30, 2021 and February 28, 2021 was $609,243 and $0, respectively.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Recently Issued Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span>In February 2016, the FASB issued ASU 2016-02, <i>Leases (Topic 842). ASU 2016-02</i> is amended by ASU 2018-01, ASU2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01, which FASB issued in January 2018, July 2018, July 2018, December 2018 and March 2019, respectively (collectively, the amended ASU 2016-02). The amended ASU 2016-02 requires lessees to recognize on the balance sheet a right-of-use asset, representing its right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from current GAAP. The amended ASU 2016-02 retains a distinction between finance leases (i.e. capital leases under current GAAP) and operating leases. The classification criteria for distinguishing between finance leases and operating leases will be substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current GAAP. The amended ASU 2016-02 also requires qualitative and quantitative disclosures designed to assess the amount, timing, and uncertainty of cash flows arising from leases. A modified retrospective transition approach is permitted to be used when an entity adopts the amended ASU 2016-02, which includes a number of optional practical expedients that entities may elect to apply.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; "> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span>We have no assets and or leases and do not believe we will be impacted in the foreseeable future by the newly adopted accounting standard(s) mentioned above.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.</span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Basis of Presentation</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Use of Estimates</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Cash and Cash Equivalents</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at November 30, 2021 and February 28, 2021 were $0 for both periods.<b> </b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 0 0 <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Income Taxes</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b> </b></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company accounts for income taxes under ASC 740, “<i>Income Taxes</i>.”  Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs.  A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at November 30, 2021.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Basic Earnings (Loss) Per Share</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b> </b></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The Company does not have any potentially dilutive instruments as of November 30, 2021 and, thus, anti-dilution issues are not applicable.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Fair Value of Financial Instruments</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>ASC 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of November 30, 2021. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span><b>Related Parties</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The Company follows ASC 850, <i>Related Party Disclosures,</i> for the identification of related parties and disclosure of related party transactions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span><b>Share-Based Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>ASC 718, “<i>Compensation – Stock Compensation</i>”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “<i>Equity – Based Payments to Non-Employees.”</i>  Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:  (a) the goods or services received; or (b) the equity instruments issued.  The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.  </span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The Company had no stock-based compensation plans as of November 30, 2021 and February 28, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company’s stock-based compensation for the periods ended November 30, 2021 and February 28, 2021 was $609,243 and $0, respectively.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 609243 0 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Recently Issued Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span>In February 2016, the FASB issued ASU 2016-02, <i>Leases (Topic 842). ASU 2016-02</i> is amended by ASU 2018-01, ASU2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01, which FASB issued in January 2018, July 2018, July 2018, December 2018 and March 2019, respectively (collectively, the amended ASU 2016-02). The amended ASU 2016-02 requires lessees to recognize on the balance sheet a right-of-use asset, representing its right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from current GAAP. The amended ASU 2016-02 retains a distinction between finance leases (i.e. capital leases under current GAAP) and operating leases. The classification criteria for distinguishing between finance leases and operating leases will be substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current GAAP. The amended ASU 2016-02 also requires qualitative and quantitative disclosures designed to assess the amount, timing, and uncertainty of cash flows arising from leases. A modified retrospective transition approach is permitted to be used when an entity adopts the amended ASU 2016-02, which includes a number of optional practical expedients that entities may elect to apply.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; "> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span>We have no assets and or leases and do not believe we will be impacted in the foreseeable future by the newly adopted accounting standard(s) mentioned above.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.</span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Note 3 - Going Concern</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company has not established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.</span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Note 4 - Income Taxes</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b> </b></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. As of November 30, 2021, the Company has incurred a net loss of approximately $1,157,088 which resulted in a net operating loss for income tax purposes.  The loss results in a deferred tax asset of approximately $242,988 at the effective statutory rate of 21%. The deferred tax asset has been offset by an equal valuation allowance. Given our inception on December 1, 2020, and our fiscal year end of February 28, 2021, we have completed only one taxable fiscal year.</span></p> 1157088 242988 0.21 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Note 5 - Commitments and Contingencies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company follows ASC 450-20, <i>Los</i>s<i> Contingencies, </i>to report accounting for contingencies.  Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of November 30, 2021 other than the following:</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital. Pursuant to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.</span></p> 30500000 15000 250000 0.15 0.0499 20000 <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Note 6 - Shareholder Equity</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b> </b></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b><i>Preferred Stock</i></b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 and 0 shares issued and outstanding as of November 30, 2021 and February 28, 2021, respectively.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>During the three months ended May 31, 2021, 700,000 shares of Series A Preferred Stock were issued to CRS Consulting, LLC (“CRS”), a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody. CRS is our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock. Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. On July 19, 2021, these shares were purchased. As of November 30, 2021, our CEO, Ian James, and Director, Stephen Letourneau, each hold 350,000 shares of Series A Preferred Stock (See Note 1).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b><i>Common Stock</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 363,024,072 and 0 shares of common stock issued and outstanding as of November 30, 2021 and February 28, 2021, respectively.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On July 19, 2021, 250,000,000 shares of Restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $7,000.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $468,493.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $45,000.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $18,750.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Stock Options</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">During the nine months ended November 30, 2021, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 2,500,000 fully vested on September 30, 2021. 17,500,000 shares vest over the next 2 years, 2,500,000 shares per quarter. The options have the exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options as of November 30, 2021, was $0.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company fair valued the options on the grant date at $2,127,565 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 per share (based on the quoted trading price on the date of grant), volatility of 151.08%, expected term of 5 years, and a risk-free interest rate range of .98%. The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the nine months ended November 30, 2021 was $265,946. The total unamortized stock option expense at November 30, 2021 was $1,861,619.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> <span>  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b><i>Additional Paid-In Capital</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $6,441 during the period ended November 30, 2021. During the period ended November 30, 2021, former related party Paul Moody paid expenses on behalf of the Company totaling $500.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $1,185 during the period ended February 28, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>The $8,126 in total payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.</span></p> 200000000 0.0001 700000 700000 0 0 700000 700000 250000000 Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. 350000 500000000 0.0001 363024072 363024072 0 0 359996332 250000000 17963817 24137499 50000 7000 2602740 468493 250000 45000 125000 18750 20000000 2500000 17,500,000 shares vest over the next 2 years, 2,500,000 shares per quarter. 25 P5Y 0 2127565 15 1.5108 P5Y 0.98 265946 1861619 6441 500 1185 8126 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Note 7 - Related-Party Transactions</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b><i>Loan to Company</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>During the period ended November 30, 2021, our CEO, Ian James, paid expenses on behalf of the Company totaling $65 and shareholder, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totaling $156,691. These payments are considered as loans to the Company, which are noninterest-bearing, unsecured and payable on demand.</span></p> 65 156691 <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Note 8 - Subsequent Events</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On December 3, 2021, the Company executed an Amended and Corrected Equity Purchase Agreement (the “Equity Purchase Agreement”) with Williamsburg Venture Holdings LLC, a Nevada limited liability Company (“WVH”). The Equity Purchase Agreement provides that WVH shall purchase from the Company, upon the filing of a Current Report on Form 8-K regarding the Company ceasing to be a “shell” company and on the approval of an uplisting to the OTCQB or higher market, $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s common stock as reported by the OTC Markets Group.  The Equity Purchase Agreement also provides that, upon the filing of a registration statement on Form S-1 covering all the shares sold to WVH under the Equity Purchase Agreement and related Amended and Corrected Registration Rights Agreement (the “Registration Rights Agreement”), WVH shall purchase an additional $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s common stock as reported by the OTC Markets Group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On December 3, 2021, the Company also executed the Registration Rights Agreement with WVH.  Under the terms and conditions of the Registration Rights Agreement, and to induce WVH to enter into the Equity Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended (the “Securities Act”).  The Registration Rights agreement provides that the Company shall, on or before the one hundred and eightieth (180th) day after December 3, 2021, file with the SEC a prospectus supplement on effective Form S-1 covering the maximum number of Registrable Securities (as defined therein) as shall be permitted to be included thereon in accordance with applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the WVH, including but not limited to under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices), as mutually determined by both the Company and the WVH (the “<span style="text-decoration:underline">Initial Registration Statement</span>”). The Initial Registration Statement shall register only Registrable Securities. The Company shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment thereto declared effective by the SEC at the earliest possible date (in any event, within ninety (90) calendar days after the filing date of the Initial Registration Statement).  The Registration Rights Agreement also provides that the Company is obligated to file additional registration statements under certain circumstances.</p> the Company executed an Amended and Corrected Equity Purchase Agreement (the “Equity Purchase Agreement”) with Williamsburg Venture Holdings LLC, a Nevada limited liability Company (“WVH”). The Equity Purchase Agreement provides that WVH shall purchase from the Company, upon the filing of a Current Report on Form 8-K regarding the Company ceasing to be a “shell” company and on the approval of an uplisting to the OTCQB or higher market, $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s common stock as reported by the OTC Markets Group.  The Equity Purchase Agreement also provides that, upon the filing of a registration statement on Form S-1 covering all the shares sold to WVH under the Equity Purchase Agreement and related Amended and Corrected Registration Rights Agreement (the “Registration Rights Agreement”), WVH shall purchase an additional $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s common stock as reported by the OTC Markets Group. false --02-28 Q3 2022 0001852707 EXCEL 32 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end XML 33 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 34 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 35 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 86 222 1 false 22 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.betterforyouwellness.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Balance Sheet Sheet http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet Balance Sheet Statements 2 false false R3.htm 002 - Statement - Balance Sheet (Parentheticals) Sheet http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals Balance Sheet (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Statement of Operations (Unaudited) Sheet http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement Statement of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Statement of Changes in Stockholders??? Equity (Deficit) (Unaudited) Sheet http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3 Statement of Changes in Stockholders??? Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 005 - Statement - Statement of Cash Flows (Unaudited) Sheet http://www.betterforyouwellness.com/role/ConsolidatedCashFlow Statement of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Organization and Description of Business Sheet http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 7 false false R8.htm 007 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Going Concern Sheet http://www.betterforyouwellness.com/role/GoingConcern Going Concern Notes 9 false false R10.htm 009 - Disclosure - Income Taxes Sheet http://www.betterforyouwellness.com/role/IncomeTaxes Income Taxes Notes 10 false false R11.htm 010 - Disclosure - Commitments and Contingencies Sheet http://www.betterforyouwellness.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 11 false false R12.htm 011 - Disclosure - Shareholder Equity Sheet http://www.betterforyouwellness.com/role/ShareholderEquity Shareholder Equity Notes 12 false false R13.htm 012 - Disclosure - Related-Party Transactions Sheet http://www.betterforyouwellness.com/role/RelatedPartyTransactions Related-Party Transactions Notes 13 false false R14.htm 013 - Disclosure - Subsequent Events Sheet http://www.betterforyouwellness.com/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 014 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies 15 false false R16.htm 015 - Disclosure - Organization and Description of Business (Details) Sheet http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails Organization and Description of Business (Details) Details http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness 16 false false R17.htm 016 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 17 false false R18.htm 017 - Disclosure - Income Taxes (Details) Sheet http://www.betterforyouwellness.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.betterforyouwellness.com/role/IncomeTaxes 18 false false R19.htm 018 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.betterforyouwellness.com/role/CommitmentsandContingencies 19 false false R20.htm 019 - Disclosure - Shareholder Equity (Details) Sheet http://www.betterforyouwellness.com/role/ShareholderEquityDetails Shareholder Equity (Details) Details http://www.betterforyouwellness.com/role/ShareholderEquity 20 false false R21.htm 020 - Disclosure - Related-Party Transactions (Details) Sheet http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://www.betterforyouwellness.com/role/RelatedPartyTransactions 21 false false R22.htm 021 - Disclosure - Subsequent Events (Details) Sheet http://www.betterforyouwellness.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.betterforyouwellness.com/role/SubsequentEvents 22 false false All Reports Book All Reports f10q1121_betterforyou.htm bfyw-20211130.xsd bfyw-20211130_cal.xml bfyw-20211130_def.xml bfyw-20211130_lab.xml bfyw-20211130_pre.xml f10q1121ex31_betterfor.htm f10q1121ex32_betterfor.htm http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 37 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q1121_betterforyou.htm": { "axisCustom": 0, "axisStandard": 7, "contextCount": 86, "dts": { "calculationLink": { "local": [ "bfyw-20211130_cal.xml" ] }, "definitionLink": { "local": [ "bfyw-20211130_def.xml" ] }, "inline": { "local": [ "f10q1121_betterforyou.htm" ] }, "labelLink": { "local": [ "bfyw-20211130_lab.xml" ] }, "presentationLink": { "local": [ "bfyw-20211130_pre.xml" ] }, "schema": { "local": [ "bfyw-20211130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 200, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 55, "http://www.betterforyouwellness.com/20211130": 2, "http://xbrl.sec.gov/dei/2021": 5, "total": 62 }, "keyCustom": 17, "keyStandard": 205, "memberCustom": 14, "memberStandard": 8, "nsprefix": "bfyw", "nsuri": "http://www.betterforyouwellness.com/20211130", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Income Taxes", "role": "http://www.betterforyouwellness.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Commitments and Contingencies", "role": "http://www.betterforyouwellness.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Shareholder Equity", "role": "http://www.betterforyouwellness.com/role/ShareholderEquity", "shortName": "Shareholder Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Related-Party Transactions", "role": "http://www.betterforyouwellness.com/role/RelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Subsequent Events", "role": "http://www.betterforyouwellness.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Organization and Description of Business (Details)", "role": "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "shortName": "Organization and Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c63", "decimals": null, "lang": "en-US", "name": "us-gaap:IntercompanyAgreementsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Income Taxes (Details)", "role": "http://www.betterforyouwellness.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c65", "decimals": "2", "first": true, "lang": null, "name": "bfyw:CommonStockDiscountPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c65", "decimals": "2", "first": true, "lang": null, "name": "bfyw:CommonStockDiscountPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Balance Sheet", "role": "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet", "shortName": "Balance Sheet", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Shareholder Equity (Details)", "role": "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "shortName": "Shareholder Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "lang": "en-US", "name": "us-gaap:PreferredStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c83", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Related-Party Transactions (Details)", "role": "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "shortName": "Related-Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c83", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c85", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:EquityPurchaseAgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Subsequent Events (Details)", "role": "http://www.betterforyouwellness.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c85", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:EquityPurchaseAgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c2", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Balance Sheet (Parentheticals)", "role": "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Balance Sheet (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Statement of Operations (Unaudited)", "role": "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement", "shortName": "Statement of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c12", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Statement of Changes in Stockholders\u2019 Equity (Deficit) (Unaudited)", "role": "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3", "shortName": "Statement of Changes in Stockholders\u2019 Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c12", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Statement of Cash Flows (Unaudited)", "role": "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow", "shortName": "Statement of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "bfyw:CommonStockIssued", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Organization and Description of Business", "role": "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Going Concern", "role": "http://www.betterforyouwellness.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1121_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 22, "tag": { "bfyw_BetterForYouWellnessIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BetterForYouWellnessIncMember", "terseLabel": "Better for You Wellness, Inc. [Member]" } } }, "localname": "BetterForYouWellnessIncMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_CRSConsultingLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CRSConsultingLLCMember", "terseLabel": "CRS Consulting, LLC [Member]" } } }, "localname": "CRSConsultingLLCMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_CRSConsultingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CRSConsultingsLLCMember", "terseLabel": "CRS Consulting, LLC [Member]" } } }, "localname": "CRSConsultingsLLCMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_ClosingSharePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Closing share price.", "label": "ClosingSharePrice", "terseLabel": "Closing share price (in Dollars)" } } }, "localname": "ClosingSharePrice", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_CommitmentsandContingenciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "bfyw_CommitmentsandContingenciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "bfyw_CommonStockDiscountPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock discount, percentage.", "label": "CommonStockDiscountPercentage", "terseLabel": "Common stock discount, percentage" } } }, "localname": "CommonStockDiscountPercentage", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "bfyw_CommonStockIssued": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock issued .", "label": "CommonStockIssued", "terseLabel": "Common stock issued" } } }, "localname": "CommonStockIssued", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.betterforyouwellness.com/20211130", "xbrltype": "stringItemType" }, "bfyw_EquityPurchaseAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity purchase agreement, description.", "label": "EquityPurchaseAgreementDescription", "terseLabel": "Equity purchase agreement, description" } } }, "localname": "EquityPurchaseAgreementDescription", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "bfyw_ExpensesContributedToCapital": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses contributed to capital.", "label": "ExpensesContributedToCapital", "terseLabel": "Expenses contributed to capital" } } }, "localname": "ExpensesContributedToCapital", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_FastTrackSolutionsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FastTrackSolutionsIncMember", "terseLabel": "Fast Track Solutions, Inc. [Member]" } } }, "localname": "FastTrackSolutionsIncMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_GreenOhioVenturesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GreenOhioVenturesLLCMember", "terseLabel": "Green Ohio Ventures, LLC [Member]" } } }, "localname": "GreenOhioVenturesLLCMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_IanJamesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IanJamesMember", "terseLabel": "Ian James [Member]" } } }, "localname": "IanJamesMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "bfyw_JeffreyDeNunzioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JeffreyDeNunzioMember", "terseLabel": "Jeffrey DeNunzio [Member]" } } }, "localname": "JeffreyDeNunzioMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_MRKTSGroupIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MRKTSGroupIncMember", "terseLabel": "MRKTS Group Inc [Member]" } } }, "localname": "MRKTSGroupIncMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_OrganizationandDescriptionofBusinessDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Line Items]" } } }, "localname": "OrganizationandDescriptionofBusinessDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "bfyw_OrganizationandDescriptionofBusinessDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Table]" } } }, "localname": "OrganizationandDescriptionofBusinessDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "bfyw_PaulMoodyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PaulMoodyMember", "terseLabel": "Paul Moody [Member]" } } }, "localname": "PaulMoodyMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_PredecessorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PredecessorsMember", "terseLabel": "Predecessor [Member]" } } }, "localname": "PredecessorsMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_PreferredSharesIssuedAfterReorganization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred shares issued after reorganization.", "label": "PreferredSharesIssuedAfterReorganization", "terseLabel": "Preferred shares issued after reorganization" } } }, "localname": "PreferredSharesIssuedAfterReorganization", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_PreferredSharesIssuedAfterReorganizationinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of preferred shares issued after reorganization.", "label": "PreferredSharesIssuedAfterReorganizationinShares", "terseLabel": "Preferred shares issued after reorganization (in Shares)" } } }, "localname": "PreferredSharesIssuedAfterReorganizationinShares", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "bfyw_PreferredStocksIssued": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred stock issued.", "label": "PreferredStocksIssued", "terseLabel": "Preferred stock issued" } } }, "localname": "PreferredStocksIssued", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_PurchasePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PurchasePriceMember", "terseLabel": "Purchase Price [Member]" } } }, "localname": "PurchasePriceMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_RelatedPartiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for related parties.", "label": "RelatedPartiesPolicyTextBlock", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartiesPolicyTextBlock", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "bfyw_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "bfyw_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "bfyw_RestrictedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares restricted common stock.", "label": "RestrictedCommonStock", "terseLabel": "Shares of restricted common stock" } } }, "localname": "RestrictedCommonStock", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_RestrictedCommonStocks": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Common Stocks.", "label": "RestrictedCommonStocks", "terseLabel": "Restricted common stock" } } }, "localname": "RestrictedCommonStocks", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_SRAXIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SRAXIncMember", "terseLabel": "SRAX, Inc [Member]" } } }, "localname": "SRAXIncMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_SharebasedExpense": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of shares based expenses.", "label": "SharebasedExpense", "terseLabel": "Share-based expense" } } }, "localname": "SharebasedExpense", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "bfyw_ShareholderEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity (Details) [Line Items]" } } }, "localname": "ShareholderEquityDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity (Details) [Table]" } } }, "localname": "ShareholderEquityDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_StephenLetourneauMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StephenLetourneauMember", "terseLabel": "Stephen Letourneau [Member]" } } }, "localname": "StephenLetourneauMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_StockBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of stock-based compensation.", "label": "StockBasedCompensation", "terseLabel": "Stock-based compensation" } } }, "localname": "StockBasedCompensation", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_StockIssuedDuringPeriodShareNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "StockIssuedDuringPeriodShareNewIssues", "terseLabel": "Series A preferred stock were issued" } } }, "localname": "StockIssuedDuringPeriodShareNewIssues", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_StockOptionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock option description.", "label": "StockOptionDescription", "terseLabel": "Stock option description" } } }, "localname": "StockOptionDescription", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "bfyw_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "bfyw_TotalPaymentsConsideredContributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total payments considered contributions.", "label": "TotalPaymentsConsideredContributions", "terseLabel": "Total payments considered contributions (in Dollars)" } } }, "localname": "TotalPaymentsConsideredContributions", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_TotalUnamortizedStockOptionExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total unamortized stock option expense.", "label": "TotalUnamortizedStockOptionExpense", "terseLabel": "Total unamortized stock option expense (in Dollars)" } } }, "localname": "TotalUnamortizedStockOptionExpense", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_WilliamsburgVentureHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WilliamsburgVentureHoldingsLLCMember", "terseLabel": "Williamsburg Venture Holdings LLC [Member]" } } }, "localname": "WilliamsburgVentureHoldingsLLCMember", "nsuri": "http://www.betterforyouwellness.com/20211130", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r52", "r101", "r106", "r112", "r179", "r180", "r183", "r184", "r210", "r245", "r252", "r253", "r254", "r255" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r52", "r101", "r106", "r112", "r179", "r180", "r183", "r184", "r210", "r245", "r252", "r253", "r254", "r255" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_FinancingReceivableNonaccrualToOutstandingPercent": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Percentage of nonaccrual to total financing receivable outstanding.", "label": "Financing Receivable, Nonaccrual to Outstanding, Percent", "terseLabel": "Outstanding percentage" } } }, "localname": "FinancingReceivableNonaccrualToOutstandingPercent", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r93", "r206" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r13", "r147", "r213" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r54", "r55", "r56", "r144", "r145", "r146", "r189" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r134", "r142", "r149" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock options expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r49", "r85", "r87", "r91", "r95", "r101", "r102", "r103", "r105", "r106", "r107", "r108", "r109", "r110", "r112", "r113", "r179", "r183", "r193", "r211", "r213", "r230", "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r132", "r133", "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Voting percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r173", "r174", "r175" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Paid consideration (in Dollars)" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "terseLabel": "Owning, percentage" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r18", "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Ending cash balance", "periodStartLabel": "Beginning cash balance" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r9", "r44" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r35" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes effect from exchange rate changes.", "label": "Cash, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r47", "r49", "r66", "r67", "r68", "r70", "r71", "r75", "r76", "r77", "r95", "r101", "r106", "r107", "r108", "r112", "r113", "r114", "r115", "r117", "r121", "r193", "r249" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r97", "r98", "r99", "r100", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r54", "r55", "r189" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Shares", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common Stock, Other Shares, Outstanding", "terseLabel": "Common shares outstanding" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Shares of common stock" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r12", "r127" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r12", "r213" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock ($.0001 par value, 500,000,000 shares authorized, 363,024,072 and 0 issued and outstanding as of November 30, 2021 and February 28, 2021,respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r159", "r160" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Deferred Tax Assets, Capital Loss Carryforwards", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r19", "r51", "r104", "r106", "r107", "r111", "r112", "r113", "r204" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Loans to Company \u2013 related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r50", "r152", "r165" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Effective statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r26", "r27", "r28", "r54", "r55", "r56", "r58", "r63", "r65", "r74", "r96", "r127", "r129", "r144", "r145", "r146", "r162", "r163", "r189", "r194", "r195", "r196", "r197", "r198", "r199", "r239", "r240", "r241", "r257" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r191", "r192" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share", "terseLabel": "Basic and Diluted net loss per common share (in Dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r50", "r153", "r154", "r157", "r164", "r166", "r167", "r168", "r169" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r25", "r150", "r151", "r154", "r155", "r156", "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r37", "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r40" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in current assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IntercompanyAgreementsDescription": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Description of product support, consulting, business, or other advisory service agreements entered into between the managing member or general partner and the LLC or LP, affiliate of the managing member or general partner, or affiliate of the LLC or LP. Includes a description of the key provisions of such agreements and the amount of compensation for such services during the accounting period.", "label": "Intercompany Agreements, Description", "terseLabel": "Independent director agreements, description" } } }, "localname": "IntercompanyAgreementsDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r33", "r36", "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r20", "r49", "r88", "r95", "r101", "r102", "r103", "r106", "r107", "r108", "r109", "r110", "r112", "r113", "r180", "r183", "r184", "r193", "r211", "r212" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r17", "r49", "r95", "r193", "r213", "r231", "r236" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES & STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r35" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r35", "r39", "r42" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r23", "r24", "r28", "r29", "r42", "r49", "r57", "r59", "r60", "r61", "r62", "r64", "r65", "r69", "r85", "r86", "r89", "r90", "r92", "r95", "r101", "r102", "r103", "r106", "r107", "r108", "r109", "r110", "r112", "r113", "r190", "r193", "r232", "r237" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow", "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r158" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net loss" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r188" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r8", "r21" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued Expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCashEquivalentsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Other Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "OtherCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r31", "r238" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "terseLabel": "Paid expenses (in Dollars)", "verboseLabel": "Paid expenses" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherGeneralExpense": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.", "label": "Other General Expense", "terseLabel": "Associated expenses" } } }, "localname": "OtherGeneralExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForFees": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for fees classified as other.", "label": "Payments for Other Fees", "terseLabel": "Amount paid" } } }, "localname": "PaymentsForFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Shares" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r11", "r114" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r11", "r114" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "verboseLabel": "Shareholder owning preferred stock" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r11", "r213" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock ($.0001 par value, 200,000,000 shares authorized; 700,000 and 0 issued and outstanding as of November 30, 2021 and February 28, 2021, respectively)" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r11", "r128" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Voting Rights", "terseLabel": "Preferred Stock, Voting Rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Loan to company \u2013 related party" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r23", "r24", "r28", "r34", "r49", "r57", "r64", "r65", "r85", "r86", "r89", "r90", "r92", "r95", "r101", "r102", "r103", "r106", "r107", "r108", "r109", "r110", "r112", "r113", "r178", "r181", "r182", "r186", "r187", "r190", "r193", "r233" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r131", "r203", "r204" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r131", "r203", "r207", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r201", "r202", "r204", "r208", "r209" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r14", "r129", "r147", "r213", "r235", "r242", "r243" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r54", "r55", "r56", "r58", "r63", "r65", "r96", "r144", "r145", "r146", "r162", "r163", "r189", "r239", "r241" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A", "verboseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Series of Individually Immaterial Business Acquisitions [Member]" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r40" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock options expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate range" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Grant option exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Stock option exercise price (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Stock option outstanding intrinsic value (in Dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r135", "r136" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Stock price (in Dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number", "terseLabel": "Number of vested shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r139", "r148" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Stock option expire" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Stock options fair value the grant date (in Dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Transfer of shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balances (in Shares)", "periodStartLabel": "Balances (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r46", "r53" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r10", "r11", "r12", "r47", "r49", "r66", "r67", "r68", "r70", "r71", "r75", "r76", "r77", "r95", "r101", "r106", "r107", "r108", "r112", "r113", "r114", "r115", "r117", "r121", "r127", "r193", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r22", "r26", "r27", "r28", "r54", "r55", "r56", "r58", "r63", "r65", "r74", "r96", "r127", "r129", "r144", "r145", "r146", "r162", "r163", "r189", "r194", "r195", "r196", "r197", "r198", "r199", "r239", "r240", "r241", "r257" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r54", "r55", "r56", "r74", "r217" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Common share issued for services to the Company (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r12", "r127", "r129" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common shares issued after reorganization (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Purchase of restricted common stock (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r127", "r129" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Shares of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r22", "r127", "r129" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Purchase of common stock value" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Common share issued for services to the Company" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r12", "r127", "r129" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Common shares issued after reorganization" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Expenses paid on behalf of the Company and contributed to capital" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock or Unit Option Plan Expense", "terseLabel": "The total stock option expense (in Dollars)" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r12", "r15", "r16", "r49", "r94", "r95", "r193", "r213" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r27", "r49", "r54", "r55", "r56", "r58", "r63", "r95", "r96", "r129", "r144", "r145", "r146", "r162", "r163", "r176", "r177", "r185", "r189", "r193", "r194", "r195", "r199", "r240", "r241", "r257" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balances", "periodStartLabel": "Balances" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r48", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholder Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r200", "r215" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r200", "r215" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r214", "r216" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r78", "r79", "r80", "r81", "r82", "r83", "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average number of common shares outstanding - Basic and Diluted (in Shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r246": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r247": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r248": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r249": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r250": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(2)" }, "r251": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r252": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r253": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01" }, "r254": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01" }, "r255": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02" }, "r256": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" } }, "version": "2.1" } ZIP 38 0001213900-22-000893-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-000893-xbrl.zip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�V)^2^PI A[6;@B(N+ M'W+L8-3%H(O_9I"C'I1D*BB6LOEYYD LMH+_'EB^@M^W">8!BLZ[+K3%P5 " M^HBYE*<;!Z6Q;LG'O%+0@101<$HR,^:B@2+V,-DQOUJT_A&%(*3:G$NHQYT&R.>6"Y MA"1T8_26[AI\^%_Q-[(3@CSE5XV'6_M]Q/DM,4MJE2"Y1-! MWTB!%_-M<7F9N).@:*1QTN=(6GI#G)UJ\!.*F&K=FBH M0$20^9]WAG#F'EE\L@*'>6C==X/&=]Z/:H"1#"/JV0KW_D,!+';V\&G$DR1? M??BOX*KI[D^Y)C6\$>Q&G5X9NXKB%8SQ'%U"B1_$;S\92[R_"'7ZJ24W_Y$( MW^*_.?E>>:T [-<$[JNG&\EX0_G;4_>8^*M]Y%R\ 4K@P)KT2N M^&_"\_C'13'F6RC^W4\.\*D;3>KV];F,_.+_UA _8*'Y5*@A^2RVV*YGP4\K MIC.^/A8NN.?"^T)G"Q3I3T];Q? G!57JS7A8G!73"Q9Q(X6-CLY?I^C0 MX%&%T(*L_@1$BD^,BY@O"^2"X$^ I$P?+YO7A5GV43"JCR30F4)\"EWB40QU MKR#P4V"E._*-CX1TFXT\.EF$C"_$,@N5;N3"J#A>52\-FPO\__LB)1=*D9#( MEWW^&R-)ZU]02P,$% @ *%DF5(Z38HP !@ !"D !4 !B9GEW+3(P M,C$Q,3,P7V-A;"YX;6SE6FU3XD@0_KZ_(L=^N2LKAH"(6NH6!EE%1(^ JVYM M;86D@<')##4G"3, MW61" ^)2#Y'F2:)FZSG;NKQ,?#K5M _'?^BZ]AD(,$> I]4'FD7]CNTBKKNNW,-=Q(#3@+G U8*FZU+@2*3%0 D\TJJM M0"LZ1$ON:V;F*),Y2F:U6M724LE4ZN65#\<8D:>ZPT&3=A-^DIC0U*\SO$M9 MTT@EDVECM#'QLO.HKQ:F]O?2X6[S\/#0"/\ZWLK1O(U2K&G<7Y=LMP6^HR/" MA4-HW_31-ETMZ69*3YN[?>XE7G#3M&-&,52@ MH866'XE!!TX2'/D=K P*UUH,&B>)>F/0DT)2IFFFDTK$1[7RG7VW*.$4(T]A M?^9@=12[!2 2FA)=JUQ.':(.0@"3' ]HT .,"?"02D-M-B)E&::,MA[<*F/;>:^U8CC%V!=?!;H!#QRM)JZ;LA;X XH$W MLEC)VP2QITJSU(VI.Z4/JPB@;*0..W7 )XF ZTW'Z7PO(:>.,!((^#2$RB N M+0HCH>'P>A@.P]<,A:T!6/#12HBVGC2'4?%QGORAZZUL8SZ *JT 5D>^=9B2 M906,A8X6@\D+U/TXP03#.39]&(>Y([ODXPR]TZEEN,/@@>^'TG0DG7[T?H-1 M?R%7@BX'$V4>,%E-$EH/4+,EU.,HJE;FXT:T@.5DW/.NS8@KI/+8JE1'[^3X#$(!9&YJ@QUDM!M](LD$!XH<@[!P<0 MB\7S]$S$P#;<)IJK2>^9"]!&(UJVC3XE,>,_HV2[V70Y[&>1B8K5-:'/>1Y2 MECKXUD&R\[&<#A(.CH6!*%WCP/UU>8B$:4A'>A.ILP+"002\=WB,F,' M?A 6U#PTD(OB*6Y+J/TM\M0R\ WIVMM(VIHHI3GB_:3"]Z;2\35@^[W(0E0F MJ9OJ7R)+RV]VJ'F[(K*WNK09KVYMIS_S*O?ZRGNZ;CVYZ:AID R_\WX'"(_I M6C>KQ9B8'WW]2.?2>L]WFPX#4\D'OY-9+%MX=-M5OM."_* V79P9=<[=H> M)+_DSB[*1MNWVSOW]RA=+CSN%Q%F3Q9_2%7;]^[#(>KN%/=HYE 420[R]Y F M@QM\#;7/_F/U(I.NBZOK,UZUC/)^J=-,IHH9:/S= :NZ7VL&#WN-R[V]A_WB M%:)F-E,OIHWVW9VYS%0=JL=1F1(3"6+ M)3&,2(ZKT!;.HNR6PT#-$[VY]$1,L&;?VG)GL!#;J(-N\KI;!O&2.TN4QY/K MIC5LU9/G'G9JT#!+QZS#ZF.TMUOSQH/3]:E7(FX9[2)IT=F@QE4A'6.0CULHQ#8 M1 8/94_/MO@*",]_\S?TWT4X1$PWUFH251T^4W58?226Q2$\33Q-X7Q5V[Y# MOB^]1.$7.=%8+^'+%,9 :LG#R\]+,OO=(!;2EE*\W9'M^PA<#MDAG9FHX<=& M6I0"(@YQM]:BS%._^AG#O#7J,V5?)QBJ![*MJ]*Y,^R(-+Y0P-:_ZZW.WSBC M+T9FHY]OI'DN@,<+TO8*=)R!&B'QF\;$Q^!!'NKQ3*^75OZ;DKDZR)%?B-;Z M-*:,!;CQ$KV?)5ANR=X'WZFZQ=.59 M>/'X+Z(P-X!6&[0?C_\+3S48_P)02P,$% @ *%DF5(VO6W7F' ;[ ! M !4 !B9GEW+3(P,C$Q,3,P7V1E9BYX;6SM75MSVSBR?I]?H?6^G%,ICWR) MDTDJ.5NR96?D.);7DG.9K:T414(2$HK4@*1LY=IK9K05 'G2=MP?'OQ\=M(!CNA9T)F\/'@:'G<%%KW?PK_]K MM7Y[\X_#P]8[X !D^,!JC9:M"W&R 3>.07K<-#3'!-\@(!0O!U:S@-6M>&TSIZT3H^>WUV M]OKH9>MA>-$Z.3HYB5[Y[8T-G>\CPP,M++?CO3V(<7H:(?MW%TW:)T='I^WU M@P?1DZ^?R"\2SS^>AD\?OWKUJAW^=?.H!_,>Q&2/VY\_W S,*9@9A]#Q?,,Q M"0,/OO;"7]ZXIN&'2!;*U:(^0?YWN'[LD/SJ\/CD\/3X]R?/VHB(G['\#9LX M@;-V],<#@E>K]0:Y-K@'XU;XB:_]Y1R\/?#@;&X3R/F-O) M\?'QZ1'A]4_RFZ_HZX7K>*X-+:*D<\,FWSR8 N ?M CIA_M>XFM'P/,JYP_B9$ A]!B?E2"%R/N:=BRECM9L .2(B M)]Z7-P*CL3TTGL2 C+\N;XS-9M GGL;#)H8_F>@$!QJ"NF:14^+)(M=3T8&M MB,@3\![8Q-G@Z0>[11*#&289MD*04FE)F\T&P<@#?P=8:9<+HCFQ09ZB(/0,QXE0 < G,X [,10"713;RJU&0-VRXG&WEA(Q&V4^A ,K!N M,.^$5.#)!XX%K+5:B-TC![VS43/&V2W7/1FJ5MC(#]]B#P#B>&,?^Z MR:7TQU<0QTPF-.P[UPO%[XP\'V$_G$716X,Q-KQ1B,B*7ILXL3:P?6_]F]"M M'1X=KU*!_RS%>#5CE?ZJCNBO95MT=E)016\=:A)6AE+7RU=MC MY,[$5.:[65!56A"#70.UPP)OI;%CZ1KK!F#HQD*O+7,E&F.PTZBQ8K.-ZXD%F;*1U?>G M .'U'B9C9<55HJL"EHF/V7&5%:'',[PJ^D/5#K#A'F^C@Q/I0V?@N^;WQ%:, MXK"&RFXW7%R>)E@8*?-I=QAV@$>@%7+_:-A!3K@N02-Y?-:QNI[A4F20<=7D MHL2A$Q&-D(27ZRA61X:)5L]51A59>)3%91W+"G' CM2 5L^Y,.;0-VPU"QH* MKRC-LOMJH6)5/*6(J.:>9/D<8%T:R('.Q,-Q13 +PG"PBX$RH9IYA8-M M3(OC[^H:#5EYG<"?N@C^V XOA9K,L-2;Y)&CQ2R.JM(]>7Q[GA?4J+L5NP8F M@UC@*I)CLGP M)U!7WNSVDJDSW4OK],DIT?Q9BH[2]3.-EZ"KZL_)&5"LLLNG.7 \[!Q5"D_G MIC1 J7$TBI6@P+K$/W2$X 6[G:HI1E9]_2N9?!,4)HWZIL0S"C_GI\EMXH MN(JKXLH:B&CB%OB17#>NIT8+20[Z7$X)^%.@\*SWQ8,/PN,*2QJ=R FPTE?: MQ^$.7J.>&QXTL<_K0CO @8^Z)("X-$T9517PYD@1B%C )P G4\REL\ 23,!M M0+ZS/PZ9QH+RE$Q*U"\HRH[/;%6!+DPRK)<]&M9#C*X,@@OK#9185-##/ZJ9 M$7+8B(;8:TI#8Y1W/$:FL!$+9?8>'M)AKO(S2DF6.221R,;"V-UA@[NTPZ?> M'GA@$K4PD9F9V4AQ81N>A\<7R3%TGJ!B.\IP4[@FS3VFQM1;PC9S=99%2U5) M9(Q1=W4D4$6^+,M&5=R7.>'(5 7-+!/9L1R,>*J&Y>CCZU&-&E$T'U:R8E%DRKIK^8ZY$2T>D>6RU&9HE2XLGS,U"@JQ4NA0\OGI&QONYQ3 M8YEI7$<4N)3D/G-Y*?)M=.7LAG^KI!\^-U=Y'^U#8IFE:O/L0^RPNZY%(]-I M4';)UN@H&2K)C(833QV]X,02QNP=Y3-+@HV^[07ZTCH[J2214;6X' !$SD_4 M-K^P^&D=)'RJ8<+%,=/(.;[5"B$R/<1' 4^67@-W5O7(7D\_.&8 MVJ3G^ !KZZ3WT*B[4C9:$'N5(X6"HU$R$1JJ7#++]S>=;U1B]=D1QFAA41% MC=T $;O SL*-ZHAOP6/X%U6I(1[.35 6'X0JS\EFN4<6I$6#:=8[4$8JHK\, M@K*+Z.>JF P%8X);X!-:6'D+B%$]7SYXY,3EGY\)L0JPH):\S 26KDGU+IWY4CHQ-VB4'*/G' M0Y-[A;F](@KS7/$W]?G56G1"@4O9*=/\=9^Z_;,L*ZT99-4Z+8*9I\^5X+%) M!#"[+HC^C0F\JCE2W<:!E_UN;"!P3H-E8%6TS9H5(7O-04TZS6&L,7%9WN39 MFLV#5=7*A-/#:%Z":C_$7$&_94!69-V61UI1T2C_9VAVLGKG5#G:+@.VLL:^H03A)E@Z M4+A\6A6JXA^FAC,!]]@&+\=CH&B&%9-DY_+%)8U $'\U9RNP+!TGW.L.#SIB&^2_L8[2&V_K=:%'M!P@,,1*.L>< MOBOY;NE"ZAUVQ5:3:/TI74.M2PTL7B2YH@T=@^6=2[8#7,<$R!%N>%_)O:CM,"]%,O$3 M@L&('"/U,=FN&XS\SL@-_#CDB@<;/WNM*VRI]I-T(8C+4W7:M!G\V@U&Q$5YU1;VU)\#9 MA&^B;616-#LIFC4-C7(25+SYK9"1VO%34@2-U3!"=I'NPE,&[1V>;V)-P%=7 M(\OK17/K^FJ'5P'+*BGT7,IU#25^[EH/P_+HF]TGAPKJ#H^8^#[]$!F.A[^6 MW/U0X4IN&DFE@Z>0J7CL1B-=U_@IPU]?9,>K]60;OA+([FZT1Q9KX.^ -+== MD%E4^,*)%!W%6YL49I5R!G&*ZE,$^=QT;RNQE9A>Y5,0V]F\6S9;>+X,?UK^ MNOM(Y*(7G@]G>'I34W>88J'U M!&,IC:6Q4506FE^U%#DJQ9D#+LYZS\*5TA@GE(7UGI7RIG5HCLJL.:.+CI>B M5I+K#MIW (7)ESKT5,138QJAG+8*P5-6@G=E0!2U$-KN3/4<+&DPVPYN)S\,.)!H;!]I'!.-?><=W^^"D&Q M(\;:APMP9QN.RO$D(L?.:[82R(6=)455?@L>8^(CU\$_FB VRNN8_$H+T92* MI/+H>>RJ7X&[OP17].;(2N8N[XY MU/G*'#9:@\/R5D[3FE*/F66DR%WFZT>KJY2M(A5.TT/^UWBW_DO'C[IQ<+I' M_'Y,1_A_:?TP&:@*-=2[/S9N'!N=4K3$[^^$]:33U_$8)TL9)=;!\K3!Y]\D MZ$.+;Y.C$BY/)E0%MQJV'1-'G5X$BJI C\9+T5"I+Z2C@EA<"O#;FW\<'K;^ M\^G#Q[/__N>S.0^>OCAGKZP?+Q>3+TOGH1L\OGN)7KU\?_+M8;CT[)<+\\>1 M?>VW_0&X_O'R]/O3L7GC'_UU=74R>-]>/)U??#E:6 /TUQ_^'QWWUOO3?=&! MSN*/[C/CV[1K?SY&%^CEU5_FMZ'W; JZR]O ^7'U#'8GE\'P=G8W;)^9+]]? M#()/G8?/\/3VZN_7EQ#&WV_\+Z<#+]]-K^\@HMG MU\_=LU?^M=,!W<_@U%GV[0_@X=WLK^&?9Z3[N/7_^Y<7U>^@>OSP;79^VOWW\>/SL0_#Q\G;^[>6??RS: M-XL7C\^OO[PZ>G=Q<_EX"M'#I^.GIZ7W]K^MB\']X:$\JR<_(@ 41L3%7+4& MR 6NH,C@4_BIZ7A4R%A1L,RE.JVQLTSM\<;-0M=-6,#$O%WD?4CL0A?=-9%^ M36_!,WT-';\J(O.I\N_ON+@?D*@!FP6I2;NYN2B!*NW=G8>6^M%20Z205<]P MKHT9*&.LJ5YF_PW[;Z4^A^Q$X?H! 22_ >'TW#B92$&9]MI(;W#_>_MME/(_=+B"]A+(WH>%F1=N>B+&WQ:%625PY9-8;=1+OCZXB+8TGA?&9X_ M1(;Y?>#:09A9+8S-R(%#! T[9\V:&Y-+'44"PFB<EHCW/?!\/.C]E4"=1P-9>.6EZ YT05%T MQ/92M2ZJ B77WPP,&ZSBX-N ?#C^3\P.>TZL]$6-%901H/FZ+P5W8>9(TJX5 M-D!R#-*88-D^NB2/O;XSQ%O%"FI."&K<@+/3-G-5E[N M-,T\'5YEE.+P;@2=37MP:(5WT+J1GXB"AV.E8Y-+@)]F1/+!77@^7)+&R;Y- MS$=$69*U7^AMUG%;WU&7)907K.&K+#G**3YN+N@M0K:F.YL;SK(SP5RCVVNV M7ZO$,(JY-ESK'+"N5/JJ2*6[>QO0MHW K]EZL>]/ =)P_2.$LZ$%&"\:.9'W4)-T8[#1N4I2\U(6%F9+MP.XJ3XLE['@>\#'3.?0-NQZ=\7-O MC@I+(*KDJ$ETISA<@(WV"ZC@EM&/4!]J\ 60"&-VX%F-8R\; 27A;+Y@5T%N[!-7CHPE'I5P7YS?+\YOM\KJ%]K!-1B/$< !+KG@ +HE+#[_S?I]<87DPV8T4%!0E4/, MZZW4"?RIB^"/&CM5Q5AJW/PKM:G"BZ"BFJ0D6^Q?^RC,B49E47< A9+4H$ J M:TVGVB4HD8ZFDLO]]IWBI V\5+\9:7>3L7C&BC%JTU><9^.5E@!021MX5MW: M+7@,_\)9G\!%25O1ID!9 !\T"CK);WOXQ>K7N)20_V83YAO6AQ>6"E5W6%'+ MM'LXF2HJA&6P:[";2L)6V-9*=#L_W:)6<1S.XJ>O_YR0NIC0*6LG%>-::_S- MP[=IJR@N+#FZ2.W;:VL8;>E>VI)/VV;XJ8ZXF0P;K:F\4/M87;?Z\!!0[3JC M<&VHXF@8KK4G:?>>'IGR+8PHKS9H)43[^#7018E5TEKBV)V+A=,2$9V3&T_S,I 9E]MT$1 ^_@UUJS,BN;9X!,@22!@=1;8 M6B9@]9>\&7SWY@BF[$T*CFO3Y]H@&:FC6N>2E?RQ94!*_GM X,:_)P=722]! MVRVSW;H.3QK[FAX6&CH>--6U#EV-FDE:TK&RCWTOE\A -97 M;S7#Y^5*W;#BE!K4N#9!R5=>;O-T=[;AJ.Q\26'5-$U3 %NK1TYI7RC?T/4- M^\$Q9B[R29E3C'6NGBC)9 XRC=@!X,9DK0IF]9YXD]@5'T67$B4X-&GYE\)F MK01)>=6M\M?M]]:7DH*P@Q^"HV#5()AW2!01:@+X)6!9*X21,-34I9!V9#_6 MK%"@RH5),P-F0=T+)S'!HPL%]/F[%W(14F37^3T,R^HA5JG#@TGECH:B,\&^ MNPUO=YLRQJWN!IA]FYM]FYM]FQLV")1&7N=MX,7+ ^"D0?^#K#Q7"ZBR^H%;UF.EF7Y MU,HM) J)B!6:4\B6Z'K.(J!P'X#2]YP3ZFVQ(?/[9:P1A%*K2:F&^!5U;<\I MO/1V#N8PRT1JE0:8F@L><]@IC/'IW.II*\MJ?LXVU (5J>Z 3F6I*-AG*TIG M.W0):I+?$YW"4F7/M5Q.&E<)A8Z$H1JE-S]&^>/UG5V="0ZHR417]C0"!QEM M&TAE0P4>2'8WI.VZ9A!N'3M6U&"NY^!'9^%F<_FXU@+PZYIBC! EI$V,7@^8 MOT_15!K)B-1-VQ+I$FLL1[ M,(&>3ZHU;XU9-9WD$M3@8$ZL]%B-I]]-W%G>T% MH+T($,(UU+4 M^Z,!.N'!J;C-7EGM=+!X%A'QRC:J*2))24=]V"Q/T/(!.>AE]W"0 M^/0>+&48>XJBEGH[0?-.@\%QTZ8H[I&/NP=S4ECF3$AOJJ!:!,PDW 2+9R-3 MV")/3!%7T ;H L\N$[P&DH!_DEZ3G'L*B>(6=Z)A9-0-5$:@DT^Q$1Z' @9' M.SIAW+:RO")ERT8_3K4!RU8&)!S=XT0GW,', ML.WSP(,DPR7!SR?I-PNB7$(7)L,LP]2[1)[B8/ M$YZ>:J(S[;\# _D V:%HB^!FBS;!^.B:R M>Y(EEW"%K0#+K&1C'?MV'O L!!R]MH2A[CFFB[ ^0YG"SN(7;N#X:'GA6C*V MH]CT&Q#F<\$DO:O4EO/0>.I96%8XAF;(7=K H%%NAE\J0$=V]Z4MRXYE(;SB M6/U#Y&.UJ.!51A[5QHR.7$@XV@U55,$%_K&/ANXCJ_2PI )B-)L0'5'QX.@W M5 G[T ?VT1UR%]!AMGXJJ8 TX<9I(8,,1\N=2JJXLT9#C:I=#+7=^T"2?24HL\]O]0 M2P,$% @ *%DF5!A:"8N+/P .Q4# !4 !B9GEW+3(P,C$Q,3,P7VQA M8BYX;6SM??ESW#:R\._OK\#+OMIR*I(EV9LX]ZOQ2'+DR!JM-'+BI%(ISA C M,>&0$Y*C(W_]P\$#)'$10P+T?M\/NY%D''VQT=UH='_[OX_K$-S#) WBZ+M/ MCIX??@)@M(S](+K][I.;Z_W)]?3L[)/__1Z __KVO_?WP1L8P<3+H \63V : MKS?7RP#,$R]*5W&R!L^R]:=@']QEV>;K@X.'AX?G2S0F708)3.-MLH0I_@/8 MWT<+%DM.$X@7_!K,[[;@K1>!PR_ T>=??_[YUX>OP,U\"EX)[<'+PX/7QX4 S^A([]^Q'^HC7]X248???75 M5P?D7\NA:< ;B)8].OCYW?GU\@ZNO?T@2C,O6N(-TN#KE/SQ/%YZ&:&D$BX@ M'(%_VR^&[>,_[1^]V']Y]/PQ]3^A= /@V]!;P/ )7!%H4D1. 24E9@BN%T<' M,,S2XB_[^"_[AT.#[TNL,-@UO J1[$0KO,H.E/@]7(1$S-!D_(7! M:/_F^I/ORZD@7H%R,BAF@U^+^;]]2T'X'M3PFB1UEGG)L@ 2_:A +!]QL(R1 M-&^R_1J.JR1>FS$[BPU(!MPA"M"),!Q$W=OV^I2J+,R\\EX@6L[E M@N:S^>0 M77EP$3_X?G=-,8E\2P*DW+3V"5C7*ER8=%4-^*>WWGP#KN>SZ8\_S,Z/3ZZN M2XG[]\W9_ .2N)/3L^G9G)$XMTI)RGB!IA+3J%(%G03Q#!G::UB>C8-:2Z*] M>M9B,OM( () RNAH4%E&7!O(B1PI^,:*CPQG8P4VVV 7#'EH)X\;&*4#&3SM M71RHJ!80TC,O+D8#F \O1<6!F C9Q H('T%#A7(!,RIPYW$ZC%#4=[!M M5V M%T@"&@-"],\N.<_E \OU-B('W_?]::$C"G8BYJ$.-3\.E.\(YV-V&-M1L%\0V%!0RU.KM59&PAUL< MHKV,$Q)"R;(D6&PS;Q'">7R!D(VC#"&.5KL]BY F@.E0$ML+: ]U+LFY.M0D" OE_[84X0)RR]NHHO.Q=Y$?NF1M3K^^0&N7_2>3;X3[O M[.2P__]S7T ]8U_H^LY#J\RV&;Z,P5L/H^=:N_1_"NMJK"8H"N4#G@41H),^ M=2R)(E;5A(J+7L^.AIYRX$$B^\[YE/ZH"'W(ZF$SJWD:>FF:FT*3QV 8-U2\ MVP"FA)9YW 1$\%628:4YC$Q?-'0<9J^(;UQ3EXOMSJ)##Q&<5!!'Z-=T>/'A M[MB[*ZXE0#Q0!$*4^TW5V*8_M M#2U&V65PZ/CI>!(@L[@1=[>>N9"5 H><3P%C8_,"9GC%RR2^#WSHOWZZ2:%_ M%I4QW,DR"^Z'2T'HL+V#4+T^=)+([1)+WQ9-!,B6JL+Y7CG7L2_=70(:<#MDB?>N))2WO;CD5(.="HIW>1+X$3(53&=+ZGC$52)$&@(JHA*AH)* MMB"NV%FT3*"7PF-(_WORF <2T ]WB/KP"JGTD]4*#G1XFT%B^_K+"$J9&).A M6--B@7;IA>PD":S@FI/(V"C 6TXB'_\'&[+W7DAL6/0!)J22[6RFQ8O!$'S[U010S!C)';&:@:Q$ M*1 WSU"8);=>%/Q-7II,XRA%J_OD%R2_EXA]2'#)KTRR?>D3#RMR_4!F-0#7 M"\@"26;7W@.UU8$7^8!=O_[RH]IB-&\_>I6Z6@I<;QS8(5Y(\X?FWN-QD"[# M.-TFT$(^+G\_NQD^$DCDJ;EH"JCF"/)SG:7G2EG93M$5XV_JW,;K=9!1&45F M14P. ACA8\"2B'6#P/+%62?@1)=IU1I$G=9648BF"]/41")J)FIGFIE?R353 M.R[B;%AI56QI_5Y7!HWP'D64XH@GCT0*]5@KS_-IT<)4SJY@B)]^7WI)]D0> MD>/P*3(!!I4TY:9VSU\5. )ARZ' MSE%[=I5_;Y&2@4GX= 4W<2+3 OIL;:YI[UV/! H5N\OA@(YW=&QH\*8I"#Q$ M=_S"+XN0^3$ZAWJ1B?J* UQZZXA$#0B50-#! (T&>+AK5(%\[ M>SH-0GBQ72]@LI,\M!:SK!*:^XO23,DP@,5-RH>$OP:8G YB[K!-'F >)IKS0.0!-:AJY+L6%RRJNL+1Q-O"8L8::)-#;63!J M"]F\&F$W%N6:$+ZC,0U&6^8SC]8%9UM8&%V.X!+FX>5='/41Z6HM9OD#;^XO M8"X9!LBX$42Z1!PH^,Q%RCC2-=TF"?)1:'PTB&[Q^;&5O0S45?""A5W8!'Q0 MY#H^GP/*28#.2M(SSV,B_?II>X&'=A%U+#!T45 M"BOGX)LSKQ C]U(CYU@S\"7$?">IP='Y9(KLT]LXD979[G*%4JWG)KQ5@T%] MDY* 8JRK.S0)*]IW*77,S(-6UVLO#%]OTR""TLJTNIROK^>&\S48Y)PG0T$Q MUBWGN:RH<[Z-F3GG3]8PN44GSYLD?LCN<)$7+^KCV^>O:]-KD, AEX9B"J!S M0#[)M?;H0TS:B[K1%FU %$+RR*9=T!F.HU%B M!C6D@X_J#J?''0S#_E1';3D7EB4+@.+@P",Y"L+1T<'A0^/D:&*VD[V('[S@ MF]=X^6>7.I_:'JIL>3=:0@:2PE\E,VE=P;V\#"5@9CL7'AUF-IQ7%3%,-,ID M#2,?YX:=AMYN0E1?R:X>J>TM>D=?C %XD#OK@DOQ@M-M1 PU1NZDG@;IT@L_ M0"_I(X-7N*AM[2 "1!2MSH-7=#S $]K)O/:#UPH6E8%L&;(FWWR1#DI7I";) M*?K;;IZH>%6KB1-",%19O;EPY+G>9,H($O^%/&KF]O+Q-BT>(.7S#JJ.YFAJ)%$R\\BWSX^"/LPP-IKNCDWKL! MA,*\I(,!&0W0<+=!+ %+&O8C!T'#EZ.3-(79,/4R\Z6MG1GU?:4]'B?7UR=S MQYUDZY2OU5>J$.BE;3"WO^.@3X2U-[=I;G8%3G2GSO0'G5P<<[N#YEU!1].J M6$L"NG0'[:5( K-);AG;$LKF=M9UE!@6D>-SQ MN:([WL)YS!17J#881(HDVUF7(C$LPGP@+TI!%A>!5T 4UM$W(,F+;FQP=0K' MQ374#&7E2D&#'8H19G$=1+846[HX+.4@B0M=XO'@9 S-:K78 M6"O;IT:YO_)3EDM/N3OQ#)IL,D6GBJ[KM.K4LV.X"I9!YK@;5<=NFDH;RDRF M+I'$0"2:U$H;KB@W;Q_[S7TY4 CDIQP)4M*2ZMG_/#\\/#S"1QRXQ_/V -IW M[Y#^#Z3T8LG;9G=Q$OP-_6_ J_R?< F^0Q"D*=9I^)>XNJX!'NEZ=1'?0YRR M"EX>XF5?')%QIW"1;+WD";SXDOYU#QVTZ0:2!+3PR:WX2N2&E5L1P7]')V4JH$"R+9VM*%T2<'25<,6QK5L5^AQUNQQ''I M8&H)\I8^(R>,-2'+M[-N"8IAZ2A9]$1VZ5RHN:@2)P;Q_N]*[F&RB'=A!J\O M!AE##5D0/Y!6)ILZ@]R&/?ODR6%_9HZ=?LZJ/4?QL:M3OT1??,Q)^QJ)B"FZ M$NO0P=P'9!+*!NS*U-S$NC U(9"43X\CL=OWN&>'=P]MR*61='3Y 1.F_$;%DR[!C9!VQ$_<-^;!,[;IKJ@8[;SUCM MGW&_99YS-I8/6N&=:3W(,I^DI@H/V#=TBB M70U$9#DVV-8*E(!]T/YR\/=!PQ"./XK=1(K](G8@] [G PGHT!#A\39!Z]-' M]>0FB63Y#V.-*G>U;HBJ(!(]D<[M2Q*8 4B %_#."U=8HM&L\A$1EETD35D2 M+(C\9C$G@N,J05^'_:T\?26M=D@PC5=!AH^&@?)_RN7=)(X6VPLDZB(W"ERG MB#694$_5J2&QTUL?@2!=P ?R+\,(@=[.#HQ.+< 45P[LO2'P5FA/D$ $AQ<% M?Q/;:KPZI\5U7;U3IXUICW#^!M30<"*0S:U'5"5V+DD^PGL67_7((-N?O@W%4Z2>_JQ.):MI<^*8SCA!EVZ4/_]=,-VN4L M*E,W)O@E$:W/-F2>C@$8+FR#[F"*-.SD^@=P>C[[Z1J<7LW>@=GER=5D?G;Q M!DRF\[/W];IK#H367"Q8 38DEZEY,/'_V*89KF";XE)=&,T@A B(ZIYT'H]! MV@U67_^BO^.^\%TN"N$=[EN44J18 .D^!6X^-; XY'Z[B1M)JSJB[I^0M!=#!HICUWHU)NHMNNT6A)2SL;6 M@XHZ4"E*]([B"4$7MLJ%3H"_>2!0X"J?!I&'3'?7<1@9&".*PTC U(S#G)Y= M3"ZFHX_#:(B%1AQ&1:ZN<1AB:1:YG-,J41-[FIS7R *70+J ]7MM&32J;%9% MKJIM3T&',Z7#H,3;O"!EO(30)R\6KN#&>R)!BMF**:W_= P7PZ@W[(R*.P33#%2#0P3Z0&U+?PX4Z;, @$*]B%'DZ MXOII'YBC9.ILJ*1_+GW"%.\W%#N:&T/-W)0@T$H!W@4R/"PABPX>^79 MXDW[[68=K=T*#4Y#+TTG[TB1T$&D@;.-FQI2+ C2"YE1E#_E\:5=%*J%DW%@ MGKG;&5P8V%W78F)PA$5G\ PP<9XMJF9)$$L*;*O MML^2FP.*BGQ'%PF $GC493@O\S*-DILC*+@IEAL)EH;Y"C/FH> TCM(X#'P:=(Q\I/=2')/$O\Y6 M^9V?%Y)F!R2(?ARDRS!.MPF5/]ITKJ=D$ MTV42D%0R7!;G]39%$E2K;^*F'NA @E V"I"N\:(,Z9]XBTNN MW5XBD);(#!WV^]'04C(6Y(.= M"V)G5MY,E.VN-;S(" M^HH)G?6TONDMC+#>M"58'4%PTJI0'S[)95F^"#$V:\NX%D%OYN30E,B:(2^T ENRT:I.-?T.L2HFL9B1%+Z M^HG]E\EC,,Q;K0[;]^_TA@9ZK0V87*T!JM9^Q2-_3B<##5)-JK9PM+IH0$((C:NN2C 3.\+2Y.=(^" M;ZRBD>'1']P'_M8+>U4J_-4MR(APN&U!Q-&4R)B/:RJ$0$(&@:R "/;PJ*>U.YR32)H5Q#V-S) MDE6TO()IE@3++,^+FCQXB?\F&:IOB"$H#AZ]&0$J33_'"BPI9PH:HX^M9*I2 M/+1+I\J)MDOW)0_K6+)HK=]37N7H+&)L_F&$N@L #D2Y W@B ?;H^9N.X!V% M";MK0MJ5'#N()L<@1)_$$F>LW"(@WL?X)J)X%$A')0/URC,$Q;ZXF@$J$%PZ M&G=_S!=P:0?L)@T*1T.71KLH6N8S&4:1LANXJNXFKP!(E,.*=EML:4-W)=TX M=?^$2!FZ'H7,3>/U(HC*;+S SWN-%I1!@G8TJ ;3 L"=WM(!3_2L K<_7+*3 MV!ZVSFOKFT@ 3VMI4ZB'DY?9ZSJ#&T9ATEO70DGBDEY$2\)*D=J2XNZ V;XI M[0-H4:;S0T3:SX_KB.Y#;!2B;T9 XR 63FO#32Y10O3].@JK7R@O#S5KO:3 M\Q00"3/T?+B!Z/^B#/B(,4M$:N"5"^P!OUK"<>T)34:W"I,HJ6(L?*2A+:Z) M@Z7\'CE@.!4KFWI)\H0^?M(I:!#QT]G7R2L2-5RBBS57^#1I A<,=QA(7HY \IB M@Q(T=S !R\+ N-L!D:A5G."HXS"A;5EL.CJ$M"WD-DIQ'XT>?JX16L]U08/(JA]P.4@RM<#V*+* MO\7*("VF :2AG'JT/0H/*_M]$;'?)O/$7F2<:OL];&N;CZU]+0N<* 2) +I# MEAB.;[,WU. >+^#:R>C*=MTVM2W"F";Y$7?F#8RPU _9O).WC_V0-P<*4:V. M-(V7 "<.:N\AG5@UN4QH9]YP"6844&'J)N*G0+B6@>BZ1-W1C[."-8=M.HS\_ MG\6]O7 0;M%B#Z\'H #][BX+3GHMVXH@:Q &]]XBA!=QY.&..5XXCV?;#%<@ M\*F0XNUTE)Q60G/WG:T)G!%XHBNS:B!7\"QG0AOSN\B2-J.+<6''O'?$:9R< MPH':>#7W<%+.L0Z#R#!;X^^^7C'=11%'/E-J]1LY^)C?"@C.R@OX0/XEU3K, M]%9R<6>@ DI1EQ=L&HU.'V "Q]#MM!/OZO<+6B0Q[8!;)3[E57![-Y#W)MG.^GV &!9UX6 \8P_D M";ITTGC*"/.X*"XFW$+6GU6Z6RC2,4R0Z M1)8NT=J:89O6+,OL;@$@^O[I.*H D!F+1O)SJ*W'9D1TK^(Q7!1W?:_12JN9 M) GN%(Y]J==/U9#B;Q#H3^\V4(-SZ()SV2YA"'.7(+^>Z3?T2<_ M]-?5*Y1NOJX^41#EP)%_Q*[M/1J-0Q^M]UVNOJTAQ*SU;?5.XN[?5A6MH1^M M\'F"+"#7GNHB M>"0I:U6^AT[AL"-T$V(0/J434^FN,P6GZ"V".'_N0>2>@M MS/^%9_6.SY21PFZ]Q+\=O'2^D-SJX9CV^"J,JNQ/'1]MO'](4S6+\9E6NV AY-D'/MXZFF"39"X2K<8 M@2SW8K_MR"+C+CH[ZBD&WC,$5A"EP7*X5X3#0>N@&-!0N.A\LDPX'@3%;)I9 M+"AT\!$>WTK9[// EK-C5S-\!XWRGKC0#65"XE?'R%D\]8)DX._5 NQ.S/#A M\=+XDE.P0J/S+S>[@^"61"9QP5RU2?Y1'M0=Y;G/P[D+VW8SR@?VC)F+(Q>G MGMK'U/0IG8/C>1MXZ3+/@[3_VFRW,E M2I"CH+&,W6>P:H!$0D,$9EO-["(\MI,:]+E7)CAH$L8\A8QD=>=+#524K+:# M[8!E;7=9S>.B)H10T;BJ$-%D3JLV1 V[WF,$]S!9Q!UI?*@B\D='UT/33#+R M 1?O1HM2TY!T@$Z"Q993(4BFLU4+67VSIP.15&UO\KEEO7'R-H*9/8I#OS,; MZ\I;AT!F[V=HN>:BLD99,K=KPJ+&,G:- 35 H@@%F0@V1=65LC2RH#*R?3'2 M9UDI1)K4,+< D#L4I+/5)6(DKN) ?*;(OPYNHV 5+#WD(RU)80[\9CD. ]RR M?M@6R3L!Y"(4MPO HF:4>$FK^]L-3='.\?7CS*OGJU8\O_KB9/Z7AJ_OEWX?A MV^P@NX9O_W[U\L_'H^5Y=OC+Z>F+ZQ\/[A]?3S\/GRZVT=^GGP7'MR?;^<7Z7'ZRQ=O@S#Y#'_ MX^?EAZ^"^\_>_BO^_*OL;32!QS_#E]'3+'P';]ZL?YG_\/G+1?;CN]?I?'IP M\<7YYO;PQ=O/X>K?&SB=?W%SN_WPK]79O_[UX8NW/P;QT:O/%V]?'OSQ_OW1 M9^^V[T\N-G^\^N'+^X/S^Z/9R[>_O'M[\.'F\LV/3Z^_F&=_?G6[_.XW,+V^ MVM\W"V7#;>A#M!XZ+2ZA8I=]5X@$A1WT%@G7H(3B=/+O)*! M#LLR);P6Y82 J+L.@*F0/R20X+@VEP@BFYHL)T MQY(!K4MR>J.$K#5T\"+!"^XAOJT<4D^9P#&2HAI2(&4UZ_;)4H!=R[7+N(,X MJ%,OU(0RE^,+^,!$B)(X0C\N(:,U;9AVG8&P??O9%4"A&L7\"Y\ +6 )JC5! M?5'']WJF0L&*LA')S"YP+A/H(\JF:9RD[V"[_HK@4.9,LQGU%L @KK98# 2_ MTI&_.;W)$Q.]/'\%R!E5^CWUTFR>>,L_K^.0WO@A9=B!V;+YEFN*2$ 1VNUI M!L@44,[90U;[\CE7%FR+@@9O2IE0(6]<"^_J&M\,;T.L;M+S\VD'V1#-M:X- M!("(XIQ7UZ :O@?0>)XX6*^.)^=$52-/@JQQ+CCU;G45^&D,I+C\!=_ES//KJ+G0*#J^$:&CD+E2\A>>;P"! V5_[NK'^?7;Y)XN^GF M[/+FV>4T!P(!I\E(0(9BC]:Y$:@B?,EK$8J&O'X-,T32TSCY$&]_@F&(S<)N M7)>O8)?_4EA$-^-D#EC%"4"S0#%M1($.+1Z5 J*F@:&H_!2$8>"MT\4VN^-!:R*J9H .10'S8J87) (K)HN"(?1GJPKQ2E+3)8F917%]-?NZF M:^HS[#L4[/8B-P*-V1,=*=;=!QZ%*Z>AA8Y92U(&-.193V'C["Y\2;T- AKGW]P54KIP^#D:FU2VVBQ3^ MM44G_,D]^K\A+R>X.]F_>>"!(3K0R[& #'8J&5H,,2[P/(BX\'?J6UQ"B:1P(9 _8"T'@U_I<*>2(F56+:5:B.D.O2A#+TUG M*]HA?C@QX6S3LQDA$Y'V[L+. O$Q-"X5RV3(/@TH M%IQM+(I%>W>-+.>GME18CA:H><1*A@#)SI*1)MGOV#.)PP"7@/9/HBS V=/Z MTH%68"0#_=:4"L46%B1##H&P'6TU 10S.%)B443TF(7%1 -C0Y.5D\) ?DP@ M'%"CJ'>UJ&"4P(@"WIPLF#U03'4K6IW96RM*H$40,Y]WEMQZ4? W28SW(I^I MWQ&OBGV/8>8%83K'S8^TG.+.BPX0\>1)F!%P FECER'/HYF%L"U42N.S?+%/ MP:]D/9=Q%5-NE\ZY$?&,HJ\==CI'OYQE<*U7LCR**UP1D M48=1WUUX;R*J=4(:YTS'ZW60D2<9:#]<3BN(;F&$:\1TUJ"Z:]D(&70!2&CL ME;-I*0EV_J@T9$AC>$^MWJ*;(NRRGLT#N@-FY<< MH=9S,W184^5J*/$WS?07+-SMC%2O8O-D5$)C)#"\0W L0B,^^?1H8>1ZLL'? M>>)%J;21_GT;RV$EWF:,J MP7BW2P=ADI =%->\(S1 MW$PJF2C)?VF@;G3L-9;L?MQ)%[!J)TD T10->53*@56MP9S*-E+AWZ=\=#2H M58O8B[2K0#&1%&Y :332(K&F=6@QP"?LQTM24]!CFPS4@H%AG ;1;;V-+Z^1 M2SZ0]B2F_8J?NXPC-^%NA^[XF/7L#J@)'*_7<413H(*45)BZA DNK.7=BHE- M)N5-K?Q\VA[N"9U/?.Y2^J4H<4.H"@(X$?P*+%K>3(L7 :V$-A;R4\AE)&=Q MLRWZ>CU,>#37:^GBE N#]71Q\SD47:_*+D70G\=3;Q-D7BCD4M$[;5E- ED, MEG3:^I R9-E>4F/=N,BFY<8E,/)@DT">G5TH_XLDJ@\D5C)E[=Q%G<%-- M;XU5+;X V12KT<,[+;28AQ<$26W%YTZM<%V\6TSL1K"^;Q]ZXV<0T0$BOEYL M\3.,G7@Z5I86J!NSMDX[E]\L/G=3N5%Q6;&/L2O&\O$Q"$C8T4*S_["HDNC* MFMD\XF,S%#D'^,$]^I*\JJKMALPG)1V2/+E^0U=^/HJP>Q]%Q-V8%UK;;9<\LG$LG^NTX.\A0C_RKB-JG6*8VZWJM)K MDAW/W:=47S*S'>I_/CIMXDNP=L(!:AD<;Q-<4!TF04P-N OX0/Y%P\:-X$,] M[.*3Q4"&6+8A*[K415I(\MFD1QHG7*/-&S1"-/0M:DR3W05!&2NVT'>JN0?MG.[&A"' W$3HQD(']=^X%45E2G>^$6]MJ:J[; M\D\H/^.='O%JY/C,TJ"'S>MII0]TQ#5W)9/&D!73A_-W9)4/78)R/);HSG=X MXE@)6![92Y=6%H'D:3;I)&>?3L_5+^VJ,$E=;KXQQAWNU%W9Z_02 M8U"/X\AFYK>P^B)/]KF#G3)BQQ*30SAWDM-6%#OC?0/\T1]Q@/#(VAL9[>B7 MD.ZJR8[9,%P\T!Z3^'T0!;?8C9&.,PW,6CS:M#/UXB7"HU@H+,TODL2%F\,>-X#ZSX([^B#MC M]'Z7+-;FO+P;KB)O#G1T15O2CBWB))YCA]YM;G4ZHCBX&6 M=D]KGLJNCW(60.G/-@_75@=0;E(2 M.\AI*E*W;J96OPY^!W;N95M[J+L>@^;-Y2VK>U7Q$44LMCW)&-@@*5S%R0)9W=XR$W&YG #*:B._%G.<5Q048L/CDP)U*V=. MV9BOT@ZS[ XFU(J8;;,T\R)\;: HAD1F[@$R%]#)Z+=JNIO<2VWL>.S1)(D= M5[#\MLL8.)NS-4D2Q!.2E_OZJ1J2)S!.'KS$GRR7,,3R!OWWR*]%X--GE4)E MBE?)W[VR6P%F+[!X NRX?#] -L2-P,HM0;[G'J"[.E6U?9.0JX.'X9-EY3SQ M?7) X%S8P#^+%.6?JN$ CP=!!#@!2Q<\%R#"XYP49[L?NP 4N1748,)^Q01> MG_DQ<4-LT6@0PF*[Q)/5"BZSX!XB)S%>P[GW>(4^URN(,0_"@'[IV2GTT6<< M7F=>MLWBY*DV6%A K5@:T.$ C0=X J@OOP>\#.0[@'*+YJ0]D%OXKAG> \5X M8M$;(VSV 6>2D"X1[Q5OA/-']0FXB8(,T&D SP,.4SSEJ'"/0PG2-HD_8T)E M53M9+":1?XDV*QYZSU:G0>0A*:)R0T[LM*H2I2PHQ>ZS!VH[D?Y8[%[882UW M ]5V@*E*]2O>$9 M'?5J&XJ"7,=H$"Y9]:E#B0D:[(\V3 C(!V[3/&0V3#\O(H8N$J%TZR MP^1.!1X*I[B-LEWJGWI!\MX+MY!1 V=1FB5;1DK$F5E! LCLNOIE%ACKUZ6% M-X]W'0AF\TQNB53GJ),TWC2&[TD_TN0TR.3#X'?:+O T"*$\/D3' 3S084R' M!S%+83%&CB3\TDMF"3%6?/(I7N9Q13U!1[.Q+T#GY^KKL@BX.KI0[8"D0O;E MM+%BOE7R%),;0%\M2&//M"9@$X%=.X> MU3[YC8]CU:/$3QB24!/%F4=1!3=5O@0WKNOV!!"'<@486HW !;=1L J67I0Q M+B:V?@.8*CUR9G;-,\_GCRA4HX[77S7LU&GQ,3QYA ML@Q2W)=M\/O/?,L]P&S:N@!U=@/:)Q&%-Z#]<\IVCI*'^ZL3=46A0+\P<8^S MB&DP*A0EC[:=SXWXJIPQ7:DX7X.(;HJ QP]_@FB+CH\\VPE]V1K-YUC!U^3 M,4EXG]:.]+5^U4D[QJ>TC" "/MSZQ)A(Z.TL?1:&M?P\OD"DQ _%XA"M=GL6 M91#W^9 6HWB=-O -UD#Y3;@'P?P&Z$.Y+5MP+%7JXORONAF-#=Z8D7 M5O7)>> M@C# ]8N10+?1$*D-9AY1!W2T:P:KL.&Q3H\"-C]LK%[2V8J]B\60 M[>17D36Q552[&\><,_*X'/!V%ZKP^+X[E:U^J,8IC^6]U 09A^O"^M] _/)R M#I/UT8 ^&G,/R.R^!XK] 0; M=(8CK)"QVU /EH5RHG_QS;-R/WF/"XRP^ % MS"HS"C](3^\ND_@^\*'_^NDFQ0Y*F9P_P1EF5/DJ7B8P>V$3H]P-H.U W8I% M_XPW!<6N6$J?X8V1%_@IJ)XX5)L+'CDXR=[LGZ0\.1R.=59]S3S\3^ZU9@F! M-1(W56_>=Y!I^,*CF#B22X\&.M*;#R[J%J\_KF#F!1'T3[PDPB^?T;&Y76]) M8XQCB$[20/A%%S-!,14\8R:#?/:GCC](-7Z\STN7*N[OJ=C(T6F<7,/D/EB* MVX7)+JWJ25>DKV>QG-N(;"?,.UQG26EG.99:KW2I+"2WD?JHBZXJNQ+/\B>% M3*$$(CO\&-+_,L9/_D9&9;06*X!GQ1J?XIN(R@0M'P^-Q?[4QUD0/NU$,:OQ MTD9&K=#G'4?:L"I7N(V.#6)B\W.Z1:HWRD[15^J%'Z"7G$3^L>3953X>T D MSP G^ H!S7$D[3(TFM:V'%W[02"36U]9\.!]C,Q2' %]DKV=LQ$-JB A#^Q< MGW$6J-WKU7Y7)EMRU,]C]-U$C -DH..P67,+@G*1QQY"V7R=8+YS&3W9Z_3Q6^TB@6 M5*>Z!:"\?1F-4X[UTM M\L4("]#A#6]1_0:1NL)C [F]9WW67O^E"C$;#H\%;#?1BCRWN-+E2RFQK:*J>D M7T'*Y:UQ"VP>U06XV?P\CG.^S[U'9+W!+,W=97P/,_62Y&D5)]C&$Y*]6("4 MIZ!+[)71!;P*J"WC.,J@C2Z/71UI93]H1 M@:+Y!KZJ*:#V)=9ABU\9)$ *2 MX&_QOH.^A9B&7II.%%6'Z7,/,A1,QF%#M:$7!5%Y.-I^T6KRRCB_C.4]-A;4 MMG-T*:O[X+@+.2R7R\@T;_+%A3*RKBD5CD\8?9QYWU57BMD*O5+Q.GDD"?ZD M:!>]B%1\8R>/H)J17]>Z3G5H(\'_ED3(CB#PJA,K+6.@5?R.Q%B6^&L:0Y4I M+F;Z<4G[IK+@VRQC.SMKLRHN-G9MQL&Y@S834LQ=7$#;>&@%!&2&@_,0@%:0 M1HL23I-*2!!"FR/Y$W:WK6(EB*AYP.!KT6\I'2B8XGJ<:K\1B3T>.!(7D4(M M]0Q9Q$9PC.N_FF4^QS/<<@N9)4OI1]'G.^?:54RY/?W,7)>(&(JNO=Z/ZC'1 M9D:FZ5N -B8_P>#V+H/^Y!YY*+?P"JZ] ">>DM9PWC+#]ULP6;^P+J@%8""' M#)2@ 0:VYD.0C^D9B#DSA-+M0B;L*F)9/NU5V1F.#"/8O4EB<:$HG9SD:M$\ MYS676K*P:^O$C!Q<\=F!L!8U7U$>"\GX GDA6'*O,[AANJ84KVCIR]BSB/Q3 M F&]JP[WJ6/1AH99'#_U@!NV,_F2U?)R,\S*+3#;22&;EI!ZF#)9?U'>CCH'0CZ?TJU1. #'&?L4K $'Y<#!YC M2)3@7)2ICF*#*T;^.3WJRT;9@6U*R_'$H8J.RK,533/<)?Q4K(5+,-'51AUS M:J+>.=3$I]W'<=G#>T=U%:1_GB80%O$01T_E,!@ PU&%K>HOY3ZFRQ]=.O=Z M"=2-N8[Z6$CM_7K"I/"6W6V)FE:2/*XU84\=GVY,E&F0Q49ICGM*#M;RG"2)@LIBL%8TVNX M:0EV:'"X\=X+2=V:C'SDZ(.7'MAD*O4&F(T9(:KXA,"!$1WEEP\K9;@Q)HZV<1)GD2 3M0IKIN9KP#P$NY-;BF&?!M<@RC6?9Z\8&C^G_,@@L+:S\U"J?D/ $\" ML\AEV28A+GQ&")&V;(R3TGC"VRP:#6GQJ&&^K16]STW7YT '?YW)\7=3=_>RQ@Y4N$OP4;#@"XM M-#H)H%DMH]FE@5;#16JA<;"V=?"4^9]H975Z*QKD/J,5[2#R""LL+&>@2%K^ M7L '\B]&=^CY%1=:@PY('3\4TL&SPX4YCT!V3:[<]*9)SP@N[*^*0R9%W9:\ MJF\Y"]!IKN(F,E3XBD>&MI-H%96'3O&J/+F['K%RH/2%B,CC5BV,K1?KRF"R MI,;VY#:!Y&HK/8;I,@DVLA(?[$10S=P#S%S7KKD2.?Z]BQ9%QG.T]-*YI)9% M(6A<,K[39I?6)3+:N>I J?&NP>W1SP#"(W4+%>LA7O+UXL;/]_#8RSQ%=+$, MPI>3<(:_UPHM.@JZ\U 11=O%:%O,?4%^_A)"G[0.1E8%39I(9ZLK2!H_77I) M]G0,%T)^%/-I&^9GU1(@7GT*\E4 60;@=1S?*^JBR_M4NI'*E4+*!:G#NZLR M+C^:2)88'84*XR)ONRSW=K,)B0GBA3B2=AK&#V<1.I_7--]3P1AV.@U%X@4 MLX+@<9R;JNE:N'+/^"YDLMH;L/J:R>-:K*/CJ$MWK+K68Q?1:8WE@(T=<.:Q MLC/)[%KB1=T IE! 51!@MGH?9TP_\S2O&2!,K"E+-=0*,U0+X@P;NF29[YX6 M11I\EU=L9F3@\7L7@MI,Z\67MOFS-T7B*+VS+IX CJ#$)0=VX;TT#T7;9&:K MT/,NGRF!6]7UW5W_2VOKMS%R\#"RE=U+G^).(EP2 -_^W,-+1..4UBPW3(D> M7]UV ]RYYH4I"2WZOT5<\=];='+")'S2K%92CF\5*W$71&W@( JAV9UW76B<'&0X-OFXD1MEHS-W>73^/D%(K#9L4P$L^DAP8>[CIJ4 >> M&QS@X6Y0X$.:6TM\ M) JP,)N57Q&NM@Q@UG'*K"[XROP)?7K9;D%?*]LCO:S)1_[3V\3I-T4U(U4I M-U=W-#6TA!.%QO%UDDT6\S=[$M*SK$B:1,J+&K #($L##:P"R",A7&='+07V,^:'1;O2R MVO1M"^9X+;M01XG& MA[+M.O0[5-0_>83),DBQ1=9X(9K_BT9ALIX*&#*@<*H8%N TJZ"-*#C7.]7U M WH#,=QV+\(K>$L*\D79A;=6Y<]7@P$>[3QMO@X\/]N%AZ!E'=UJ<#C99G=Q M$OPMONOC]GFLIHVG=%$3(=X'I,3?:N$H+[V;1+ZZ" ,O;D6R(G"M@K'7I]#" MDLLK??*X;GRF_HI$84;^A^3>]M3YF'0H,8:JD+1L7'5/OTNF,;O,>)^SL%!V M"),("&65A\4=#8*(EI35Z\9=7DZA>?3;&F]7;@6*/(9I4<7BK>T4O_]+H"=[ MZ3@E45\TJ/FPT;*!QL+:-,S:>-AOU$&_O9/(/Y;4)BWOO?.'0R>X2I&K"J)" MZ$4WWAP4;1[9S?81N"E.LXR%I#Y;L_T&[3C4*NWAV!+609*G6O2)8SV'>)'" MO[9(?$[NL>6G%2"G$P"=P0^&.PJ%%M[VSY!7ZY/GOR%GK"?;SD( MX%$.W? :M$T]Q$'%Z>VI,O^]XRTJ+QM^%/>ITN1WG5XP%JNN2FO%MVJ_NRB9 M*BSIWJK5;MGGJG'Q(LY@AX<"8EG'"RD?"XQ"S 4HZTF]E%[67R).(6XR&IY% M/GS\$:H*..6C 1D.T'AG]B@7>GXI MMPDR+\11EO)]Q1ZW+I/KVL$U//G6)X<4UCOWM<.,FF$'2116(_HPFFBL1@2B M YGL1F/C59"=2YH,MYJ*XB;LQ9=TB2N(X!O+AEEU@2B)NRW'I&U4^9$Y3@XH M4.4'8^N$8+^AN X@*9\>)\(#'?GHI!X1)D8QZ"Z!*XI&BO @.*R\=$$0R6[;\\>OZ8^O\0;&$Y1LSNC6G%M4GR0H1_3886@VL:J3];<72T*>"@@8]V_.1;RB"L7=20[ MJX8TR:JUKI&UL[5U;<]LXLG[?7Z'U MOIQ3*8\OF2235#);LF5[Y#B6QU*N6ULIBH(D)!2@@*1LY=Y&?XU&H]%HO/[W[<+IK !Q(49O=@Y^V]_I &3C"42S-SOOA[O=X7&_ MO_/O/SN=?[S^Y^YNYPP@0"P/3#KC=><8+Y9#&W9&Q$+N%)-%Y_^\Q?]W=CMS MSUN^VMN[N;GYS::?<6U(@(M]8@.7_:*SNTL);DD>$\ (ONJ,YG[GW$*=_>>= M@V>OGCU[M?^B\WYTW#G6"SI4;N2^V8EPNAT3YS=,9GN' M^_M/][8?W D_^>J6_2+V^9NGP:ZC+LSZ("5[L/?IW<70GH.% MM0N1ZUG(9@Q<^,H-?GF!;R$ M>NMT7A/L@&LP[022O_+62_!FQX6+I<,$"GXW)V#Z9F<\7=]0(H<'!P=/]QF) M?['??"5?CS%RL0,G3/='EL.&,IP#X.UT&.GWU_W8(,; \P"A&*^Q?P,GYJE_7IE$8"\.?"@;3FN2N&3I+6,I4\GVP(,/?KS@C*K*G^2 M')-9C=##.=7&'#L3ZBM.?OC06X\HD4-,GLK(7$"-BJQ6.S]U\$U5]=[1 MV5,W#P=D9B'X,_ ;%IKT@&L3N&3_P],CWX5,&AFYN>BJ4O;07RPL*L=T"&<( M3NF$05[7MK&//+J27%']V1!(#8.3<@B(FL&<84J9PFX#@F1$CGU?W0P,Y_;( MNI539/3KZN;88@$]YFE<:F)TR P3&C](8EU$3HLG"UU/10>V(:).P&O@,&=# MEQ_J%EEH9=ELVDJI-)>6LM5LZ(]=\,.GH)VL&')RDSQ!0Y6!ICW%T3KX20KT M FJJ!.;QVCW@65 NUA$AK]*E\GGQ"@,38Z!P^8ZXU0KB9U!1J?X"QUI!: ZJ MZKQ,TM]6L94\6LJDS?.Z%80N(ZDNDHN[XDIS,IN4$LON8=MGIM=%DQ-J>-ZZ MCU@&(O!L,L(6TKM;VY<$N/1#P6\OJ'@QP<&M!] $3+:B,[HJ-M&A55+N#K9C M#!V6;L!DR\^QQL!YL^.[NS/+6GZ]VP4.IJ>0>GL;6LX5=B&3O3MV/4(M**YE M)JI+90WR$5/+'0=)B0V]/:;^/>!X[O8W 2"[^P>;W,2_A!CO28ZJZ[J !1D: MY-Z0OITME\8F\99!1V[3ET[JQD2O!"#C0/I]6" M"?5J;W;V62*/BC\%A(#)1:C"7/$"V:AENB#XY,:7"$-S :TQ=*BHP#WV"1NI M5C,K8-=*"(O4MX'UP 2L/1^,<&3YN9=/"ZP%[(S"6F[=43"+E&9RC@Z\.2 T M,"8^99D:D19 2UC>1P-MP+5,?ZHFZKU*I'VP;J?;>B][A]:A!%K8LYQ*,W'H M8?M[+ 6N.2C+9=<4MYH%5Y&63/K1JRV_0, /EN,#+;!E\=GN1DQ-O#*[C>*7 MJ2=5P$GZ2):WP$@S<"DFAKVE"&AI!9F,/[N32>#5J7^WX*2/CJTEI,Y7SQ8P MA]>=Z(W'+E=;%=:ZQ*23 ?&:Y7X0F)Q8!$$T2R:E_S27JT[63#VFKG/W#%13 Q+PFP1!UA4@P<%4#=N(7-9F M7:C<;./5JKI-1W7L Y'A1LQ3+$WGW=3@G=:DZ0Q&;93G@P$XIDA5&YB*J:%:UV<>OFUU MV%PZK;#]4>*U(T+6LC@7\6OIMJ=0A1M\GU7&5PFX&M?C/%YM#*US];9!\[F9 M6#HEENYUN)#A@P V:P%^H01=X^F)Y)4H^34B04EK(B*/EVS9QY+=VJ3HGMPN M 7*I;]8I?#XWTS%,"82Q2H]\E2E+)4CEQJBU4ZG"B[A.%TVZDP5$D,GFP178 M2*LG.\;'VJ1'+#7T6!Z>4Y5&\ X<,[L"/,F$-*> ._TML^=;'!,N8Z FCYM3 M%E2/BS0=]5?QC.H*J217YDO@A?)?8%F/3.U@L85)F1D;.4C@+,Y ME::[HI+.P*6_& ,RF ;"138K"=FU&(JD*(U?=ZNJ6E5*Q]0FL: '187JE[L- M>>WUO3R!;>H^Z)7GL6*Z[$:A["S4#D>)F.MV0/6DRE9_6E/PFR%&17PT$ZKX#;#70 MF%6-L6G$_,FSV70"-:XBPUDAPLK-XH>K&L$KXM>4\RL>( OU9C(-$16^AQ<6 M1'HF89I->R9AAHHBB0@%L4ZX>+(VAQC1_[KZE[!,CJ9+U+D7L6Q]R2>'G$H^ M,7+*I7T9:Z+_*[+>G-- Y6N9Y RL;1TK6,!:A*#>Y4NR44?V122-6!9S;(@3 MY86T1'W*;G.IN,RE$=,<5FUSL7D:4WA92PK)A/P: \UL3LVH8.5%,4=;D51Y M(V+G\C@MDAB+6&"%A%LRW]1'MN-/@LY[)%"!YQ$X]CTFV0A?8F1CY-%Q46JS M/J*V#-RZVAY(B=:8B""5TBR^5RB'@WSTMZ3;:4RC$(MX%<.'>BK[LFOJFP]T M;M&>1+"7C5D%3Q!6B?9\PNPN(!X4>U^"F^ ONG;0/)S;@2Z?$M5=Z%<)=6B: M1K!.LF[$8BR#=$J'IL+$^WUEI/R[.Z5$KP&.M!+F*DWC)M;H20H:2%6V7P&.TJ+M?0:K7H_5[E]W.OKM-UK4] MN J[YND_#0HO]IG!KWNY)OOAN^ L3B#\-S*P366J[G9(O.R;6$^H4$3,,F;_ ,S&+=&'X0C8[)!F 2 M- FZ!DMK'<2Y@VGTS?$>&.N9P=S,VVT XKI6^)"!7@=OV+&;7O'5V(6(NDT^ M6QH(&9RR)2.=D]O-&2W]86ZA&;BF!GTRG0)-2[^<) U,_0M:BB0"*M^POETZP([*<[8ZHCZ:8+"S]#[YQ\F[7*1^W1E7=49%+ M)X9U6JR_ 35Y39G#. _3>PA!4X\G"1/J,ON@77CN,;)N@R58Z2XZ/LZ](W(?3=3PL%PVOTJE M04FJ>J=;(4/SS_,4XIFY+]0=3)J[![58P+!PDFX2PR=H9@!M DA9>XM0[2:H MUC2/Q"2H^#)Q*2.]DTU0!*.5>%*6D>R&+*+OA["219["">_;5IB:Z\X^=N^%(W#^+%%[QSU?H0IE>TMF=$+.12M;#'UW:D^R]G MT],ZR4J9RD>/>:3KFF$5WG)+ M4-)\#IW#K%(^)$I1?_HCFYOI X$R&),9C!R=M3\!F];2 M'4RCB2\:]AM,\5<2R/1D$TO^5].]Z3=JWKM@,#UQ/;B@"ZR>(N@$"\-7U86P M36K'<#5[=C5-I-.$BAFNI^DP6@9Y:D(3-.>]/&_N(#L9?W/L4+0CS M<6Z57^94II%>YI$\!!U%X13.N1U:3*$%$[)$!:H:C*OK[S)8;D)RNC10#< 5 MN'(LI'-2RLC1 N0KJ5E5VW&Y2Z WD1$2C.B/-HAXDSK68F$AVE/^)JY?=:W) MFUPWWF/O)3J_7HFI@&YBK_P5+IS"1"62(@(\+I(-@54)?T^X#=LN<:@C*13Y M=T1*WE?7TT4XQ0*#=X!87,\WK91XYO(1?R:TOV.!Y!"O,M, MCF:6-*7^,EN3\EEBIQK"CV]?JWO[>C_Z]K5X?>NF0[%&GYGFTA1/R0M AIX4 M^DB595M'Z^A?M/E+ ?:&L%;A/464+'].XU1)$L5:E^GSHAELFEB,EV_]>;!6 M]Z4TA)H FUH3)FZ6$\UOK9[\FND"$CFM9HU?6;OTU__W\Y^.[#\_^^Y]/ M]M*__8R>O9S\?+&:?5ZC]SW_YNP%>?GB[>&W]Z.UZ[Q8V3_WG7-OSQN"\Y\O MGGZ_/; OO/TOIZ>'P[=[J]NCX\_[J\F0?/G#^Z.++]V_\/,N1*L_>D^L;_.> M\^F '),7IU_L;R/WR1STUI<^^GGZ!/9F)_[HGGZY?DY=,CW8_?SX>C;)_OS2[AZO9T[+U]=^2.CO??S^_(=SW#U\>7'QY9R\ M1$M[C#]\)^<' -U\_OODS7\[Q\/KW5W!5QVNA^Q.HN^P](E[<7$L8,YYWVVG M3>=J0E59A0@L?0N=6PL@XEP27S$:[//R[ M<6D #>[$>8RV"*V\0R 1S9]:KD>GOOU]B!T_F/QBWJWH^V92_KQ:+1RYTNZ& MXG=Z-M.W:__PH0L#I>G*0N;Q,C$A5.0;7&'@9G@GU)?R?_!'X8-I'$[B"$]]RG'5_P:[^$&@Y&3)D9A*4GH]+"&,T MF!3 5%[;9OSRE4_LN>6"*P)M()*?SOA>TS'*'*NZA_M:M:;(%05&]JD5VR9M MCDN#JNO,)V?5'R['>#4\!KA(%F+F'#?']2=_[59-84Z\7$@[M@7LFKYM+<2W M2(WJZ@JD>RZ%HO1\PJIHPV=' A&O@>M1S^IMY.[>6&1R1K"KJR1+2I3&>^I" MRY#5O]'KOD/+ 9MRPTN?+;KT/Q&;[J-(?DZ/J8@(T'(#$=*UD5.S@H"-6C.[ M967-Z!@^8':XNGU9P]ULC/0L))*BM-M49/6OZDA/_C*DSI@B%46T&.',R$'% M<5^E^4ZCUS%$=RVNX21X/QF'GBF4ZD#K+.<2X&',;3Y=&SE]+!"551-$O%)8 MA;OU1/V['-F]MZK+7,0%:_,V4PTR)J](!Y+9>+&TT+H[HX*%;\/<*T2+X91S M;;-5<.A4U3WH9K^Q#>6AZ_I.CK!MZYX-&FJJ5ZPFTQU MQN"L-6FVS/-./HU1KYO P'D@9+(.H&,TN, UVV)RCBF/),SV) MRP)V1@_0!%]'*=*:,D\E V=OPX^.I.NZP*/"+2%[);T6=/FYMPEL 9TJ\X]2 M]X:G4\!>X 9WX[NV/' -;(QLZ,!0P]XI8/O@X.4LG]):QSZLQ2I4R&7X4JR@ MQ2A!0NG9?-.>6(KL'QZ?6S:1/P;IM4;+I.LL(DLS-V7&$N$E1[U8AG+5/B\F=Y1P!A#;#9[B*R&8JS.S5KL+BQ&WM_6 :)I#JKPE-2?"PYG2>FM7E4(3WQ9L:=;879 ?4:!3OA? I&LJ>2R)7H0N$3+L(WDS=O4:#9-; !7+%@X!(CR[:);SDC// ] MUZ-##:V,27_#6@.*4J MM=U4FO'4>,44]8-X;CQ/*?RIYV(*PDVGN/._7%Z"T&-K_LJ8 M<,V!6OOP/S;B?VS$7SR)'AOQZ[OORZ+;$?385;/[/@=*^U%E4ST,KR@%@S[0I= MQ1--Q5NFVSPM*'2*CTV4]351KOMXY;$L0V'3=Z%^:9;OO,-XLA;IE9;XCN'] MI^0['LF!JSNK:&XDPY%LC:A!-@;)ZO?4];TY)O!GC:VS(BR;EF@L/HHI49_A MTI:X>'1N#4B0 0JK<*X "22N >50?O$F>,JF<*)OC8H( M2QF>D;/[VD"-\FPWLC'MF:I^*2JCN@0WP5\XSU*Y*#4KTLG$C%,EJ@,_/KSN MNQM&RJFX\,G^9N,7O9P!*ZLSJ>X+PQ9QUW VUU3/6<"NK1XPKC-EG;=D3\23 MG80U;SN*^#4LJUV(::'>3':\B@A6ZTZ#AV^K-I5W@-C0#6[#^/K*/Y5+V9X-IP:$ MMD97ZSO.L?&,R\8C8/DV,.FNJ*W-P.8O6<%#\Y:? M0ME;$]+7!N;6:JN_T5WO6K499V23DQCG-6"%EO3W[*HJNP+'+A$#LCALUFI6 M81RMR@\: 7IKW"H2CD9\CT:DIQ8DFFVS!MG;%2'4 >:VGLA0=C@O;:72KB+YK5:YJ7@, M=UC[I8?*/O/.S+JNZR^VH>L2L.3I!\PN#3I4']K:C-&GI*]SWM>.1;2V74TAU6KS"%'6UL,ZZU''6'/^7SL3',/"$=G&G7MU!KL,_A7 MP_B+-8_;&2G]2^QJ)'Q$LD>IL;;H_M@%/WQ*_F3%-@75WLQ.4M/;#CV/F? N M,4<) EW0BPC(W-_/IB<6^)82,=M*KLQ6@O+-0F 2S<]E\_EQ'B/Z%7W=SW-X M&4D<)"I7(L;T MZ:[A]BU8JYA "8K-"K_*IDQ2'0K?!I5%*/3$UV#)JL30C+4S\ZM%_X6$VS&+ MBG6CK#FC'&2GT 'DF*Z6,[K15H!4G%Z[%J&$+E1U6)2/L\/.N"J"O&R*+?%W M.>I0V!=1&J'[H/.4_D9-HB-)LQU>+ETR17$.DBV4+H$DK05DG.3D\^LC&A!I'(';P^L Q M]I%'UL=XHN+8M9A^*W9,7(HRUC/M7L*1==N?T#'!*;0#*97-LSS*;7&()?HQ MU6#L7K3N9$*UYV[^8>,H:HO""UL6U1;-N$RE*&RK51&L8_KC@(SP3=%3[H)0 M16BV(RC,U8C"YEJ54 H\]8!<$;R"J+ 9FB!42<(MQ"NE&X5-IBJ!=H5=SW*^ MP*6B("23;*LBQFS%*.O )%R'Q$0BP*J,3XQ0&S)^\9&;:2W$Y+C +'L_QTC% M;BI%K"5S(ZT$97V"9'=3E J[Q+@"/H"@)&S';%@D6JO*J MO/.W__MSZ+!'[@>VY_[C76.O_HYQM^?U;??A'^\ZMR<7%^_^[R?CM_]3J[$O MW.6^%?(^ZX[9B3<GO1X\$_1L MGP=>Y/=X@!^P6DTN=^)S7.P#NQM$[)^6R^H'K-'^T&Y_J!^R[WT(O>P\\;C48+#B1^*7<3 M_SAO=^K9/D^>^]GUG;V ]_8>O,?W\ 4M'#\8^JG=T,.>__ >OG@?CD<Q7?Z_GV^^)H^'^<\GC[X/ M%=JL$! O-]FL-9K:(C4X=&HA!81IZS3:M?I1K14?%I[\,>6D^'77"KAZ//"3 MO=];09>>A \)Z C&9.4HJ#U8UFCR/CX_?T;?QHD/<<+-EX M_[_?OM[V!GQHU29V$MB+_ZIX/\BP\=)#)^]!6!4?/GKO6D,>C"Q8]=-O V[U M/QD,_^^WT X=_HG]]E[\PS!^&_+08CW/#;D+5!+RG^%[\2)BU5_ZWK]\:??^O8C"\*QP__Q[AX>_< :]5'([FS8!+OD M3^S&&UJN*3XPV2WW[?MW]"O[);[\([W(_6>S;U)O@?E\;G-'9#&-Y'#:]?6 T?1JT-++%P+O1$MKMY4 MZWIAZ WE9T]V/QS@1NN_OIN =2VP_^;P)3[8]?P^]\5JGQVK]X,U8<.!Y]C] M^$NULOB^H;Y_]^F__ZMQ4/\H]SYQ@O<31R@==4"_;NJD]];0=L8?9JVM0P76 M3TZ&"^;@:>GMST!;N8?ZK?OI^^7%W=FI<7O7N3N[!9[N?GI]9[P]._E^[(E[]F=XP^__\:X'2C1>T_]X M!_KOAU.O!\^X(=VPGQKUVO_\]C[UVT]O&/63NQ"+K>V@A+ 9N!(*^3_>@1+_ MX=[^R?NUT(]X'@[_)[)\V*,SON$CSZ=S'A_N'WS,8E0<_W^^=V[NSFZ^_F7< MG%U?W=RQZ^\WM]\[EW?L[HJ!^+M#&==HL:L;L.1V^KOLZIS=_7[&$LF82,7. MR1U^W3AN[0MR2;2?-T$H+^A0&\(# R356M\:U\;<\FO:UC/ZY^Y_5/XV;M/EU=_ MG'W[?';#6G43G0>-+!%OS_6KB.0U4 >1P-7-UL"VDOE2YM];3I K],EG9Z/# M)B7U]PND_MU-Y_+V F7[7&+_M!+[KX4!4+9[OA$.. MCFF$C$KOLWO>&+/2V M1ZBN]=R)T6:<7WP]8Y??\6KY,.LR2YCMS WM<'QN.QR>[>+^ZO5ZK7W0/&B^ M 749(*@XHKM5O+$8^F[X@QT@Z8>7\,WF-*K/%-0P@/G87U[$_I1Q#9-=N+V] M%+ED*>G5D,_.V4^K%QJ($>;=,S_&!+,"%HQXS[ZW>9_9+K/#@/4&9,?LEL-* M4YQ_\C/;[7-@<:=>BKU1^Y']H]RU'P ?JA!_KJ@7RO[EX[\?O*U^X?_[H4 M]VHJ$,:N/@0AV 4CWWM$(DJ;$(*]@9L\'S0@"E[=XM,G7N2&_OC$ZZ^1VXF> M+_FCU;>F\F[83\%+0J/Y:XGTE'EEZ2C*8N#.^GF!G /,W",LJ,MRK; _.JPU MC^NMXU9K-OS?A_Y\9+W]P80=(FD&EX@'*IS/_AWY=M"W>PAG3:*PK3\(R']; M9U4ZDO]@N?;?]/>N+A\536^,:4I&XL7>S=[M'CL;CAQOS/W?NO[[3RS--.S2 MV]M-;P_)&"X)NA^*KL$8A]6%M?*%]:XT<;"80.WT^SYHBO(_7VV7-]8L3!NM M_6-V9@4A^^Q[5I_=AC[GX0RE=/MES&P/2P&H3^"?5_Z=]P1ZWXGGP/T5!5D0 MF(O:C7)M$N!7_C7H,#;F77RZ^GV6\?@BM(@LZXE'\_7K%(\M!<5K#S1!Y_^S M1R6H=?NM9KV]1JUB,Y>*P-^.A _:5]<^$)@]LAQV]I/WHM!^Y.SJ'BX8'NQF M\?Q:;E:@"(8DL9NW"X&QU 7Z''[?5^G,7NMU-'_@&B5UQ^>6$ ,[!XW]W.?P>L&!%H1>#U; M:<)YP]E5>>2V82+:27Q+__U?1\W&XEO]=GXD]XJ>T0SPE-!=CP'GV][@,' M)0%58N:@)>)3'#./'Y\%*B5[GO\=!6#[CTM((YC^NO5A^\+MH^N"&]TQH),# M\ 8O,+9?;R-KWO"'R!&.S-O:'=M1'-QL-??D(^' IB#?"(-\ M&NNRF'6-];&NV'R\<[$.\G.PNS3C:5!#H$D^W"[&JYAL628#XK1 $_'A:K%Z M/6 R42>)-..CV,_]E '.:SE? .5:+!@"@\*+?"6I#:Q7!#;<@RUS>G^?W]LN MI>20!P=MEV;]8]$NZ.O&1_78Q /J>Z1Z^/XX+TL#]0O_1#ZP3H!3X$%9QWSHMUS,_TM$D)\]Q>4_6[ M!?52T;LYYD8^%%%HY,I@8/FPCA>%=('@30*?C],K*.0OW#@-4$(]Q Z*'ODV5,OZA"6_FFY MD>6/68,JFYLFHLU''SW\/RD1S@E[@-Z42&B\ P'?L\%X"O[Q[N+R/"TA@*QJ M?2^LR4=RXD5$,;=(,+=$>%<)W;UC 1B9G!Q=D6N+%PKR?/>I=5@WZX=-\WB_ MK82*VN G0]'P/1/K,WH!N1X/Z_"[>ITECR"LX%\==NWS>^ZCCUX\3G0N @P: M-^QE@Z(OC0[*Z03U@CAN6QM4Q0VH"AI4Q0VLGK-!50Z>YUGEN9&*P/@(/_Q/ MQ%WT+C82R% S./&# F0?Y"#[0,-A82*RGK2O[3:56!&_N6@G79];/VI=#G(5 M-CZB@\RQN^7?K5/2QHAH6X5%?IH.97U==V[NV 4#8%U<=BY/+CI?#;@ KVZ^ M=;!A0:;[P-JVDZE]WNB)1=DPFR@;-I*RX0WNYOQ?'7:.22MW/O+=K>=$%*P4 MVWDN$%D.=K!D8/ZHHI7"MZF<=WTT7\1[FT\OSL7%>:\=S(@MA@33*LX26-@7N#E$&?Q M0DNN.WN'#78ZH^' :\3OO1ISU&HYJ\T!EAN-4+H32_1O$, M@)U3-V@6Z@9S'W,505? !4M3?J%EUNGU? QJG/T<<3? VH"EK?*YC;AEU;[" M14IFFBN,?4E ?;6MKNW8\S%.X]"L-PYG,DZ!S;FL6OYB4=3:/(I:(-GJY2"H MG&MR>]6"K=K,*K)W;MDI7 HYFN.KX\P5A*?&C<5LV#P$1CQL59*R?$DY%SXJ ML5B)Q=E;I:R8@>< <0?*"7+VG\@.QVSGE-_;/3OY77-;\<+&\/>_5ZO9$C#C,?"+R.+)\]X@M,B>>Y@3AOMES^^42Z7"<*!YYO M_\W[4[/EYH?J!C?5%*EX^+]Y@2VS]JSX!1^? ^@7E!BX/,#7OJ%YDR8/%X,V MK#@'>-=./JN"=^T;FA>\4R%NUCP2GYH,WCGBU/'! M&9=]\99E+J3!38*Z6$T]G*VC/I,J,*^;L57H9BQ9D9M7*3C1,OA7TPBTS.[G M40?6LX$MU04F\N:?71%8=D?M-6@!FP?WLZH RQ=-'+3,>G,?"R>V2 =8.W#7 MNYOMO/U?P^6O@7K&S=\Z,%OU/)I]4;?_?NFW_QHC\)-;ZL!S"';+ >7![H-. MP7K6R XMYX727W*@:SC/A7LB3E-,AD?[!^;Q_FR_]7/184D^Y(7AU# ;1Y-E M>9M3>>6EC@?V;Y+D DT( G MO<(ZH02P)Y"2.133/C3K1T?KBT+,E^O]ON M/!!PK#CB(;"\J;!':;RK'U <; [$SQN]G<*2B\%I(L*Z,J^L 0JM>4*F:R#S M8B*>JY#GQ0F]!8ZQ;9D VPF%#80P8D[OM6U>Q\9C@\7X+KT M$ B-5!<']2L"3VE-)Q"@F=8D*[26>!;6VY[>!UO7]V#*AFZ5+$&1? M82M5\<^)S@E,?"Y:)ZSAG,N9&$L!)0\"90V][7ZZM-TT:"7_E#9GM_MI;KSE MM[R8@Z@7;]NPF1X*I2V\GCX50GN6EE6E[J_@=110^")@T''[G10$ M)'T5AY?:K99YU-Y_)16JTX!(=4P! MJG4M[,4OQ?=SAOJ7$,W=^_'3!SH&G6(.$=PTFR\T$V()H;HH> [JQVL S]HE M9G&DTXNUNR+UX\7)D[*TEU@15GKPM#R8^L&!63]^)3T!-H6<%;2>A9#3:#?A M?R65(5>%KR^BS'+IB.8E#YGC!3/EY+:&W:8G3*P@'P$P%V[/&_*O )VY4K^6 M%9(%<;X7&S">CI(5I.+B*%E6-$Y'22437[=,_&P%=H]\6J>V$]&D,RDE<9Y9 M/!X&]>C7R:,IL=E&)AT/<(H!($D^[YCX!N./V)7CG+6*K[^46 M5U72M4"ZOFK,54+XE0CA=Y_^I+@DUI+!*IA.D8SQTF5M>II7C4V(Z:UQ5BU: MK*< T!'GOZ3C7]T3=VEU>QGFFU$CV3 /#O;-5CNO[''9K- M_8:Y7U]715 F9V]+4H>V*&MOS;O?-+06R@AL5?_+=I"L[[V9+# M72;1.".!D%4)A*D$PA,:"!R 6#3FZSBW2QZ_A$,?]&-UNE/^;G-NDCY!KYIM*2X^D20,EI=&GU)B>7<(TO6G=Z M86[NX]+[%;T>:(^BK48!C,K>QU0$%;X\H9:7@+(U[#9GT")./+1D2B:I7(8: MKBOQB2)F*\#ZK.2TW6PHAAW3'E,#CRN6?!TLF3?,^B6RYYO#;MX/,ZA.VK"( MH8;7H@F/^.-$=>+1T+P5(*^P/6VW,W&>=.:@TYRJ;C05FE\3FBD)3_I*8LQ. M!?*T@4HWQ)BOX#45%"LH;LMK*BA64-R6UU10 MK*"X/@5NM>9Z>6GRB^E^L\8S+PV3SY9CN3WX0 !'Q6_$7PWY*49REM"ZR_=I*%2%[<_;)ZR"_%2'TRY80WM%; M)[SMIK)G%G(K$-;QI@FK$E]O4'PUZBN#>?[__RKDW8:\V(O10TENTA6IM&A7 MB])HXUGNV.=P/5>R<9MD8_.MZW85Y3T3Y;5>/>5M8);AFX@CYK_KV0ZY0>MK M6XY*[Q6>*WP6N'UN0VXI;NKSFWBJ<+!_';;2Y]: M=0^DS>&P6^:YK,L'EG,O"_39B:CFIS8:V(#!M[O4\2CTDJFXN=C26DR7R 93 MVS*70X8S^ERO[M4H@./&3]CX=;.A@.+7/@MRU^KAWR_-W[5%4*MXO>+UBM<; M[;?!ZQ7!E*4%3VU\U5AU#O)%$$2\?QKYH&>*!A]44WL%VIZ_^*S[!6FDHM,M MI--Y!=M!)=@J@BE/L*TR:NG5"[:RAF3,[8)8X_$N>4A;%'WEY\_6V(;4C&?Q M?"V7A[MNZV2+TVK?1++B.NI1UJ4*/$\YRM9D+&XSE562J))$;T@2/4]]TM9( MHHKLGH?L-EZ]5)'=:R:[9?_=V..J]P7M_9QW_8J!;@O MK\Y[BVCFV6K%5J&6C9?"5M3RXB7,QLM8*YIYP1)FXZ6G%;5L(;64$\(^7#&$ M+8< B>$_%V[/B1"CUYZ/[^J$(OL:A]'<>9>>2_G8GN/ (Q?8T9D'X9KBW!4E MOWY*GF%>'VT3*9=HFC^7EZDBYTV2\PJ.T(U1<\L\;.=-0=X*:MY<.XLU'D&; MQB4G!-N4(\:L>YQ1Z'//?[!<^V\+(9T!=)GLN:E[='.*S_$JXW@+LO?$1!_8 M$'T53!]GW#XVCX\/S%:K.2\'556A+Z4J= '26U_:Z'2Z$P+[P*SGSJU?'$1E MX.:U2K!Y#?WR:NXJT;%IT3$OSLNKO=H6^+QA(BC'-&@V-GB!%*G^6W.3%-FP M%14N*HK*JY;:%OA41#"3",K+D]\P?+:I&\H:3QK/CUW.29!ZY<:ZR):;0#.; M.S]^^A"+8>'S$QIU!^7O M34K\VJYX8*HO\+!>7T2;K@3)2['C%J"^^55F&T+?-XP$90CA9;(<5$E6^A8L:*&1=BQO)JM;8%/F^8"+;&3EY#C[^6 M>=QN;*ER6M'>\@*HO,*_;8'/&R:"K3&17[D >@$=(]8(@*KWZ$9*M]=M!&QC M06+5)VB]Y#OOK?\\LX.WIO7:-E-9)8DJ2?2&)%%Y%28O0A)59/<\9%=>D4M% M=F^0[);=VXRRFA7F%"W4G_&P:=;G-ZZ?O4%C1=RO@;@WU5CWA1'WLT^IH:V7 MW5M4M!;]9HU9J_$:NHK^\KR6UG1.VU^ILP3E,UU%81!:+J)BW4TDMM$:W"(" M>Q6=A1:@S^?N++1*5?$VDO*V:4-;Y.MZQAA:>W,B><%:GA=AOVX1#;\!^=S> M7OD\?]W0-LKFBHPW2<8'VTO&K6/SH'Y8D7)%RG,Z3[:J2W*1X^7 /#XZV!ZB MKGK+;B\]OX16R0WSZ#4TEWU1S64*V\\"@;" ^X]VCV>3T*JJD$6THO+:SHK/ MSSW_5N)IJIG:WJJ.$Q4-+4U#Z\L(GH^ 2#;/W<*^(ISE"&?>Q(KR6O95F"L7 M<^7UV:LPMT7"NE52_=@"PAKLPN-*8&\)VY?7:J["W#:Q?4E56PNP_>'V*/B; M:V>R+06"517D!M]N.7.'U1>/UE88[JXZ5 MY;M)GJM)WFO%P[R.QO*:,5>8JSCH)>-A3@[:+Z]S:X6Y;7+5/T^'QZ9Y?+PE M[OG72S#SLGIY?6$KS&T3JS]/+\4M8O5G+W=?X_%>:&/$+:K(?*O=Q[:( IZW M(^0+3KZT0/41 6=>S;K.-OHN%>#A?( M=7S\'+25=8549#4O6;V$ M5F)M\^C@.33O]8T:>+8DBVQ'L+R&8)@,K^7*OTQ6VA)+8UOZ@S7-X\-#\W"_ M4AU?/AD]2_N)YO%113K;D=U:WO2U"G/E8JYJ[[9MF"M%7.\_?Y.P=JMA'N]7 M[NDM8?RJ.^"V8:X%YQ3IS M"K)*A&WR\JEZ5&X;YBH.V@X\S,M!5?.%;E;(A7?VLQ7P/OK/ M02VP\$6R-?]5'13*L>WJV81VX:Y;3/87A7#5W7D6U41496$ M5L5:VU83,^_-65[OE8ID*J%14<"K%!I5\XF*9!8DF:KU0$4RI:;"[F^LCMRL M'QR8]>,MFF!>E9)O.6U6I+F)$'/V-/N+.S8V66%^Z3WR89?[K%7/K3&?D7$ZY*/&]1QGH>4-]@A9,$:_8HVWZZ W>*&)/.W!:@( M^.T2\!;WM3C:/S"/Y\]=KJCX-5/Q#/_'5C74*'2>--J'9OUH[L+)LBEZ7J]> M185_,P;H^7F8#_D\&>$;J'4/+?[#=6NB- M/K#Z1R;_5+NL)\0[4JMD5] /T>,(P'B9XE7O!IQ9O9[HIP!P8:X7PO&P_P*< MWX95'GS+82/+#^6@PH # BQ ) XGO+==R^W9EF. .1/R(;PVV)NRQ]5/.7.% MR=_^GUJ-G=ODO M;C21:C+O/L#/9KGBWVE'0;*"M>KPW52B2M-G+FISME,G4:F=79WZ([L;C^#$ M'=_JVKV/[!+X5D#FTD,@M/0?O5>_(O @:&/ % &JZW/K1ZW+05C NB."N+[9 M@YS-(D 3Y.>^0=\4;C;!5PE4-C]JQ.+TGCPL24GRZ;?NI\\\A(^,<\]G?WD1 M^Y,[CLL#6 D$(_!,-Y%8&]E6]]/YOSKLW I@+1^I]-9S(BH:,PW3/178=_PU%[ MZN^T:M"#2](:!S16AFC.Q-CGC7)%9[>%X M>3@.(O@?[YK9(Z]9H,;(AT?K^1H58FJ]*PO2(L*ZM%TN / -5AX$[,SM\_YO M7?_])T/%RL3W&# 3GXNPF:3"A6$\=SQR$ML3@<*,>D1G!#70\RV4'Q\B.(L/ M6AQ_]^FD<_L[._]Z]>7/)19Y.G3*"GP:SZ@LD_E+3T1WI1/'_^: MRR?3#8CZ\@8$'!&N(6_(YTX(:+2;\+\\2Z 2'G'WUU?V<',0H)._]]1$.)5 MAXW-?. @T*7A-G E=O%3_'A; 3G7/K_GOL_[+QX_\4D(1<$L'!T6A?5>((?1B2<;3KPH'*:BLQ,5 M<\N4RFT=KYT,+/X0GH14"I<.E80\#!@EMMGCFUU;:>Z3*;!,,FDRRB+ MG5[/QU:EDO8GM+(%5-D5*(JTU) -]&U[SW:8$5_'G\',%ZX5PJ( MG1B&\Y@1!RWS(#>K>$DB6]B@6$2"9?#S(B7V' X'"5?-Q\!B)T/N79=Q.YQ? M7'8N3[)NAQ<,LU(5.MD@(" &I1 =2"4P17O6R XM9SG S3/7JQ3-7)WF)#G, MG7\-;_C(&E-@\^K^1D#O&H%WRKM3,H8:[0/SL#W;,"A95RE5 M3L1JRTC>O*P[5A'A7-7EA1F#!7K%N3IAOEZQG#KQ[))$HI.,1+(1X>0E2OIY M:VGWJ21VOFY%6\9A/BG*VJE7KXXGA>K[4*L;HOMEIMX=D8) M^POA;'\9C$U/.%M/_=F\J#J8&U4%F53EWWZ^NO9]_.+N\Z7]GI MQ>W)UZO;[S=G[.J*$#S"'9X <5(^0C+YIV\S^72I M/99S\H625-M5DNI$DNK^BT]2+8<:UYBH1CF0FWO3\Z;)SK6U\W]UC-R$699- MF'VN'5ZB #5"C\6)J^Q<24D6)]:6ETL[N4G,<++OQS*A=EI2L;CH+J,AK-F; MN&KQ;]N->+\#5^S_N_(?+-?^F]3@$\ 2BWZH^/VKT'5@4/2GU?W\?&3TY_: M0<_Q@LCG=_"&SX[7^U'KU?\?ON'_-=XQ#I?Q"!G4CWCVXE[W>]>0O9K!/MX1 M3-\FAO>-4SB4;U.*!MZDGZ/ 1J;*TL'J>]$$U/L40C/(SF)>HM>*U:P-X+KY MCMG]K >LN']EN.,03$#"W2$1BB(ER<['-#/D5'RRPG$ M;FR7'B/((0U>\D>K;S% ]RGOB>9 #>H-5-_+) J?QUBE23\(HFY FF$(5(M6A-VS1T2U-NS:4B2(58KD MUY.;\;FGR\]1Y >1)7)T+V]NV7&SL]K3N^._V[7V4[,6OK" MBKWV&-I!@ : =(B;98J]D'L4WZ1_RY[@S.S6BH!KSER QUAP6?RJV[/+OS3^ MEI\"C8!%"A+"4^#;-:?P;+):U,O\RL S:K\4.&&W43?ST^2+Y+Q7D4_6,GS> MMWW>"SV03__D]_<^'X,TN(SL'^XO!]'R\K61U]/;>G3R,W\1>%# M>>KT%!*W'0;QAY1A"^)'XU\2,@ESJ6GITX]ZM!5'G7[&XHI$9@^'O&\#T:$X M]VW46[P\)F>= &1_;V 6_V)(D)LJ_+J\ARJ-!1>,AVJ/]^0"+0DY1%>+#2O[ M8SQ'CB#.H"=W,7HH=\'B;54"+"-?VF4+L/VR!=BUIF @;5I=[Q$T=T^J3$:B M,N70V;WM "%U4+=Q!%-)JHL5-+DCN^$]/+TUV9*@N']3F^75@1R M RF &M_L:):)^%CJ'OI"$F'MD(I8J1/1P<"DL&8A])E/9>S1Z"7/MI-M+K)[B.']%%;O ED8PTS\8. M2H'C74[S-!TU&X\C0E!94@A M*82:OL(#\*<+-R]NX>3[[<4UNXS(W= =R[^_.%X7_:-RAC'M8T(U 8YL-1I' M1W\VZD<50V7I_;!LACHHFZ%TLNERQ^:/',U/B^XQ(ZUAFJ!&PY;[Q=-_7;" M>@9LTZ.@:..XU:)K))1.A&@XM/1W91T'MN/0QKI<'0+XRG8?/>>1 M:ZX7,+,U'XO^(3QO!-QQ\K]$W@G (IAT/NB?XGTOYR B&28E M"(P+R><]V@'5.:(',W$&@5G0)ZC*5%A N[94YFU2VQF-?,L&H(AD U&8Y[FN MA$&LOF5MFV(ZM5U#J(\!Q4+AI?@,K:[^F./82 X$+=H!L.P(S9-<0XL)3P.2WT@8]Y;MHSH4<3-ON9X7.?U%B3-+FTRCS8]& M2>0G%ZJN@8R4/BK[&CC<@*,Z)<>M^U"J/>@>=CCNVI#$\;MT'"MVS%X23_ C M3!)UT$2S0.[*WPF% KX=<(>D?YYF!E"*'*H!S'T E#P#A0R(?@ !FAG2?;W' MLO9DQK^M+#XKY5P7-QG)->4;T7:<7REL,IO$BFGX?&C94FCE[34&8E::37I] M\:E3Z>S-]ZW [2NE;1\H!6QEGV2;V*.1[XZY][VAN'K14!L(6PU$L(=91OWD MA8G&FJ"[X"9-1QA [. %+I\WB"G9T M9=C=&&$DB[P,W7\+_3&8XD;$%=1/6<%/I_@QD4:!ZD*;@K=]&^])O(^!(PPD M0PLX:8#\_D0*9#_J4;T?L8 ,\^K$7<3CNI,DX?=$02;&R^4D#'%11AH*+.O1 M([_(6#A"I (%^[J/@EC_R@,.Z)HX!*+2R$>EI;0L\J4)VH@H\FF+4!DIA/=9?3.FPUR$6D/X MD8SFY\+S/@RK[; M7QY[2+MQ2]W;LSM#S'RB: M A>4)M)!-)^+ZTK_L.#BI P36%3L*_.#*6FP].*!)30(#S1L/\3 \)C1SL5V M21NWDJL/;H N4$6B7TB=)+%I=*\'JNS8+E,XHGST#.!E\L@'& ,C)8*T#G08 MD%$ 2/U/9 ?2D:/,&_Y35KO"^65K ^7J!<.#7C]E@ZSO 66%H"EXOH%R!&@R M>5Z_J"OU/BLS&J4G7M;+%AJ=6,/U)ZQ"$!F^%ST,V#\CT(4;1\J5<')SR_"8 MPJPWV=>O)YB%]N?8&Z*(@#^UM #5#%]4U4^:R7<#V&L0?R 2Y*S(8=\\KS\F MV6*@^-":ZNM,;.*K\+/I"2/'J_10T#OBS9TS4C3Q2LL:0;R@/XXE[0-%#SJ$ MP=3SM%=I#9?T7CPEF7X-V_#ZXF W( K :@CE:3M/EM__XF<:ETZ1M,NSBKF*I4S,&*%83 M)[V>:*J"GF21S@W?A6LRE9K+B-Z-:^G69TF&KKY(_&F<0MXEDQ%L30_]I3,$ MH=2H5%.X<7SSJWP'6"#)1/T"[W+9U0"$X!_P2L!;H):4'\]>\,O5[W\D1[Z M'_[3(E3AIF]#/D(]Z"L/0:*ZW(K,5%+P$^@= ]/P).;4B-MDMT!->*Y3H+#D M)0@$(,Q9$JNQ@L0"P7-U3[)"1+SA#TT,7[AWB3:ZJDS.BRJM(*=7&#RS3*+B M-$%L)(?4I:_FTJ%F-Z.1[_VTA\+_-?UPJ5&H^PL=3A7N=!*%%JXAM+?!W+RZ M_\,+M>$YXBE?.WNMJ1T>2)B_^W1TO'WE% 6T;@VPQ^3%PL<;TTP^WRIRZ31V.90Z7)\)F<^$*H\S6S87)P0V= M"W,/B\)<6(P6&F9X#\$2V/1,WEKHI<7)&<)AZ8"V3,EXF!M@]WD.>7Z:!<(Z#N]2T[? MF#+DN-7.!>QNZN*.[_5K4#BU;$Y5H9)-+M']&>+$PY%H,-<=TP.)?B#BF:1( M&);>:"I7PIC"S$94SG4?=WE/* ]Y%Q%@Z &[=Z1L(2WEP1A8CXL*\:.7(,2% MVP)@GI7FCSR5:5>9$A.*?NDE=XWF&HI_Z40/\)F1N).?N"S^L2B&[_;5(*$\?M$+A"YG;2=@!VDZISHE5.H_2RG)A167-?45?BH#12#LJ4W3K=VE@A#E-"W*)Q:!X? MM,RCQF1?8\U!X>>'+:C_C! =]_FB RL ;_YU=PN \Z*1S-^4N?O"94QA7RK5 M4:VG46)@#I16:Z&21(7AB:;FQ*KSQ, .4C&CYJJF.ZH-FN&G1F,+8P_GH9"U MQQ.#<)K=U\ZQ^0!00\^/T_][#DA-_"-(,MFEB!25897M-R$E2B]F:I1>S82= MZ[.2"!E+:A'-]J1P2D=/,!-%S4LP,9_!Q6$"02BK=-FCY5,-X'_0PI39X!:\ M ;,H@+ZFL]0J08T2PK#[9J-U:.X?'R\DSHSYQ5GC2*6+-NML2-I'L,3$U@(L$&71^I3S3!=ZO/2/'UZE)PIU@-T<8BDP:X#.['V'FBY;Y.9=8;+YR ML3@#J*+:S/)]FU.Q.!,=B)*4+O2 *@QVXZK:+OHA;>7;4U2A2.(MYK<>5OFM M$_FM!U5^Z[;8)*57M#4V4=*FKOU#=>U/Z[9YT,IM("YS,6,O>8 M4#$(.8!]N1[OG.1:[V4-GGL/')OMV:HJ;$OM^)8XV P0M^B5R?'54 M#2H31"_;CAF(7D!CB*H914\<&_)Y%(^(W50XG-@*K MCB8_P2FL0-NC#"82I"H[S7;! A:;"_;(Y7<7@EQ$K%3OSM1 MNQ5P\GUI!-I,EZF"A@>'ZEGJ+*G<;R595U(QYO+\TALF7S>7$O+L K_TXL/& M4=G>XKM)^C34S-]TN9E-,I+_'#D>-=WO,X[E^>@J509>DL)OB^G!U @!?AS6 MNK*PWQ,IRUW^R'U4"V3^^V%ACZ<'>"XP E4F%Y=2Y%92B"1]9-G$ M*,!.M@4Y^7H>0JI8(.9/X$$7NW\Z215F7+(6EU.X %-@*K 4W' 0R$.-/;^U!#"?.\)).C("SF563*5 &[E%0[$!_ M+#(PP@$B M0E5/FL"T &^Q,,AHM,16-@SFCMC=;^,3O#=.+/OF>ATP%TF]"$99QH" 3,KGYG^ZUF4;3D M+7L/FZ57MS1+KV[1JZU %V)4%8VS!'C7!UUK;#2/4)0%Y+P@31*4X1=$"B7C MI_0B@8[H/^0]9@.9J'@GB!,NOS'.=03M%%T(?35:'._)!72SS0O[N4=!W,)> M2.EUPTZOAS8'.H4!F3W05Q8>\##?:F7C5\UR:+(:N\6<2QF-3S9G)+MC:GN% MTQS6N46I3-AD_.* ML0'*I.W)-JKQ!K>3]M:G+BR(X=9RU-A\5W!7K8GL2E<;;.P\&LNK(-D?S7D3 M&S1&H<\H2&I&X;P742 YL3,H*BOOOYOE;XN%O3!O^AI9?P+5WL?A= &, M4 D#+OE:6(4.G,P0'5_0SP(/H(NEKZS=[R[9I73[$^5WB+XL4]:Z/V)!7]V< 0LSR M#^85R>E?;4#(P@N13.)75O(UM^G[PC16(%\+J:)D)^G=I&3(FVHIZV10@&'U M*CF20 [<*T'KK)$A]8/SK@ZLG"-!R"\1\()3^TK1!\-0[0Y M0#<@IQ+>R!6AZ_RN@'*J@;*/A-.>=D7MMPI^(WH_J23-(O%HJ'YH>=OQ^2,' M@A*+\Y\8D8 _^J(!2_(C @\EC5"'5Q'WL%T)_@1(H@&BU4<,"BRXU#0>[5^] M8QD!LFC#9($-[0 ;A^&+D\M"^#\QX*+0:N,&Z305XG/+%\'Z=84S93<2'NU$VUGFE3>7/& MLZF0&"3K>ACGHLL3KJ'T/-<78+>4[<]<-&RUH#PY6DX,'2YXU<73Z9>\W8I^ MOX$+3;R:P;N?U62:G'2\-5?9\7(T=%1TEXT-:,$(E!UIEU M;D_8X7X]GEGQFYTA&?O37C)7 #'X/:Y/DZT$-<,%6ZF#;DY)9_'*?=6- ]ZK M63M&RMKQT1CI>8""O^5H!#(@(LR_IQ_B-2S3/M$X$DE,-!\*[DW9PYF^Z_+P MB ,I2P@;I_*<=B+8UQ18<37)0\Q^HYP5L"S,^X(X6H#G-/RG+ MGG0H2FS[+*(V2-RU,)B(>,$4"'@(;;6>\@&.1@[UBH2OZ;P"B\J-AL%&,H=% MBINPC+#KA.>C J!#!E^MK]P5,'^D-#Z<4L+#T '[RQ"GN8N[56-U? $64V=# M"UAK9)&HOLL1ELI1F)\0-^KX&8XBU%ZZ1%W4W,QV MJ!J1QY3F$*7%">Q41P@P]/NDGY!/"!7A.V\$2S0/ZJ:D!OM33*WX8TFFH&PS M0PX]L1QX!DJ&#(;63:/T&H'9"*_-N%U M:I#@5(#!*-ZDS^\=FIY$ZEV$7Y_T/-3.]+H#H5O&+<^'MG2R MX? S+'%(51<8H@9&%A>0*LNI7))96.\:,'32I<='J;)&2\Z%2\_<3C87(Y5T M4W7<3(W,B_#TE")!ELTQ:A09S_,+C@W$(94@Z'MC>_QBEYGP!-%OWK!47C+3J)&7:K0*Y[26XIQFV9R#VOY14]/S-4'\ M3?A]D\2=I&B"/.WD*\=2.)W(9;_'>#B/J)TE'?6)=%3AQL7:8^$$C8?\>+ZH M*A:#[*FQ%K,T7_V.Y1K\IQV*)7>3Q$Q5&$@M0K##3?_1HAXC6/XH^\@I%WW\ MJF1=ZJ4BTH'0Q:JU"%$<*-<86=B$#UY%7OAX_+""$24_[3$)468Y@8:<@-8#8UM@A+Q MZCVYJ7PSFC%H3-\HR]FHUE1%!,O)9?YHV8[U@_3S%(AYL,8F;4]8$;@E(R_/EZ*O(%9ED5*[N MX7^(# -A0I-&+0XO8U9;87^I6Z%5]JU08Y(\68U] MSQ*^44CX(N?4IP1^'@0VDJV,4V7E9)I)3"!UK3]7+LML0H>9O_/!\Y'NDKEL MC;QDME5(M[T4Z>YOBG2Q].Y"B$SAE\/8J9$5W2*%EQR?MAL3?4S'FO@M5B!, MQFUZ@VC5 CH$Y2ZHO_1."6D&PB4#>P@WG5\0]71>-6+_ M#;WDH[IC$H!E7K<88-@.WWO8,^-V:2*ZOOM1MB"D5\7; .V+5,)8G0,XDKXB MIA3[7E>..,9N0_G"9TDU3A8/A.!0.P;(( X MBG&D-+)Y1#XX1+"2W?*N(JE;B8J "[[TP$)($,"/V:STJ M/ZO:AN?6I+NL1NZR?.^8[MWJ3[BWL%*'*^;1>N"X5BBKB,AK963=;0$O>)N\ MG5&9]+%+F*H(VD@SG=PX^):P5'/)?(O&H@D7-YQF05VC-<\7K97IWH^?/DQ= MH6S.!"3*]S.Y@<(0PB:H9RLB"5D4M-"\1++!".B]ARF7@7#%M37G MIMRK@9L=Z^Y,$_V9XC&ESPJU.N[&1_6)@IA&XJ@Y=9+Z$^-T4[,-D-UV^EJ: M2T;=FXNV]J (_&>\8T^T=I97(]ELX<+%C$2X!Z_AHELP2KK$TAL0;K2K&FV+ MZ?O:B)1[.<5_S66;>>1U\U@?R<5LL1+9EDQE5!6!(XN2>@M]EP:% QH?Y620 M-!&B0)53J[%+"'F> [W&7;2A5=E:E,M%^4\4%7)D2WO9I')DC47ANSZP4I41 M&#BUTAMSSN*Y(L(+*28O[K&[]*^$7@G_C7Q*&]-<)-2B$K-;\'/T(& ] J66 MJ50ND7UFJLPO,TG],F0:EZ[$!E&/&JTE.Q1I8T\N]X.!/:).G.(JD:UG0,NR1CXUTIVW1_AKH&UM:Q\R<]-]U0DMV#\EFZ8K( M-S!%0#)-%K"UZ^U:.U4=)P9Q,"6GA;)P+44(MAJ_A#>?J3>KVKE$&Q;_7\L$ MH+Y0LP0S;3%])CLM,S2)@?DP) "P_7!<\02J-$AE9RR=;^CV^"#KUG:L75J" M&A*+2C I%51BP4?\=*64=09A\2-]CEZ."BT+L-[R"$P-M3J>_N*J9:MOLS*=%1Z#D%>.G$A(2GK0W95P4[:H _,W>@&*'#M?6[(]4XF^02$ MBUO('-2/S>9^:Z)OC$H [,_8YQ*M;Y;:YV2K&U,+E'^997(,#2RLX5)5VXVCB*>N. AA^P\\[M M9^47Z=Q^9_A-K=Y,0GA?.;:P83NB1/EHO[F[IS^8>"[ /@>FH+9M4]^#@C328?QI.ZN3\5@UDXUZ$]Q04MGR;VAA116CM!CYB=%41=#-+(0F*5 M:2HR?HPEWITY:^Z[)P%0#&ZLN#%B!J )@4@.CV*@F1QT+3Y(PO;HQ4-$QQWL ML=6EX#N4FR;6XL73&U%Z4L:4:)-91%42)T8'R+THH+_8BV2.K" MG"H<]&A3:X6A'2;MKB+T/5+;S;C^AEE];Q2J'4[ 0$FIN-S1DNT3T,DJXC\ M\!%ISI@QC$S2MT4X"1,BZ24V]9H>BZE!<4^OC?=V:AZBSVAK3>(E\QJ;>7F- M:[KV6ZM>^Z65&R;7_I]"P!JNI]?24H_96 KT/9*_7>[0H+XG'HL@&XSRGC;9 M =V-(+-%(KIH;R;;B+C\R9'%SD MH5F!"C<\WI5OKZWI/$;PPABWZ!H@0//D:I)TB,)J/E M1KX%@\G;@-9'7@8!Z?VD8XF^'=B0&6]01^T( M$9/:U,B3=XCGQ\WG2@("J@&4BVU4'2H_$)DOD!Q,)R#4+2SM?J/'/!HP#;Z8A"S(!G? MLH.450?W&IQ%E/+G#NU2]CL0H0(EAM"R!(DV'VA58K*H2,96W=E4%S,C[F(R M=1"8V#G3=DXEB_Q!F'');T.P#_L (#2Q2/U!KM*L22_ .G_/_T'[E(8GMJ\ MM"F7OJ#C[47T)7ZTNE_6=K=N$J'NE72.P/4<_A<-*O0!@4),J2D M(=1\8F3WO !)Z%M2(26"O?#X?91R,L0^(A+'Z>Q]/#AU[18,XRFJV3/N2,^S M<9=4N>631)<*I'IG,K@WR9)22O#(,1$E. M7VJP0_ L4Z3%4F-LUYGLL1Z5-.ZC/W56^)R#%W+6V)3:N4\ELB]D"L."DF]. M'#V#K$M2I$'4J;ZHU+ ?5,1[6_C6TU(.KS1XM] A0[VE3N*EE(,SD;M5$EY+=B?/K5:GVXM',V7V*XH$I"06KM_\3:;GAANIN>%IEPC5-B" M"6H(*S("D@)>6+>\^4H*2=C8FB88P8^IMVUQ6D?#;+0/S?K144$"BL"I<'-( M:RJ'(+2Y(82<4>2///+%)ZF^])SRE] ZD_C<(+#4% X02QTBI1.A9RP N^9^ MTSPNA)Q*329?%VK-J&I$H0=WMR_'-4X]6UT_6W.ALYVI=\:2]P;>>,-1)H$8 M(@;HA.>\CV;PK=I6ZN'XU+6F=FS *X=S-R:._*N053I&10DWOP H7/V8Q!;^I3*;4$=1S\$2(V0Y8/JM[C6FNE/X# MV:"(?=5L>7R(U*#4D^DDAIYCV4,L%J64" *GR?#W#Y;(P!&M7W'.Q(B[EA.W M1!!>--5:5-6:DO.!-&(QU@ITJZYP:%,\3DL.BB_J1(F5+3*%BJP*M)*-H9+IDS[@C4.IGA\HZ0N7LLPDN&^PLL)D+>DI81 _,OS?PC=.-D[#F>QX@5&H T)0U5Z M0Q]L>DM2B&[*.FR4$;@?XL+$GZ!F [-HA'].MY@.]IL@3E8\3X4\^$_>BY2I'ZIU*/"8\X%/L M\G8^E&+?.XAA#_L5:!VZ#,U%;:+4!NH/8R&*O&#*N&CL I&^EP! Y;PWX>^P[ME,CCA6S69MHA@4 !L[+M2Y$K-%^#TE#5*Q<*F M8C?L^C <\KXMG #Q3S9.VU0O%5S+]U_="U=!+MI$@PJPCMO%!)X7W-,:\(KY M0H9H&T':@$ZG=%]/!T![<9\!%0,)IB,8X$6"USV<'XTJL"FFN0(:[4E7 &5Y MDL8@Z<:Q@ SQ=I+A=1%-RC([:@%"KQ*IX_C+J[L33-JFSJE??"\:[;$.JG'2 M3>I[/U(>LYT_![H^-V?"[^! M'WZ0_1K=AQLJU$?][Q(4-FSP9SEWWE4RT4MB?1K*]_>.CW.0+C&J3P=3 \/2 M@[.>O5!LP\K;_FK*6^DQX-*5-S>Y4\1M<'O3^5\3HUU[J)>=PBWSA-QWDM'# M\+%8$9O@L-PU=995D0'JRR-2?"C''!-Y,%\'>4>?C#"6:^A];)3>>2NRV]FU M_)W\:*KEC9 CLVL*%%;\2TQ1<\*K3VJY_+[\KI-CA-O%;505ZJ;Y&V' MJQ$H =U0A@#Y< BL*J+(@1X B9<0-I\P@4&6^00-><3(1;*3+8NZT1B^E5<4 M '%@/=J(?;((*>5#>/SQOO2)PT=1U[%[8I!'7];J J7P0(**(CWIUD%/W,$. MVZ2\D>,_1A">.PMR\N#2H!*$S2Q-X'!Y34!U:3GW_'/.I[G_\^]YP&1?9,U8 M#KOG,JF_RV.[VJ!@O(B$"*7 UM0N$X ?XEEE"-_"P8="#8K[GH!!+Z(+8[DV MD* 3#FC:]!./LV,I>P-C7+2+> R,Z\$:<&F]'#F\BOPLO6J]@P-GO$(A:I 0 M9<5"%!&O1KBC.)TE366V5)[X>T*7"U 7<0B)']7 BY*K0G(SD; 0#9#IDE9- M?"3?*3&%01FLM.&U[KC6HV(M*[#),:4(&FM^>*"I:WFC+E]PMC.*PH'G8.A8 M]'-"9^\*?NJY%]Q4TLD!JXD>=V)33&SJE:2>K(K,.!5Z"3(H'W^_V9^N?15M MI2VB:_H945=.JO#"L&\MC;6-) I;$5S3/J6IC&+TB?'$:?= :GA663D0,041 MM(2OHQ/O<+J70[CQ\CT=TO"CF\G"O,ZD]?T"^1SSV;?Y9[FV_"L?,QNX<$^J M2<%%VMPUM@45)ZOOP9DF,QQ2 8U-(D0XI:8B8Y/;T9P%4_=T6$ @,X#2LEXLK9-),@D_A@*LQESMDC:LNX^F[M!]I>^04IWU0C/ MM AFT !":3Q3/;KQ#;3R5D-A;[I]?+1*UZ@"-SF*G9^"O(Q\6WXV72<'&\_3HQ)G,R4WDN?ZR8.C&CAB7E"+[/.DBRF#I5'0WK _1H]1 MJW2C33IC-"5G(4],>]L\,=I!7J@;9@(5S^B#F=C+O/Z"UD'+K#?WS?IA\YF= M,&L'YSKW4H+[)9/PHKECC EWS+P=J]^L.^9PZ0ODH/3(KZCP"^%)4>OO^0^6 M*PM,30.I$C/R$T> L!.L"$-M+O6*>K9ZXTVURUQYCIZQ'Z0^S)0,_?U<#VV!)1\<+\T'1QO@@T[T (LQ4*@D)PA20:HQTO0B MIL4+[]QT=EEVQL02[-(X-(]!(3QJ'$Y36_P";H&O/O,0W(DM;?"9+XB3+&'&BDQB#$_BS2.\#%L:]*LLR&I_<$>2'K=O:Y# M4UP]7ZY^_P-_';O2";"3_G/CC=X;C<;RF5KUY[@YIE/\$D5,RU+\]*"&,4M] M2D=BL^-LT^*_*,]4E/CI]$\.JGBRHRP;$AJ=*AZ2O3=Q:"/EHSIV$"8C+K6B M(=67G80-GS5*:6G0GXA-DGETC5LL3AH_S,\9?T/9>F)E<"M5[W0HR3N M^3(I#ML;O*#,@WK3/-Q?WN!).#:NP.S,/VV^;QY5-<&NO(<2F8KJR2401'B/'"02HG MI;07;PMBED]\:;3+1(R60^YB*;%((3<*QB>G2^I5*;V8:!9@BQV_9P>B>29H M(=2 2#54*R.];"?Q\DCLI2[@_T\)!&>)5N^I EM,ZJ<"F-, MXICQ=:!:QJ6=YD)@3I>32Z1'IX#1G0V,;A88G5Z/.Z)_]1^,)'KC\9OIEJF5>-2=[^@CJ'JEL!C4G))$#(SM)QRK"L :, M6L!['_J1CZA:&U%+0&CI"1E W/"A9;MBX$:(1\/N-]P?@G7:GB (HB)FW5,A M/FIS<@#FPX./8U"PG0.H?VX !XU3ZD2NO)[CHR!DD3I]J>6[2M'7:@)/*GKT_5.A@ :#-.INCUN2-G*>M-2FE&S5!L^8/,!*1[Q"C_'IE7U.>T;\N(>K83S[? MT_TG\FA.KNQ36C.2BT VL4R!X;DNRFF'QONPD7,?BHT+ MUXJ^_)IK0SSV[A:AX=-,R#QF0ZR694(O*!B7\K)6GNMDSE MZDK+9[PV#M>@*Z4+L[1N;=>6W:]=N$R.@BFG3&M;%-;ETRT;I>=;YHYZE>GT MH(.!!G4/BH-NBYU,K0N=>RSV5+1L V2N+I0N1H!6%) M^?-29$SI*7A@[N]/%CVQ?N*TDZ._"B3^GG$Z[Z.F@FAZ_J*6ASP#>B<+0F^) MY/ %H=>>.^#WTKFWN7Q"::/TC-(MY=Y5)JO-1W\-LW$T:5$5W1IL)6>&SK+(C*F MMZU:LQ6T0N^">6W((J<^#=S1V](5572)0QOK._2J4Y/F4+W;!^;!<4&_D(#' M.A?+Z%R8\ 9$VVH\V%*7Q*]1Z=G$]H3)]/R";G$V;GXJ3F M$Z(-7+Q766H=B!1?'$0%\A_'0LA'C>R0,9-%(QG.O;=)LN-@%G:"@TM@O1LQ M]Q2>.,=Y,D>U?^&\0DN.K=$;9G$KD*-LNMK\QF# '4>-;E26+?7%$>\4(S!$ M73"@)AIA,K(V@>[J[N1_/N/\T(']@(TR19V2R7Z1%19%,]92[7AHCEJC/7U. M69+R-7N]>>:6R6FPT]%EX2B1%,X$/HPL/E)#(G&NO/B]PLMMK2&F!%(: N [ M3-+" VRO"0=&8HCAFJZ+;2*-[0H2_A!RH.6^"YL9O@M041.216'[C-]/I3\V?5!SX/:9Y M$7:7_5H$;06* G+6-#K)B"::@^4QT*XBH!J:R9H:VC.5I=(YU=BY-YD!I.;U M]+@?6K:;-PW62+CV-AG;V>G1+*G&<:M%51R69%6=_=*/QW>()IKR0&D5W":P ML*$.0=QJHOP!V2Q\0;1!S^5L /M5>C+E;-D<,++3.*J'@UW6M\8RR7("[2CQ M>))8=7MV@BT,?8_:H$4@R:+1R*&=X?7![^]%=[0<$8@_'UH_[6$T9"XE.HL" M'G%85-PUT.P ]&B4J2 OG]ON+D)42*0N&9%P18<"86*NEQ/U14J=SY&/7)H, M[OP'[;?:+-"VA((QZPW M4%/$320N7R$Y$6QP %S\WOY)TTWPTUT3AYT-(\RTU0>8D>3L>A*S)XDBH':= MHEM2U5.Z=Q\GFQ.0/M".83_\W:<+G#X+RD.*BF_5[2@U^;3JE/<3(_Z)Q+E@ M0B0:%PZ1#_%T\H_X701G5L3-0:>4%@XQXH:6\'*1;5XD<23TBQ M\ DF&($ VSFN[S*TNMV^Y1O KRHK6E-*5.I?T0D2+,P4-].T(9U:#.RYWX7[ MPPI5H9W#]9!'OHX42!)7 K9G^[UHB%G.0*Y[;RL>TJKB(9/QD.9;CX>DO4-9 M>@I)Z' WRT_FM,1CW/<:Q1 %!4_WJ' M(/DM]-7Z--,01).B#@#P.PFUL*\>DON4=)*K=LJW'_\JO#BUP/Z;BWU+/]&B M!R*GSL7=V3?63#F1POXRVUOCGKYU+CM?SKZ=7=Y)X^:6G5[7IQ9UZYN;L]OO7.WKDZOKLIH-? MW&8/"O_/)WR])YJ1=+0\L>:"ICS).L_K *"@;&).<>VKY]%$\/BB"V)OWB9V MLN&#G\C;,[E6S7CX,5 FYDB#JC.P<5(Q,BCHH,+E#]>III :F "-8TTQS.)[ M_^8B6F3JUS7Y'J0+",,S72S*P#G!(\?"1[WNOX6Z(R>,Q!GWW@@+'&DB"HW: ME=^3FRE)_!;^%5G8/O!PU$GR;O3^4_:\& \OU=%[B7)'HCSYP9Y4+E\KVD4H MI?C\[(&[ '14-L8>['L[<90\@60/# E'.:8X,)5#4'XN*2'[L4#LQ-/8 M4[!GCXB(LK^(J2OS!=I9;C_^6&V(M$7^,)[8$%!:]K.A-?$8#MR=^ R'+N<] MB$.;._8.3"8'T'#]!83VPZ$#]1^J';W&PD%1F7R$5GA?37\RP MZ(KH2:>UEC$ES&R-_0TQ$AU^%D0D2%#,8&&+>#)RI9U =K"0$CC\N&>A;2?G("\;X-6U$+RX(/^3IAWZ&U M=1]1(($$(3XDZ=>F"8 @9=$R=$/81'R,/79NB:XBXBP]F@E.QJ<5[]J@8=$! MC]_DDN"5\E0!4;U<^F,"Y081\\M%W%3W-( 61[/?\4$&YCM.(>]IGC>3.6BP MH;!_Y.^E9\3SQX;\&8A@=#PH,&&/?9'+9J;+C^!!:I<2VN*RP;UJ8JG7P]+T M/CEH(M$]?>3#UNV1(XUX.'@! 1C!@.!%AFDW%4;&,V%AI;APIDA(L6@_0D>. M8Y.#2*Z*X.H2-GN"?LF_HY'):^5GT**4W^3J$1O;\*?7K#NI<4#^R*-RN=]) M2]*2>U[GL65SW//\YK@[3R XHH R<(1_7,UQ3$(Q>%-+49B))^G!(Y%H#JS^ MP_6>7/2?3ANC@)5CP/T*&<3(Y#,+I4=+1F4]+2PA^LO57RT_8M-_R\U,'\&0 M@KR09'"V(US:Y%[#FL036,[K@T@+!O;(4*UBI.)WALZ] ?LGJ/WH!V6GMFB> MQ4X X:')3D!Y^8%_N"#;!.G"'.JQYD-&28A,W.A!'*5TQE2X)&T ?(U& 0.18Q&G&J1'M*"=&F!3-F M9Z]Q5#?Q#X9_X)3SY(]6G=X=_]VNQSD9-ZF%TS$&5!- &Z'$(HTD R5KTK\5 M,S;SR$M%\P/:001B$U#B$V!%DR0ROPT^2(Y M_S7A4!R;+G(BA)(!EI(+U:7BJ^JU1+03'.-34W1S65%Q\: M(DT!2%JC"<)H@JWT8GFKL'B5:5L:#L%2 ;9#)O1MO)R]')+>,SH!:;-F\2^& MM#=SVMODE"0+Q(*'NKR8MR((B@2"#2O[XP+IC&)& T#^8DE%6F;!XFV]5DJ\ MUF0C69]=[Y%3B#\K['. C;&XOM%!L>P(RI*@CZ/Y4D#?\AZ&NR764.D2,E.0 M@\)2$M*$U^.8\[8:E1:R_0] P=??V-GM72R6SN+G\=RQ:#+DP*[TUV:*3U!8 MT M>)=3;Y0X7VKB9@GB?$C]:"^2=V:G,2T:AMVOPK"38=C66PW#%I#4UN@A9 H& MBK&%_"#9DV.*Q=YL2M# IE%<*;U)ANPU.KRTQ"/,,*)Y07!Y_,"2\?&PZSDL M1_M%_YTC.S\^I1]706SZS?G=S;_D;\3GV$)9-U&>**?3X>0YCA/XLEM$O1Y_ MC1?0@>IJ>9=9Y@$$KPMJ!>[HY/OMQ;6T.=$0%G]_<;PN6,"WLH4SCHF<[BJ<<9/9+9\#.N;S+#-)_@1>E,= M\A@XCOI=('MRLP$P+1)?CK8BW!ITJ>9^3[X/NGCA1'AY]E2[[8R29&3M3:G& M6*EL:J'-D%:DM%YMPWCK2C^Q*@&@B5DV.EW&F#.(32R%\:+$+TRX=Q+;&9,X M;?&S@(/%;ZGGYT"8H1#VBCDI,Z!19(/ O%)8>6'*8X>T$J$0+#19M,@D_R;"C=' P+T897ZC#DSLY*QZ$IY M>)@/'+G+(<[IMC4L5.F03.' F&@LR=>GP!^(?SDB6Q;NJAB=E8@7[%BHDM+# M@>V'XQH-:0@'H'60!P#3S7PP8WYIM6@,A.;(BX8BB\609!%J5.LT8D,G1"4EXYA\'][O@PQ"\\4S6G$H(8*- -IZ*06^RXG MV9<=[>\UFK_NXF)?KO[X_=5"^&I"GG[SG5$Y#\#2 MN!)>85-^<6Z[H-1AP"C^XAJ7Z%.>>NP\@@UCG N$WCG15(J)C:1^_)$[\EL M? ]_8R0$0]H+!OP3%29_[VSEO0L!>3*P;'](\1#2XR9'PHCG\&@YE)RO;0D! M)@ 0B\(4AE##@!M),%4A@F4]CV&3\FMUDG*.3QU$V#.C4LN M1$\EJ,WTOJ%5C(@D_^L\SM;7#_5F/%SJ&][.3ER,#6HG#QR;LR][[',T?+" M?[ -G0?FQ8#]<\_XTPH#E"&GUB,H$K\CKPQ) T;N.P7>N;3A%K#8S1[RNL.! ME;^=FD)[H9!6PH:@"R ZL%LD)V*8:-"O.PYCL@=@-O=">+5QHWYM6:(]%:=C3F0W1$*K%N:+H M?'\4\R"PGS,)R?L(K7>OIS)*$#!_>?X/(863O8L%U0*4^974K.:4?IJR' H% M+!6=4EPFR1M4.B;-X3%^@2M-C4 !(J+>-IJ:+=LNB[[DM%1Z8^B7:AW(#M- MXG%?>RHD$[=>8K'3.@'^-AW]MP,#=V:-:<._-$B?)BDGO E!X/5L@E/<;4:[ M0TQA@^*0%YE=CHA$,*1< #(7,4A*%N,+*UG.D&Z]Y)1[[#LV.R#Z$MX?JJ.[ MM[&"#5DR6415$O@Y(@XV[/'>3](MA(7HY(IES:UB3S3UII.)F@6P5,/'F & MTR6#3&LAS(:,T".+,'\"]B$#6#8PS+K>-+0*^&.:+NHS5@^0XG,:3(_KDD@V M@:RI1!G4K/V]X^-?4=FB)%)$UE0K!Y)J[%K^+M:"A'*NHO+A2[?&H\078(_8#D;SHJC$<1JY,$0T 6:[U M(!M)J"5$]07N*$!1+_1A><3(Q:XC\NKK1F/N*W^K@S8E\H=Z 825.0HX#^EL477^A-W'N.1&FC\Q@@2#1'2 M(*>8$_D8$3;L%S$K$,"6E*#?H-@]80(9HG; M"WXEU(>X>0(@693"H]4]!F!@_ B=EP\#_*4LJZ++CDH(:!=4B(3[P+H+ESH MO[QK;*U"0/!&'M<:*N^4$$M^:/2QG;&G15[,(P"U7G2PGYK0"1"?[ P@>V$ M9EVRK[P_1JA\LQVPBUTP@Z_E;6)DP>?P!Q!;:$H$W '-7"MF,J5&+B?-BQ*E M/,K6"-NEA#9 5\J($"\AJ43R7P@Q34 *NP ^ M,6_5@@VK"@0_#;6!5*8664 MW0/#/!%YZ>W+[CQ#-'"T>_K!]YZ TS.=3.FLACSKVZ 9;0@E@O !>PU+!2#) MQI'9-Y_/__I3A-^2Q!;924DSX4F$HAF526!D]:/#P\;G1KW](B$[CZJ;FFF.B(MT"#76 MVB&4K=HAU%A'AU#Q] H=0HVU=0AE*W4(-2:)9.D.H6R%#J$J,6+#'4+9TAU" MTQUSU]8AE"W7(=0HH4,H6ZY#J#'1(;1(VLS;()0MV2#4F-D@])7>D(L% ^J M .!D +!=!0"?FXIU/4^5*&.D!N,IV,VI/RDH4%.BMC']N!Z\)NK!DR)P$^NV MGJ1YA,9O4HV0?*XW4! U#A/%#$9LLJ)J$-F.K.PEUP>V1WC ] ;8 +I>L.!Z M:%,[MUK?I\JRKF]AL$L*8*J><;B%\YFL"$1Q()):X2M*4QHY*FN=HQ?% ZT2 MC =,7/(PE7_/N,NQ&PH.;1*<' N ., H2HAIAC[<%+2EN-G$;=2G!%5TO%J] M,+5OZ'PT8^F$B!9XWV])50B./E&&M3<"W9,NM:O"#. M2'(?;=]S5?V*SX<>E5PWX">8CH4A0;2=[%Z2O.+U$'08^X-[S0?HP>O)U 3] MQJ=X6M]SK7@WN]/:9:D*)MH.#]06 M9 (-O5]8"D_8?.T)KLY7?<7\F7$()H$'(BN,ZNALAH!)D=5L/NZ)(D[EP2'7 MC?+9D*JI%'=@$=)I&\UNK:G[%&1(V "=5MAC-OHZF>.Y5,K'NH[E_J@!#\#U MM-:ZLBW%F2Y0C^/93*0IST8'R!+)N^@+T3I&3=382A\$61RC&GK04,08Z00X MC-++$(67K2,.XH1/):]DJAZYWP0J,;M6"8S)JD-]?Y3I%LBQ##BJEQH'DKE6 MY"W+M#T2[4H%6";J>V4NR(/MYASH?SYK]#CAU1%.32.W.AK#-"J_H7"R6WD* MI#9=;O-OU^FTL:_?_$D'KX%/GEF+"E.X'R2$* +'%J6TY.5AFYK[0'5'$^&2 M)MK/C)17:A[**8]W(NQC/%%W83VL,M'=)'%PJ$C,6Q$LC;:&L-A121'FT8 D M.N94^Y;(O !^%9+BET9<2_C]]E04TEW+=.KK.)WZ"G$M?Z?EUJ9J#LGI)C*9 ML#FJ9_PG@AW?C[7N8SJ/_;?*2%&N81)HF/L:V#G%B5)WS H7 M41RI.C!0S%V)]Z]T#U,YP@6V3Q8.4$$T%Z!X/7E>']OX8>1GSU2=$H!+OGJP M!WQ5,.2H^I D%M___^U=^U/JR/+_G;\B97UOU9Y:$<)#U-VU"A$]>#SJ I[' MWKJU%<@ .2WIZ^O'I!AW>_:FD M6LI%(X#C@Z)\X!>%^?X.=L8TGT9:3T.4U_1B@';GK(,>U(*+;!54HK[)S)". MT?N%%Z0>>&,@Q*5Q[]& +:4Q#(-PB,L<&.0/9 0@5+P^PG;!*O0PY.F9W-.8 M-F:C^.CRP;T\XU/"BAWR,S>WP3#!WA*(#[ W\!9$GG@L,.T0!-W95:*O+E#8 M84E@!7CB37\&T=7'[+IL>-=GALH-F0I/5&,Y[+(D''(#KZY2];I*,Y1G<.8; MJ"TMEJO)MA=8C>RXP#+O*8':[MF; /#RRAU/;$>Q'(#CIN0[]OSQPXA5U!T#+8:3[@\Y!T"W/% M/<87CCOD2;.F73K,AE/X'?MZ* M R2PJAB$H _3,Z')N9B[9%QLB'1:F _E_XS0FUMZ44[G=1?161SY@O0LCI4+ M41P;;7V0,>@RGMK5X/WI-;K-5 A&8FR=E>9(;6*;KD5O3P+2>LNT;3NG#O+= M%'LD"5.-ZJW_*X(D 'RTR GSR\N_$HGO97KXN8[&;#>L&:038WPAL #6YH\P#8UUD]>YGY#'T2T+E!X+_5H\,91' M@R#:!!G@Z@.R"[XVP0T(*RPTJ8?PU I<[;2Q%TVFRS[AF,6!O@BB.-"@;\'+ M"?)83@#A6A14$?[WGP'KDPH/N M2A&D]3O=L(X[D&Z+\3PB P=S- 2-;$H"UK$@&!17]I MV1NS(@//&DNKV+4&L')SJ\9V/MZ[6,$&7%$AIHNL0B\/T9#%L'X@=K9K@V\A M*#8,"8L^3Y>:_1Y%$$;F,Z(O"UV;P=]!524T6CI(KH)=?V%B+8M+AN.2AUE< M%BS**N?XKB.#\P)W()<@UV=^*401G'R MV%(J-S#A!.]!J)#*ZKY(\./!5:H5T(TQI$_Y",B-NTLOJ=KF"?TO9ELQ_P$X MR0*^.U3_@M!4WN\ MLSUZ0S"F:XY)VOOQ? 4O":0@8M:#0=^;7OKQS@).])Q#22-Y MG?/\\D*EA PQMX59N+!*-JOH\.\QH-$>9A2Q,L8D>!3/P_+^X7$MY9KHTF1P MQ]" SDB[&$6=Z+Z?=Z[!(P/_X;B97A8U0Z9;M--?,-T: 1A8K6N?+3?SZP8" M9C9/K(9 FR*\_3-(S> (4P0P: "X6\E <02N-[OZ0O89E.M"C$PUW9X#G4=<)S)<&<"^\GQF&/29Y>8 81Z9 MYY]^".)8 6 $\P)AG >ZVT:('>\+F8N@'!M="H7F_Y9A4NQ+<%XBSA_VF/'T M&QRU^_.81AB0Z&OT9C9EQB5'*."3_B13?X(<^@#2+3R1"H![HWA%!7-(J3!* MJ%MTCFU9+/$0@L("Y'3C,NQ%OI%].PAWM)9\XN^,#%& M"N:!C B S4AV'X#3Q4?4T! M1I6.[\_-87.I\H?J#G%OIR<39B]3>LS!@#Y#E; "79=SO@:&C"W<^M!,6G0N M9MG'#,?E$=P3GH]#]PZ>V0["*4\3G6T1C>YNAM1!#"G0$)NMFU^%2C4AY0$L MJ,$NB#&Y'SIH&X)<3<#=;PS_V"ONX6>;OH#XO#1)CYKJC.#1XG\\US)@B2L3 MFYQ(XK_VP$WZNV.)\1%TB!H1XF4<<[+'/:F.*A[B='+?<>2[\]F/Z=Q P+^?E-9:;%>=:GHZY"WAII^O.^?M-M=>O=UI>F5+\YE^@?KL7G M\U:G<7W;N6\W.U+][/:^*WVNMS\UNU*[U?DT_Q[T'Q:RHX BP<4D,:?Q(M/5 ML5\*O9_HB,HALD%>3YOGV5&S.?.0)UDC=N;;OOVNH.GV%W[ MMM$\AX,K#L<4\U0*N=NRBY)-_ME#%?6\0C[\9#[1)IVU_Q7?^WY \?TOCR.3 MS-=Y0BE@E1IGV1VB\+JO6&XARH$>=%:*"4)P(JF(5BT$ M.T (ND>AT$V'VR1=/4UU@0H-@+#I#E.IVH$T'[C#T@-,"79/%)Y A37:A$!GI%:#,J.N98#CV.")48I74Q-26H*A:3?C6G-[5<+F.;YV]WTVD&JG M12Q?CF-4\+@99)YI]GSR&8B:R\+36J &FNJ$ 4&3B$HR.FH PI:C_ \A\$WO MW?O2+#891@-$\1M]L 9S&!B0;&#;U'Y(7EJTY&A1881NYWJ[SBJJ9 MYL^\M!_*N0U"K1F% 7]+KZQ:SE\UWH>)E?R+E0)%"44&+C3C4[6YU@8375/$ M1\T.5F+AO1>#&S]<=>B!I M$B#=$XL%/DT+<=WZ#H+9^+%<+._FIB,'Q1^9CY!?F6.Q^"A"\'K"HF #HF # M87&X1-$RB^, G/* S1 2#0T>#UI1/&TK S)TX>#*84D_H#%"M1]BPJ!E A09 MF+K*; [-9@VU+'0G[6/(%WX &0U3F[ZQ'<2V8V>G;]X "X5_%"'D AAPBDV- M)3_#A>?@L7+&4(!\;["[-00L#4"D)(ANHE#!7?LC(:%.7CC)WZ-HHN? MFRLZA%?W$V;0D&#P[Y!%29?6.XI[3,I0;^-=R^;'G1K(G;%VVQ(=)^4N(6#!38 M&690V,#T"MN]SQX+#$ =QC+[O#F!*/$::' 681P:DJZ?S7GTAPC$0.$$M8B_ MR:&4ZR=HPZ-ZV8Q'\W?(NCF>.DE_%&X,K5;;; ME]OMI7AM]ON;=O.RU>DVV\USJ5._;G:DVPNI^>=]J_L=(/KOVZUNJ\GR0.X[ M3?B2'^QITP>+3'=C&C'P[V1;+M%9PN?-B_K]=;V6K:M MLFVUOFV%?]0PI,8?BWD28YC@-5+YN773I*?<19,>;H%\_'>YY9Q .7*V^9)V MIE7C=:8]XTU\9ULJ.\62MY$.X[61FM\^MLY:W1@=28D4-!;[64W61II#\O . M=#[#?+24RD?QS8OXI_9]#"SI+P98PK1/)&O9^*14K^Z7RT7ZI6OVPKA7_38I4W2O* M4?E ?J.&?4Z^WK(MGGM'11I99/#'WLAQ)B>%PN/CXX%-^@=#\Z%0M_HC[8'8 M!:(.%:N@*HY2D(^JI5JQ5B@6BW+U^/A8/BQ1Y54L5BH%S)'7B6T.-*-_,'+& M*Z]@ RA%(! ,!@%:G#7AO4:EWVUWW?JOFV'5WW6^6:T@+;NY1M[VQ[;VU[E][=[H;S MNC?5E4?[[X%B.XY%>?>F#7XVS<-HV>F<;=\M;U^YF"A[>T5?R1NV??&P='Q< MIMM>+E7DHP)AMW2YF)?9CJ^S0G#68,:T+-9TI_F/"W!^=RX='5"M_9[P/9:\ MU2/.(Z1_\^ZQ %/[W72EKX2!K.UCXUY\\JNFZYHRMGNN-?0ZB'XT=9;9!8V> MF=8H>UI#B?8&95HCTQK1_M5-91 7)IN=@"JO$LL%C[WF2O9";T2!EEY2H&TR MU!"/%VXU;2B[MC>M1%<[6N9TKV>Q!5SAF1;.M/!&KEY)LMR$!AG(Q7]DN223 MI[+\=P\W[L"TUN3P#/1*GX?BOO/ 9'P,! :U)/X>!CO ?JP*<[N(+I+EHI>Q MVU&LGD(53?[V22=3 1%4*A9+'/PD4 K+L)Z93@M 05D>%!157F/ZMOD_O0H^ MCA["M&/='=+U]?INT4I&O-^ GM#Y&*S; ] M"7M[BR)QWKR(GTB<0VFEEDG$3B3BNGX6/XFX5GI$SX1AZ\)PUV[&3QCN BAC MGDSX\I")PX;$H;(#46@@\!1"\R#JF,(@[,X51Z&W;IU(O["Z><3"L*6@Y/". MR8!&SLKT15(V%>P/BTC)3,9]*.7>BZHL!DT5ZZSY-Y9G5/ZSL@.&Y<>L-;MZ ML8DO$"<>7#"&Q,-8PK4[[_\1WERY=(E.&P8Q[Z$#=IH-\/E^5JS^2"J5!18; M8D!Z^7S8R\PB5 I]X.@!P$WVR<'R*FH%9B4CT7UC[[J@-)82(HU'^4\OB"*/ M+\C'F2PF6!;+J9#%<])G*)5'F3 F6!@K.Q5&D! 0K$PBXB,1U1U)Q+T-G24P M,$:5!60H(;@6@,3;O/7'_DP\#=&Y*L7#+ORH38;"V=C)=_<[\A VY.L;9@X1=PF< M$&KPGDA7"C5UK:ETB#?\YXLXGB?S)2K7MMYGTY.7;BROF6RS6G:&_G)E*R]0 ML M(=(N.=T6M-3N%>W.'5*$!'#>B**^1C'?/[V=R+EORXC8T:D9!P M;TY2+F5,7%*/W%2U;'EUGT?R$Q_!"P:]FRQ/0-0YLD,90'V]2& M25\F12&1U]:U3\5]8V'/6+1SI%3T\X-@"EW4^Z-R:\SZ"TCD!WX7IO94% M9;7B;X$+^=[,[X.R%_!3X@I%."EG''%A]UN(S&0)QA)3Y<+N356S)[HRA;(8 M@]!5UIY.1D2AJWDJ23G\I*DJ,<0G^M0%AAA,@W7P>7+:4-34IY=03?UCCSV= MAW:R^>*>9%![[X\]U\X/%65R4K=MXMA[DFMH[%>NK>Y)3[9V8F@Z/8\L%R@H MS$YSBAK\YFI_\W"5=LTVPV=$=P.H1NP&]$0UG.P25YPFZP_"T M1=2.8_9_8M1@!4J6IJ,R3T?#'(]-XTU$K""9U7DRKGDTB?*E;K U&9DZ^%L9 M:LK29"V],H<[)JD:)JDV3U)GI%C$OG4=;%%/3_8 #39^MQC#EJ;D*$1):#E: MV*2;TG0'38Y,H^XXEM9ST;#HFC>FP7N ZO013,$D]DI[[V7:#\.T'^]F%2,H MD4,*>7?+^ KUM0CJ0QH]MM0?15 ?.A)B2_UQ!/6A\R.VU(.0A\@/'3M(?LNV M7:*>NQ80C< &> 3=0FQM_:H!Y#=$6.@@V@5A4=93Z#C:!6%1K P=2G>6.="< M:]->WK9;@6&ADVASTT?8+7+H,-G<]!''<"E\@*SC+%N!D+BA1UZ[E_E2(T2&DI MQ;Y!VJ)NS>$+QTYHDR,LH)*G^'N#Z6/@^HQRQ$BL#^@.:!/3&BJ&]B\F4VZ' MI\?QH"UJWKM%]7;P4U_85H=8CUH_16/OM<]?%&4+J7%7R)T+6L9 MM<.BW4D[HK 4M=7"3J/MZX HYE;BH,ZC>%J)A3J/8&4EI,ZWJCTJY$O?VBEOA6M68DI4O9Y9O6296H'18OO1ZUU4)ZO:[K)C2E8?P]4VRB M0NTG,6RT@)M/\)\KQ9Q6X'!(I^^,NJB(6#A8NR/JHCA;#6GWK:J1ZO9T>"5" MB5:WI\.C7CXC*<.]TH.@V$0/R7P>9\/J /*'A0K/[BOZ=*%;34"&S?N\TGR^6 M\J6CT.B+CRU0D=C@3/@NZ-_LO=,_RV&J5QT8J.;#LA* U0=N&H[F3!MT:$O1 M6X9*GCZ1Z=XI]F'#1@01JU$(IMNPN3P4 ?OT=UTS?I[8""9))Y2>\#/#% ;' M3QYP"62Y7#QX0EG!KYWIA!)D:^.)C@(S.P:3H, <8E+;="WZ67H:ZX8]TV+A MJ6?I!Z8U+)2*Q7)!XP"F=&CX0COA"X(;@"X(-X'S45_CS0 MB"4A922RIT.C]6EV^>9_?"JF*LS-%9B?X9?/S4]?P7) 4H'I#,#GV?6*G+IY&0L'>._@[N%KEI@X<0W;UB# M4N+68$X.UK &Y02N 5?V:UN#2C+68%Z-',= C51WLG3^DI A'*Z!E^9?J920 MIXFN]37G,\/54;4QPT4,WB\Y$$5#5VS[=H#WS?J31D_GV?1!_+[.!F)4A<8_ M?U:YS#E8@/YT\2NSR;!OLZ] MC*9W$D6CU^&&,M$<15]$%<6?@4?O@(%MPH!5 MFXIE0-^UU*CPXV0831M= QDNH,F6WLST><70!CS;%0SMF3O*.N[K2=7GMEY[Z/];U*^<@M,A5__6RC^?Y/ZU4_SKXJ+4^51X>#IK?"\^J!WK MKR/GJ&[>V!_-P[IF/!R=_ZK\&)WKWV2K8=4N_NK_Z-J_CLCY],8U_KWX53L? M-MWNS?BN6ZCV:Y\:'?=K_?YS9UK\6C_[>%/X,>[\^/7;-ZU\<_'7X96F6S\; M]O=2]\>W_O=C[>'7JXI9/7:NC#HY_T;*QO266FKWE^._NA^KY9[SZ?.9W6T4 M;@ZO)\-BZ:I*!G].2*-[>#]TOU<&K4KE^^'5)\V4:]7>5;GPX\L7^=?/[I?+ MVYN2R_>D;V+KQ-D]C MN6TRE^$[.Z"37P2;V8);AM.KI-E=FAEUVY"@Y#M/XVU;;)9[:7=U:BF$SL&[[;!K\AK%1-/!229_8MFDMP+_$,#!Q9;6VY5 CR+!- M75.!3TT@&4Y8GU47BNU0GO9_=DS=1:ZVC'Y:3KK$^EJ7WG&-=@<8[>H.Z,SK MZ\9&K:8-67 ;"%_4\O(ZZ[.KF4MUD[R;OZ375LE/";)\'0#4BRY3(S@7Q M>)V"F%CW8,P%,?Y.I!E16L:^85.ZEIDH?,E M*6Q,K$OU63N&^4]=JS]2;')G:7VRNURB6-QZ$N=TC36+-[L=WX^_]7/[4[=S M:9GNY'5W^>8VZ-%J]5NERAHWZ&%B7:+KWJ I%+CY5'A?%;/B.,0 MZ\*TOION5Z+K('9)5!S5=2J.Q/HS=^6$VLR6KJYS2R>P"'K5O5!;YUYX/VZR MKYJN:\K8[KG6D%])/YITK@4]GYO3B:MD!-,?R6N5@^U[NM*Q;MOWY[Q1\087 M8!V*-[&>D.5=I.WZMP5RE-*O*Q+K&7E;@&RA^%@Z?>)Q!"P^3*S3Y]VP?-UU M2[7$NGP2P?*-YL36WH_39<>1KSA&4VJ)];DDG?MQ<-77$IOVE7SNE\J[]K?6 MWH^/:<7[0GHW_CM*H-J]=T NKF*C%ZFIMTZ6OY\,IQCM]GBP?ON^P'2L6P*P MZ>;735[-';!61V1M^QZ@73EPU^I&.4J<&P7JB;N:HY-@:#N@B:_(8&"1Z3D! M2"S-W*'!'0Z256/!\<2Y5Y*SHTNK:.Q@>^YU\/?] M.%"6J69*[WY^/RZ3F#G,8L']Q'I-.F[/)O^X=(#F _U'=SHA2\Q M-ZQFFY627#NY[YR'1I6")#\W\AVQ/*IG9L#CF\PM./SRQAT32W',N>K3A6F: M8?_<@*')SHEACC6#?_O,A"^N;>24<\,&V>V]]RMK-Z&CO\!I^#KR[6<'+6A/ M)Y1JT[7ZQ&8?1T11\3"DCU)B3L4_>]0@IO\:.6/]]/\!4$L#!!0 ( "A9 M)E2WN(D*N D #%@ : 9C$P<3$Q,C%E>#,Q7V)E='1ES,?.W:;].'8&;=-)OOK M[ZFV\T((8,C[CFC/Y5VHWUM MG%<.HT_4.Q&#%C+ZW$W'UW( MLSOA2SN'CNC:_&B_,NMQ_T&Z9^R(_DJWS +Q(RAP1S[@HB\?ND'NO')Q;GR] M:EPTVNRX6#F\@-K-Q0=\;:A?W8[JEUVJ85PRXZM1NV\W_C)P"7>-UNHU69?%S?O6W7WUILW:MZQU?VVPXG&U4#S9 MJ^ZS^YNZT6+M*X/=P?Q6H]TP[K(9XVOMJGKSN\&JM3;-4/'?QR?Y?\Y\5.]8 MM7[;;!MU-CTUF $-B>.C$AFM)Z7:NJC>&'>%VZ_7QK=L)IZ/TM%1:6EJYL9V M+T58(\\:W&5_<'W?%'X@[2$+NCPX6\&L_B]4)/^%#>WJ!7!6,ZZO[YK56N/F M]]]R1SG]O5FMUT??8RT&T@JZI,;1OW)ZH:RT6Z-[3V2 R9W1@('7S\6+::5= MGY%P=% ZI;4L-JL(LVKHU_%EGET)YTF0*)C$756(U\_*Y2V>_M1T%&S>D\[P M[+T)T6V5_%M$\Y<[+QY4#DD8+>[UERHFUNF5"5Z>H@W6Y4^"^>))BH&P@ VI M\*WO^0'S7';I^3VT+/S)/)M=B "LH6OLFQ>R_PK'<86"\(9K'I2G#<:/5O3P M#O7#/T]QMAJ2?PBAU6;<,@!# !1 Q1>U>-'"%"9QR?TA->OQ1 M8-PIF0K7+"B#(1V*0&@,:F!*WPQ[:.:B.S2Q /Y!5YI=ID+Z,>D_$+Z(A9 ! M/:D>1X)9DL7 M2"703Y"9!XG0'+?]J?O2M;&N\T!"CG1-)[0@$^B?@F$>S)&^,V1]@)=X1WQT MG FQ8DRKF:'!74N2X#RU"!TT )L\0%X/I[0^)E==9CO>0(VHIGHDO!,J21Z% M2:5":,SI?F0"%,Y/D4>-]'JA>,J?3?#G9%?XTWX-;+_ZZGOHE55,ECA6IB7< MLVUI$AH!PP;COM#8!Y9EQQ$$3"9 N(XC59>:4[,>W!>Y,/IN264ZG@K1CQR; M[SD1"?J^9PH+EQ7; ] M 1)%:#9^F%WN/@A6A<]HA0Y:%(]YH7BZ)_9UU^*I M%7V+ODI*9MR(?"2?D6.9XF1$#-(E\4#VLX%L#$1VOL%4-*9 \NSG9M]$F7DL M^"Q15TX*OBOLK0L%T0"O#L#>9U:>8D.3ARIY%PK2.@(LB4>*PCXO]"$ ON=) M*NW%P3;LX[IM+G7SL@:F=A+>$6LISI,4#K7-'24MR M7Y(M,@I4M=]W26BH*'C4"Y;2D:9VA9X2T"V %Z9.?4XH#AU.SAP6:GTF02AZ M1"'M="2.WSJ"&L+)HK^P?G*GNJ.T[NPFK1.[LQ?L3NX($Y,<"\.3M,CE<^6Y MG#P^!V]]R@EQ\8'[UHA1H+OD'>G(8$AA[;QA::G1Y-.\BE:)9TVGJ'?A^\5CH,-TW/M[0".KM\$"ZB:P?TQAW1IW6#FB!SCBB,]47VX=M3$N\B MBRU"N+!M9(?R26A7]U:6-PZ\$_CFZ.O\Q$_3%QWA3%64:7:\ M,'A=F231 Q^W%I1&V^]OW[#.*$'7*Y*()@7ZE$EXRL =9*"U*PRL1XA^R0S: M2(TS/7U'>RZI GBQ8$R_#SA/BG@]TPQ]PO]43#E':L]3 :[3"S?(4@ ,^QXB M)(7HO5>ZV" RW-I,ZUAQ$_32>\"T/>R&8[WV(ZVZ7(UC<7*(FOC"TI&"GH_8 MBP^9(Q^%$V\(S[3/+SQ%*=DWM1%UNBMDG;,1A:PN^3Z4?FUGC1B?G_B=WO 9 MZ28>B&CS@=CZK:1UK"1'XAIXOAI'MOH"I/=Z,@B$>.[Y9SIW/$3/U,*24%:+ MV0-/X5\5^6]\4BX]6ES$]U#"%KV0A*ZI=Y/WT_VF7?2H.[/?5 5H*4648!X< M@=X[-:4 5^)@=+SO,Q#\D0@2I6@ZOM3)I7XY.7K[\2$&QOLRT7[S'+?%+714 M8NRUDK USD[1&X1#$IF/HEUZAZ_"'H /V[5=<> P]Y51ZMQVE7<[LR%41;! :$<('NE7ZS'A\E&\)]TG#PI2T.?RA[A"P(]]I^CU'6\H<'?0]2*' MR9_1&?0;1\1O,R"3''&$'919K-D74FQVN(X7!%YOF21ZD^OQO$2C8G2' MFX^L>' *N_3KAT\O6\\L/5F/I8?J,#)P7.PXGX5K?=BK-WM$DN4OZ>NR ,\K M4CE]:+MC0:TKA1TI;?P09D@;J^PV3D[39[@3%NPUH]="W'GE0>[_(^.8L>Q? M"@5V*85CG;$FXL8R!'P/D=?1!+%"8?0\ZXV_1DI$H@O *YJ4^L%HL+$+_4+7 M9MSJQ:Q;A0K-YQ*A[#2DFM 1H\Y1H(,L\+'0$Y6-=V<-]_S3/9>.F>E-K5*_3TSSI:9YUGN;9V#JW;>=^IK.T MV2SNDUI$B][1G$5/7WNVX?-V_/&*,63 :ULZLRX[.O!#GG+29?Z#^?1QFVSF MQ7D;'7=HWSSQR^F#7?*#+25[L(N=;\EFMN6 2S:SCA,N*7+7@-SC!9'[@1,E MVY(,L8N=X>C \+G(I X+$=QR*RF>TX%Y'-?/1@1$J4S1.E\QFB)*^%RF:VY:!! M-K,5)PVRF7>/&J2TV#PMS&2T6+1R/YO9CM)]K-TKK=U/(;UY2%L)5_JEE,)G M,UM5"Y_-;%$Q/*7\'ZN&3^FSAA3Z]-,I=/+J<\J@MZO\'/'(QNK/4UAOWBLD M3)07*.=&C+-U]=Q _3(+NE,@;Q[("1/91>JC=3*[T0+IC0'M9Z^,_D!1VDJ+ MJ)=4&9UD0A,5Z[U7M;6T"N=D&J^JG'F!0L.E3?7*=5A%2?%/,7%39;V7XV4[ MK@9-IS&Q#K.5M2_F\KW*VEWUA$EJ:TME=MO7F=,9N^;($K>HU';]);&C&=.C M'-(_^:_C(OU?!?P?4$L#!!0 ( "A9)E1'-8:@+@8 %4S : 9C$P M<3$Q,C%E>#,R7V)E='1EUFM9(+7G$T%PY7:IW&#?3UFW;S4\JTN5^"0M[Q M06=CZL$U?8">/28\'=Q(0Y^ZS$SA1)S:W71>&<;$O66\!/DR^/2'GR$6N\5+ ME]V._%2U%9DPR9M:T]!R<2JW:_';5JK5T53DK5G(U5%7(PI?N'F(] MX0//*>\49L:W'0DUO!S8OF^/E\ ;E/O4W0Y]O=G36Y>MNJ:W.M>JTOW:ZW_5 M4)K>.52-#ML?A0^J\C7;S]:ST&_6A5.@<':>/U1U#ML96E]5M$:GJS<;<,R, M-T8?IH.J?,Q?0.<2]*LF]+5>3;MN]C.=;^WF#6AU78P4\_F$:6-/O;&$\Y^) MYS-SN@70%E<5P^:<&CZS.3PP?P3^B,*7"7'1!-84>M2Q71]L$VK4QUMP:;MP M8T_@;VI9G'HHJ\6-+)R*:2?6\/O$+M?ML4/X],255^\ )>.L,:J:^0(FSA>? M_1XOX2 6>Z@JE _I$*[M>SH>X$)G^33ZNEA( _' 9!:.Q?CZU)BXS&>H&^%# M:/XP1H3?4L"5Q\SSA"ZS@ (E(CR(&/\(A\]$VJ+K,FXPAU@H!^7Z[)ZJ2L,YX2>^Y&]:GA>7D6-5^^L2S#@O:I:B$;6W,> MPRX=MV)=?43#YXXU?\)Z8$XLS%P#L\(221@GIDN_3YA+QUA!/1'0_;"R%,Y. M"18"%PKGI\-W<1(\IG&4PINA"=.F\/'L?5E4@EDCBBB[BLKDBA J90 M'6T[<%D:KJAU3T40H;$(]S*+.71,ESU*E^)KI MFA[U9.(ZG<,?M!Z2J6YJ6 M$#J0R9Q",9$D1,K2%$;^5<"]!;(3A 8WA$?CT@[HNI-8!A( MZ&[ @H]*9W^:J6+: 1#>-@B#W^Q2IFR/55,5#T6AQ6V7X6+H>^E7AF4:BZU/ M.7@^AI:HT5&]EMZ):K78I8S0]P.*'W5<^YZ)30QN<^(]DXR)!X8Q.A E/XQJ M%#&_1U25A4VB#*6)RYDW"B2NN9=#<0R#%6&;)DPG<"&WW,5]1OP6(88JASM*FH6,>Z@ MD#U'TWFVQ8;+-!\K\?YUE,AYN0!U7)WFM@:"6';DG+UPR%O .EHV*5CU$:/F M8]L!PJ[#TXX;$$)W7J)\+)W5O9+#55< M&+B4W&4&%)\[$*4C4<^"NEB!20!]E#TC=T;_G#! H'.B;IWO_R;7H%XXX5L^ MQDARZ==2\;&[NGQF]BOHI_7AR6.H7T&_R&L;G.P21SC[66AL.4!PIKQ9JM*TD<"ZW3Y5>5%;?Z7=.[W_%'IV:Z[!IOWSE4E MB>;YXC9@C=ZYJFS:/'\U(DQ@!=FZAJ7.]1MP^_^OY;Q>_=NG_O)ZB/>PF;PS M4R>. 6T6+'HTW&889!EHQK4Q/#9YG[#EK4ACIY2W7O>V6(:. M([=T)6@3S]^G9FXB3==%&TN!.?&UF.![,N+K-/\!4$L! A0#% @ *%DF M5 P7I]-E"@ LU4 !$ ( ! &)F>7'-D4$L! A0#% @ *%DF5(Z38HP !@ !"D !4 ( ! ME H &)F>7&UL4$L! A0#% @ *%DF5$OL1'R] M' \\ ! !4 ( !GFT &)F>7X MB0JX"0 ,6 !H ( !@!@! &8Q,'$Q,3(Q97@S,5]B971T M97)F;W(N:'1M4$L! A0#% @ *%DF5$